<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
      <journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
      <journal-title-group>
        <journal-title>Frontiers in Immunology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1664-3224</issn>
      <publisher>
        <publisher-name>Frontiers Media S.A.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">7385234</article-id>
      <article-id pub-id-type="doi">10.3389/fimmu.2020.01817</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Immunology</subject>
          <subj-group>
            <subject>Review</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Frederiksen</surname>
            <given-names>Lea Skak Filtenborg</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/975499/overview"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Yibang</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Foged</surname>
            <given-names>Camilla</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/524194/overview"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thakur</surname>
            <given-names>Aneesh</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c001">
            <sup>*</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/95087/overview"/>
        </contrib>
      </contrib-group>
      <aff id="aff1"><sup>1</sup><institution>Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen</institution>, <addr-line>Copenhagen</addr-line>, <country>Denmark</country></aff>
      <aff id="aff2"><sup>2</sup><institution>Department of Pharmaceutics, School of Pharmacy, Jiangsu University</institution>, <addr-line>Zhenjiang</addr-line>, <country>China</country></aff>
      <author-notes>
        <fn fn-type="edited-by">
          <p>Edited by: Denise L. Doolan, James Cook University, Australia</p>
        </fn>
        <fn fn-type="edited-by">
          <p>Reviewed by: Arun Kumar, Coalition for Epidemic Preparedness Innovations (CEPI), Norway; Thorsten Demberg, Marker Therapeutics, United States</p>
        </fn>
        <corresp id="c001">*Correspondence: Aneesh Thakur <email>aneesh.thakur@sund.ku.dk</email></corresp>
        <fn fn-type="other" id="fn001">
          <p>This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>7</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>21</day>
        <month>7</month>
        <year>2020</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
      <volume>11</volume>
      <elocation-id>1817</elocation-id>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>5</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>07</day>
          <month>7</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2020 Frederiksen, Zhang, Foged and Thakur.</copyright-statement>
        <copyright-year>2020</copyright-year>
        <copyright-holder>Frederiksen, Zhang, Foged and Thakur</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>There is an urgent need for effective countermeasures against the current emergence and accelerating expansion of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Induction of herd immunity by mass vaccination has been a very successful strategy for preventing the spread of many infectious diseases, hence protecting the most vulnerable population groups unable to develop immunity, for example individuals with immunodeficiencies or a weakened immune system due to underlying medical or debilitating conditions. Therefore, vaccination represents one of the most promising counter-pandemic measures to COVID-19. However, to date, no licensed vaccine exists, neither for SARS-CoV-2 nor for the closely related SARS-CoV or Middle East respiratory syndrome-CoV. In addition, a few vaccine candidates have only recently entered human clinical trials, which hampers the progress in tackling COVID-19 infection. Here, we discuss potential prophylactic interventions for SARS-CoV-2 with a focus on the challenges existing for vaccine development, and we review pre-clinical progress and ongoing human clinical trials of COVID-19 vaccine candidates. Although COVID-19 vaccine development is currently accelerated via so-called fast-track programs, vaccines may not be timely available to have an impact on the first wave of the ongoing COVID-19 pandemic. Nevertheless, COVID-19 vaccines will be essential in the future for reducing morbidity and mortality and inducing herd immunity, if SARS-CoV-2 becomes established in the population like for example influenza virus.</p>
      </abstract>
      <kwd-group>
        <kwd>coronavirus</kwd>
        <kwd>SARS-CoV-2</kwd>
        <kwd>COVID-19</kwd>
        <kwd>vaccine</kwd>
        <kwd>immunopathology</kwd>
        <kwd>immune response</kwd>
        <kwd>animal models</kwd>
        <kwd>herd immunity</kwd>
      </kwd-group>
      <counts>
        <fig-count count="3"/>
        <table-count count="3"/>
        <equation-count count="0"/>
        <ref-count count="213"/>
        <page-count count="26"/>
        <word-count count="19869"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>Introduction</title>
      <p>Coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December 2019 in Wuhan, China, and rapidly spread globally due to high transmissibility and pathogenicity (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). According to the World Health Organization (WHO), the disease has infected more than 9.0 million people across 216 countries and territories as of June 23rd 2020, with evidence of ongoing local transmission (<xref rid="B3" ref-type="bibr">3</xref>). In most cases, the symptoms of COVID-19 are mild and include fever, cough, and shortness of breath. However, in certain cases, the disease develops into severe pneumonia and multiple organ failure, primarily in elderly and patients with other underlying diseases or conditions, and it has a mortality rate of ~3.7% (<xref rid="B4" ref-type="bibr">4</xref>). On January 30th 2020, WHO declared COVID-19, a public health emergency of international concern. At present, the understanding of the pathogenesis of and immunity against COVID-19 is incomplete, and there is no approved therapy or prophylaxis against the disease. Hence, there is an urgent need to develop both new therapeutics and prophylactics to contain SARS-CoV-2, given the pandemic spread and the associated enormous global humanitarian and economic losses.</p>
      <p>Vaccines represent one of the most successful and cost-effective health interventions in human history (<xref rid="B5" ref-type="bibr">5</xref>). According to the WHO, global vaccination programs save up to 2&#x2013;3 million lives each year by priming the immune system to protect the host against potential pathogens, who would otherwise significantly challenge global health and economy (<xref rid="B6" ref-type="bibr">6</xref>). Besides providing individual protection, vaccination programs also aim for so-called <italic>population</italic> or <italic>herd immunity</italic>, i.e., immunization of a large proportion of the population to protect the non-vaccinated, immunologically na&#xEF;ve, and immunocompromised individuals by reducing the percentage of vulnerable hosts to a level below the transmission threshold (<xref rid="B7" ref-type="bibr">7</xref>). For example, a global immunization coverage of more than 80% against smallpox virus has reduced the transmission rates to uninfected individuals to such low levels that the virus has been eradicated (<xref rid="B6" ref-type="bibr">6</xref>). For measles, 91&#x2013;94% of a population must be vaccinated to achieve herd immunity and prevent new measles outbreaks (<xref rid="B8" ref-type="bibr">8</xref>). Likewise, a threshold of 80&#x2013;85% is now the target for global eradication of poliovirus (<xref rid="B6" ref-type="bibr">6</xref>). These examples illustrate well that the threshold for vaccination-induced herd immunity is pathogen specific. A threshold value of ~67% is estimated to be sufficient for achieving herd immunity against SARS-CoV-2, assuming that the basic reproductive number (<italic>R</italic><sub>0</sub>) of the virus is three, i.e., one infected individual infects three new individuals (<xref rid="B9" ref-type="bibr">9</xref>). Based on this estimate, ~5.3 billion vaccine doses are required for a single-dose vaccine, or possibly 12&#x2013;16 billion in case of a multi-dose vaccine. Therefore, it is clear that inducing herd immunity by mass vaccination would be an incredibly powerful tool to contain the COVID-19 pandemic, but it also represent a massive challenge.</p>
      <p>The urgent need for safe and efficacious vaccines against COVID-19 has accelerated the development of a number of vaccine candidates, of which a few have already progressed into phase I/II clinical testing. Globally, academic partners are collaborating with vaccine manufacturers to exploit a number of different novel and established vaccine development and manufacturing platforms in the design of COVID-19 vaccines at an unprecedented pace. Here, we review these global efforts with focus on the vaccine candidates in preclinical and clinical development. We also describe the characteristics of the SARS-CoV-2 virus and the immunopathology of the infection, and discuss the host immune response and animal models.</p>
    </sec>
    <sec id="s2">
      <title>Characteristics of SARS-COV-2</title>
      <sec>
        <title>Genome and Virion</title>
        <p>Coronaviruses (CoVs) constitute a genus in the <italic>Coronaviridae</italic> family, which are pleomorphic enveloped viruses (<xref rid="B10" ref-type="bibr">10</xref>). The <italic>Coronaviridae</italic> are classified into four subgroups, including (i) alpha (&#x3B1;), (ii) beta (&#x3B2;), (iii) gamma (&#x3B3;), and (iv) delta (&#x3B4;) coronaviruses. The former two subtypes usually infect mammals, whereas the latter two subtypes predominantly infect birds. The novel SARS-CoV-2 is a member of the &#x3B2; subgroup, along with SARS-CoV and Middle East respiratory syndrome (MERS)-CoV (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). All CoVs are enveloped, positive single-stranded RNA viruses, and they have relatively large RNA genomes ranging from 26 to 32 kilobases (kb) (<xref rid="B12" ref-type="bibr">12</xref>). The genome of SARS-CoV-2 contains a 5&#x2032; cap structure and a 3&#x2032; poly(A) tail, allowing it to serve as messenger RNA (mRNA) for translation of the replicase polyproteins (<xref ref-type="fig" rid="F1">Figure 1A</xref>). The open reading frames (ORFs) 1a/b occupy two-thirds of the genome (~20 kb) and encode the replicase polyproteins. The replicase polyproteins include the 1&#x2013;16 non-structural proteins (nsps1-16), which are responsible for (i) viral replication, (ii) RNA-dependent RNA-polymerase activity, (iii) helicase activity, and (iv) assembly of virus replication structures (<xref rid="B11" ref-type="bibr">11</xref>). The majority of the remaining one-third of the genome encodes structural and accessory proteins (<xref rid="B11" ref-type="bibr">11</xref>&#x2013;<xref rid="B13" ref-type="bibr">13</xref>). Coronaviruses contain four major structural proteins, i.e., the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins (<xref ref-type="fig" rid="F1">Figure 1B</xref>). The 5&#x2032; end of the genome contains a leader sequence and an untranslated region (UTR), including structures required for RNA replication and transcription. The 3&#x2032; UTR also encodes RNA structures required for replication and synthesis of viral RNA. The genomic sequence of CoV is 5&#x2032;-leader-UTR-replicase-S-E-M-N-3&#x2032;-UTR-poly(A) tail with accessory genes interspersed between the structural proteins at the 3\' end of the genome (<xref rid="B13" ref-type="bibr">13</xref>). Interestingly, the accessory genes encoding the ORF3b, ORF6, and N proteins are interferon (IFN) antagonists, which act on the type I IFN pathway, either by inhibiting transcription or by acting on effector mechanisms, and they modulate the host innate immune response (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). Like other coronaviruses, SARS-CoV-2 virions are spherical in shape with a diameter of 65&#x2013;125 nm (<xref rid="B16" ref-type="bibr">16</xref>), and the most prominent features include the spikes projections emanating from the surface of the virions. These spike projections give the virus the resemblance of a crown, hence the name coronavirus (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B17" ref-type="bibr">17</xref>). The S protein represents the <italic>key</italic> on the virion, which binds by <italic>locking</italic> into its receptor on a host cell. The N proteins hold the RNA genome, and together, the S, E, and M proteins constitute the viral envelope (<xref rid="B18" ref-type="bibr">18</xref>).</p>
        <fig id="F1" position="float">
          <label>Figure 1</label>
          <caption>
            <p>The genome, virion, and replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <bold>(A)</bold> Schematic diagram of the SARS-CoV-2 genome. Approximately two-thirds of the positive single stranded RNA genome encodes a large polyprotein (ORF1a/b; nude). The last third of the genome proximal to the 3&#x2032;-end encodes four structural proteins, i.e., the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins (red, orange, green, and blue, respectively). The colors of the structural proteins are consistent in this figure. <bold>(B)</bold> Schematic diagram of the SARS-CoV-2 virion. The virion displays a nucleocapsid composed of genomic RNA (+ssRNA) and N protein, which is enclosed inside the virus envelope consisting of S, E, and M proteins. <bold>(C)</bold> Schematic overview of the life cycle of SARS-CoV-2 in host cells. The life cycle is initiated upon binding of the S protein to angiotensin-converting enzyme 2 (ACE2) on host cells, e.g., epithelial cells in the alveoli. After receptor binding, a conformational change in the S protein facilitates viral endocytosis and envelope fusion with the cell membrane. Subsequently, viral genomic RNA is released into the host cell, and viral +ssRNA is translated into viral polymerase encoded by the genome, which initiates replication of +ssRNA to &#x2013;ssRNA and further produces a series of genomic and subgenomic mRNAs. These are translated into viral proteins, which are subsequently assembled with genomic RNA into virions in the endoplasmic reticulum (ER) and the ER-Golgi intermediate compartment (ERGIC) to form mature virions that are trafficked via Golgi vesicles out of the cell by exocytosis. Created with <ext-link ext-link-type="uri" xlink:href="https://www.Biorender.com">Biorender.com</ext-link>.</p>
          </caption>
          <graphic xlink:href="fimmu-11-01817-g0001"/>
        </fig>
        <p>It is crucial to investigate the impact of mutations in the major antigenic proteins of SARS-CoV-2 when developing vaccines and vaccination strategies against SARS-CoV-2. The S protein is the most commonly used SARS-CoV-2 virus protein for vaccine development (<xref rid="B19" ref-type="bibr">19</xref>). Recently, 149 mutation sites have been identified across the genome from 103 sequenced strains of SARS-CoV-2 (<xref rid="B20" ref-type="bibr">20</xref>), indicating that there is a high mutation rate within these strains. SARS-CoV-2 strains in this study had evolved into two different subtypes (L, which is a more aggressive type and S, which represents a less aggressive type) with great differences in geographical distribution, transmission ability, and severity of disease (<xref rid="B20" ref-type="bibr">20</xref>). Hence, these differences also complicate vaccine design (<xref rid="B20" ref-type="bibr">20</xref>). In another study, of the 144 sequences of global SARS-CoV-2 strains, two subtypes SARS-CoV-2a (China strains) and SARS-CoV-2b (USA strains) were identified, which differ only by a novel synonymous mutation of position D614G in the S protein and display different antigenicity (<xref rid="B21" ref-type="bibr">21</xref>). Domains containing this mutation point have been confirmed to represent B-cell epitopes (<xref rid="B21" ref-type="bibr">21</xref>). Further, it has been reported that the antigenic indexes were reduced more for SARS-CoV-2b than for SARS-CoV-2a (<xref rid="B21" ref-type="bibr">21</xref>). These results indicate that different subtypes may display different antigenicity and that vaccine development may benefit from a strategy focused on targeting multiple subunits of the virus (<xref rid="B21" ref-type="bibr">21</xref>).</p>
      </sec>
      <sec>
        <title>Viral Replication</title>
        <p>SARS-CoV receptor recognition and attachment is initiated via interactions between the S protein and the human angiotensin-converting enzyme 2 (ACE2) expressed by cells in (i) vascular endothelia, (ii) renal and cardiovascular tissue, (iii) epithelia of the airways, small intestine, and testes, and (iv) lung parenchyma [(<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B13" ref-type="bibr">13</xref>); <xref ref-type="fig" rid="F1">Figure 1C</xref>]. The S protein of SARS-CoV-2 has been shown to engage with a comparable affinity with human ACE2 as the SARS-CoV S protein (<xref rid="B16" ref-type="bibr">16</xref>). Due to the genomic resemblance between the novel SARS-CoV-2 and SARS-CoV, SARS-CoV-2 is expected to display a pathogenesis, which is similar to that of SARS-CoV. ACE2 is suggested to play a protective role in inflamed lung tissue, and the binding of the SARS-CoV S protein to ACE2 is assumed to contribute to disease severity (<xref rid="B11" ref-type="bibr">11</xref>). Following receptor binding and attachment, SARS-CoV-2 gains access to the host cell cytosol. This is accomplished by cleavage of the S protein by cathepsin, transmembrane protease serine 2 (TMPRRS2) or another protease, followed by fusion of the viral and cellular membranes (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). The S protein of SARS-CoV-2 has been shown to contain a furin cleavage site between the two polypeptides referred to as the S<sub>1</sub> and S<sub>2</sub> subunits, which is not present in the S protein of SARS-CoV (<xref rid="B16" ref-type="bibr">16</xref>). An additional cleavage of the S<sub>2</sub>\' subunits is important for separating the receptor-binding domain (RBD) and the fusion domains, and for exposing the fusion peptide (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B16" ref-type="bibr">16</xref>). Subsequently, the fusion peptide is inserted into the membrane, followed by the formation of an antiparallel six-helix bundle, which allows mixing of cellular and viral membranes, eventually resulting in fusion and release of the viral genome into the cytosol (<xref rid="B13" ref-type="bibr">13</xref>). The next step for SARS-CoV replication is translation of the replicase gene from the virion genomic RNA. The replicase gene encodes two large ORFs, i.e., <italic>rep1a</italic> and <italic>rep1b</italic>, which code for the co-terminal polyproteins pp1a and pp1b, respectively (<xref rid="B13" ref-type="bibr">13</xref>). These polyproteins are subsequently cleaved into nsps1-16, which assemble into the replicase-transcriptase complex, where RNA synthesis takes place. Ultimately, nsps1-16 facilitate RNA replication and transcription of the sub-genomic RNAs (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Viral RNA synthesis follows the translation and assembly of viral replicase complexes. Both genomic and subgenomic RNAs are produced by viral RNA synthesis through negative-strand intermediates (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Subgenomic RNAs serve as mRNAs for the structural and accessory genes. After replication and subgenomic RNA synthesis, the structural proteins S, E, and M are translated and inserted into the endoplasmic reticulum (ER) (<xref rid="B12" ref-type="bibr">12</xref>). Here, they are transported into the ER-Golgi intermediate compartment (ERGIC), where viral genomes become encapsulated by the N protein, resulting in the formation of mature virions (<xref rid="B13" ref-type="bibr">13</xref>). The virions are subsequently transported in vesicles to the cell surface and released through exocytosis, thereby contributing to the generation of new virions able to infect host cells and promote human-to-human transmission (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>).</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>COVID-19 Disease</title>
      <sec>
        <title>Transmission</title>
        <p>According to the WHO, SARS-CoV-2 has killed more than 469,159 and infected over 8,974,795 individuals globally by June 23rd 2020. Hence, SARS-CoV-2 has a higher transmission rate compared to SARS-CoV in 2002&#x2013;2003, which infected 8,098 and killed more than 700 individuals. This may be the result of genetic recombination in the RBD of the S protein, thus enhancing the transmission ability of SARS-CoV-2 (<xref rid="B12" ref-type="bibr">12</xref>). For preventive strategies against SARS-CoV-2, it is important to determine the source of origin and transmission of the virus. The outbreak arose at the Huanan Seafood market in the city of Wuhan, China, and SARS-CoV-2 rapidly infected more than 50 individuals. At this market, which is now closed, live animals were frequently sold, e.g., bats, birds, frogs, rabbits, and snakes. Genomic analyses revealed similarities between SARS-CoV-2 and SARS-like bat viruses, hence bats are suspected to be reservoirs for SARS-CoV-2 (<xref rid="B1" ref-type="bibr">1</xref>). In another study, the origin of SARS-CoV-2 has been associated with Pangolin-CoV, because Pangolin-CoV was found to be 91.02 and 90.55% identical to SARS-CoV-2 and Bat-CoV, respectively (<xref rid="B22" ref-type="bibr">22</xref>). Close contact with these infected animal reservoirs is the major cause of animal-to-human SARS-CoV-2 transmission (<xref rid="B23" ref-type="bibr">23</xref>), which eventually leads to a rapid human-to-human transmission (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B24" ref-type="bibr">24</xref>). Respiratory droplets and contact transmission are considered as the main transmission routes for human-to-human transmission, and aerosol spread is suspected to be another important transmission route (<xref rid="B18" ref-type="bibr">18</xref>). The stability of SARS-CoV-2 on various surfaces has been investigated, indicating that aerosol and fomite transmission of SARS-CoV-2 is plausible, because the virus remains viable and infectious in aerosols for several hours and even up to days on surfaces (<xref rid="B25" ref-type="bibr">25</xref>). Pharyngeal virus shedding and active virus replication in the upper respiratory tract has been confirmed (<xref rid="B26" ref-type="bibr">26</xref>). Together, these findings stress the importance of good hand hygiene and the use of surgical masks as mitigation strategies against respiratory droplets to prevent SARS-CoV-2 transmission (<xref rid="B27" ref-type="bibr">27</xref>). Reports also indicate that SARS-CoV-2 may follow alternative transmission routes (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). Studies have shown a prolonged presence of SARS-CoV-2 viral RNA in fecal samples from infected patients. Urine and rectal swabs from children and adults have also been tested positive, even after negative nasopharyngeal tests, implying a risk of fecal-oral transmission (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>).</p>
      </sec>
      <sec>
        <title>Clinical Presentation</title>
        <p>Typical clinical symptoms of COVID-19 disease include fever, dry cough, dyspnea, headache, and pneumonia. The clinical features revealed by chest computed tomography (CT) present as pneumonia, however abnormal features, e.g., alveolar damage, acute respiratory distress syndrome (ARDS), acute cardiac injury, and incidence of ground-glass opacities have also been reported (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B30" ref-type="bibr">30</xref>). The symptoms of COVID-19 infection appear after an incubation period of ~5.2 days (<xref rid="B31" ref-type="bibr">31</xref>). The period from the onset of symptoms until death ranges from 6 to 41 days with a median of 14 days (<xref rid="B32" ref-type="bibr">32</xref>), depending on the age, immune system status, and care of the patient, and it has been shown to be shorter for patients above 70 years of age (<xref rid="B32" ref-type="bibr">32</xref>). The CT findings and COVID-19 symptoms show similarities to infection with other betacoronaviruses, i.e., SARS-CoV and MERS-CoV. In addition, COVID-19 patients develop gastrointestinal symptoms like diarrhea, emphasizing the importance of testing fecal and urine samples to exclude any potential alternative transmission route (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B33" ref-type="bibr">33</xref>). A recent review by the Chinese Center for Disease and Prevention including 72,314 cases of COVID-19 showed that &lt;1% of the cases represented children younger than 10 years of age (<xref rid="B34" ref-type="bibr">34</xref>).</p>
      </sec>
    </sec>
    <sec id="s4">
      <title>Immunopathology and Host Immune Response</title>
      <sec>
        <title>Innate Immune Response</title>
        <p>Currently, only limited data is available characterizing the innate immune response of patients against SARS-CoV-2. In one study from Wuhan, China, increased total numbers of neutrophils (38%), reduced total numbers of lymphocytes (35%), increased serum IL-6 levels (52%), and increased c-reactive protein levels (84%) were observed for 99 patients (<xref rid="B1" ref-type="bibr">1</xref>). In addition, a meta-analysis of six clinical studies conducted in China showed that the neutrophil-to-lymphocyte ratio was significantly increased in patients with severe COVID-19, whereas the lymphocyte-to-C-reactive ratio protein was significantly decreased (<xref rid="B35" ref-type="bibr">35</xref>). In a separate study, the numbers of T cells and CD8<sup>+</sup> T cells were significantly lower, while the number of NK cells was reduced considerably in patients with severe COVID-19, as compared to the numbers for individuals with mild disease (<xref rid="B36" ref-type="bibr">36</xref>). Furthermore, an exuberant increase of the plasma levels of interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1&#x3B1; (MIP-1&#x3B1;), and tumor necrosis factor alpha (TNF-&#x3B1;) was associated with disease deterioration and a fatal outcome [(<xref rid="B37" ref-type="bibr">37</xref>); <xref ref-type="fig" rid="F2">Figure 2</xref>]. These clinical features suggest a remarkably higher pro-inflammatory condition in the disease progression and severity than previously reported for SARS-CoV and MERS-CoV infection, suggesting a potential cytokine storm-mediated disease severity [(<xref rid="B38" ref-type="bibr">38</xref>); <xref ref-type="fig" rid="F2">Figure 2</xref>].</p>
        <fig id="F2" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Host immune response and immunopathology during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infects cells expressing the surface receptors angiotensin- converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2). SARS-CoV-2 dampens anti-viral type I IFN responses, which results in uncontrolled viral replication. Viral pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs) activate epithelial cells, endothelial cells, and tissue-resident macrophages to release proinflammatory cytokines and chemokines, including interleukin 6 (IL-6), IFN gamma-induced protein 10 (IP-10), IFN gamma (IFN-&#x3B3;), IL-2, IL-10, macrophage inflammatory protein 1&#x3B1; (MIP1&#x3B1;), MIP1&#x3B2;, monocyte chemoattractant protein 1 (MCP1), granulocyte colony-stimulating factor (G-CSF), and tumor necrosis factor alpha (TNF-&#x3B1;). Cytokine- and chemokine-activated macrophages and virus-infected dendritic cells mediate extensive production of additional cytokines and chemokines, which eventually initiates a so-called cytokine storm. Chemokines attract more inflammatory cells that migrate from the blood vessels into the lungs, and these cells intensify the cytokine storm by releasing additional proinflammatory chemokines and cytokines, hence establishing a proinflammatory feedback loop. The cytokines circulate to other organs via the blood, eventually causing multi-organ damage. The downstream production of the cytokines IL-6 and IL-1&#x3B2; recruits neutrophils and CD8<sup>+</sup> T cells, which not only control viral growth but also induce tissue damage, leading to alveolar flooding and consolidation (acute respiratory distress syndrome). IL-6 may recruit T-helper type 17 cells (Th17), which exacerbate inflammatory responses following activation. IL-6 also recruits follicular helper T cells (T<sub>FH</sub>) and B cells/plasma cells, which produce SARS-CoV-2-specific antibodies that may help virus neutralization. Alternatively, B cells produce non-neutralizing antibodies that enhance SARS-CoV-2 infection through antibody-dependent enhancement, which further exacerbate organ damage. Created with <ext-link ext-link-type="uri" xlink:href="https://www.Biorender.com">Biorender.com</ext-link>.</p>
          </caption>
          <graphic xlink:href="fimmu-11-01817-g0002"/>
        </fig>
        <p>Like SARS-CoV, SARS-CoV-2 exploits the receptor ACE2 to gain entry into cells. ACE2 is widely expressed in cardiopulmonary tissues and in hematopoietic cells, including monocytes and macrophages (<xref rid="B38" ref-type="bibr">38</xref>). To mount an antiviral response, innate immune cells recognize virus invasion by pathogen-associated molecular patterns (PAMPs), which in the case of RNA viruses is either viral genomic ssRNA or double-stranded RNA. This genomic RNA is recognized either by endosomal RNA receptors, including Toll-like receptor (TLR)-3 and TLR7, or by the cytosolic retinoid-inducible gene (RIG)/melanoma differentiation-associated gene 5 (MDA5) receptor (<xref rid="B39" ref-type="bibr">39</xref>). Following recognition, a downstream signaling cascade is activated, which in turn activates a number of transcription factors, i.e., nuclear factor &#x3BA;B (NF-&#x3BA;B), activator protein 1 (AP-1), IFN response factor 3 (IRF3), and IRF7, which is accompanied by their translocation into the nucleus. These transcription factors induce the expression of type I IFN (IFN-&#x3B1; and IFN-&#x3B2;) and pro-inflammatory cytokines, e.g., TNF and IL-1, and chemokines, e.g., C&#x2013;C motif chemokine ligand 2 and C-X-C motif chemokine ligand 8, which comprise the first line of anti-viral immune defense (<xref rid="B39" ref-type="bibr">39</xref>). The binding of IFN to the IFN&#x3B1;/&#x3B2; receptor activates the Janus kinase-signal transducer and activator of transcription 1 (JAK-STAT) pathway, which brings the receptor-associated kinases JAK1 and Tyk2 into close proximity, eventually resulting in phosphorylation of STAT1 and STAT2. STAT1/2 form complexes with IFN regulatory factor 9 (IRF9), which subsequently translocate into the nucleus to initiate transcription of IFN-stimulated genes (ISGs) (<xref rid="B39" ref-type="bibr">39</xref>). Induction of a type I IFN response may be sufficient to inhibit viral replication and dissemination in the early stage of viral infection (<xref rid="B40" ref-type="bibr">40</xref>). However, the production of type I IFN (IFN-&#x3B1; and IFN-&#x3B2;), which constitute key antiviral mediators, is inhibited in COVID-19 patients (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). Reportedly, coronaviruses have evolved several immune evasion mechanisms to restrict the early induction of type I IFN (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>).</p>
      </sec>
      <sec>
        <title>Adaptive Immune Response</title>
        <p>Neutralizing antibodies (nAbs) induced by virus infection play a crucial role in controlling viral infection. For SARS-CoV-2, nAbs limit the infection at a later phase and prevent re-infection upon a future encounter with the virus (<xref rid="B45" ref-type="bibr">45</xref>). Recently developed SARS-CoV- and MERS-CoV-specific nAbs target the S1-RBD, S1- N-terminal domain (NTD) and S2 region, respectively, and block protein-receptor interaction and interfere with viral entry into the host cell, hence inhibiting viral infection (<xref rid="B46" ref-type="bibr">46</xref>). However, no SARS-CoV-2-specific nAbs have been reported so far. SARS-CoV nAbs with potential cross-reactivity and/or cross-neutralizing activity against SARS-CoV-2 infection are currently being identified (<xref rid="B45" ref-type="bibr">45</xref>) because SARS-CoV-2 is closely related to SARS-CoV, and the S proteins of the two different viruses display high sequence identity (<xref rid="B1" ref-type="bibr">1</xref>). Encouragingly, recent studies show that nAbs from convalescent SARS patients can block SARS-CoV-2 from entering target cells <italic>in vitro</italic>, which suggests potential cross-protective epitopes between the two viruses (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B47" ref-type="bibr">47</xref>).</p>
        <p>T cell-mediated immune responses in SARS-CoV have been well-elucidated (<xref rid="B48" ref-type="bibr">48</xref>). Both CD4<sup>+</sup> and CD8<sup>+</sup> T-cells provide broad and long-term protection against coronavirus infections. CD4<sup>+</sup> T cells promote the proliferation of virus-specific antibodies by activating T-cell dependent B cells, whereas CD8<sup>+</sup> T cells are cytotoxic and kill virus-infected cells. In COVID-19 patients, a significant T cytopoenia was observed in circulating CD4<sup>+</sup> and CD8<sup>+</sup> T cells (<xref rid="B49" ref-type="bibr">49</xref>). Furthermore, a progressive increase in the PD-1<sup>+</sup>CD8<sup>+</sup> and Tim-3<sup>+</sup>CD8<sup>+</sup> subpopulation, which corresponds to exhausted T cells, was observed in symptomatic patients (<xref rid="B49" ref-type="bibr">49</xref>). In another study, the function of NK and CD8<sup>+</sup> T cells was exhausted with the increased expression of natural killer group 2 member A (NKG2A) in COVID-19 patients (<xref rid="B36" ref-type="bibr">36</xref>). Recently, the decreased T cell proportion in patients with severe COVID-19 was associated with a down-regulated gene expression related to Th17 cell activation and differentiation (<xref rid="B50" ref-type="bibr">50</xref>). In one study investigating samples from convalescent SARS-CoV infected patients, a higher magnitude of CD8<sup>+</sup> T cells, as compared to CD4<sup>+</sup> T cells, was observed. Both CD4<sup>+</sup> and CD8<sup>+</sup> T cells from patients with severe disease displayed a central memory phenotype, as compared to the cells from patients with mild disease. Strong T-cell responses correlated with high titers of nAbs, while a Th2 type cytokine response (IL-4, IL-5, and IL-10) was detected in patients with a fatal outcome (<xref rid="B51" ref-type="bibr">51</xref>). The strong evidence that a Th1 type immune response plays a significant role in clearing SARS-CoV and MERS-CoV infection applies presumably also for clearance of SARS-CoV-2 infection. A recent study reported SARS-CoV-2-specific CD4<sup>+</sup> T cells in all and CD8<sup>+</sup> T cell responses in most COVID-19 patients (<xref rid="B52" ref-type="bibr">52</xref>). Importantly, this study also identified SARS-CoV-2-reactive CD4<sup>+</sup> T cells in ~40&#x2013;60% of unexposed individuals, which suggests cross-reactive T cell recognition between circulating &#x201C;common cold&#x201D; coronaviruses and SARS-CoV-2.</p>
      </sec>
    </sec>
    <sec id="s5">
      <title>Animal Models</title>
      <p>Validated and predictive animal models represent important tools in the translation of vaccine candidates from bench to bedside because they help improving the understanding of disease biology and the requirements for developing of safe and efficacious vaccines. Validation of animal models is based on the criteria that animal models represent humans in terms of (i) comparable disease biology and clinical symptoms, i.e., face validity, (ii) displaying clinical interventions, which exhibit similar biological effect, i.e., predictive validity, and (iii) analogous function of the therapeutic target, i.e., target validity (<xref rid="B53" ref-type="bibr">53</xref>). An ideal animal model is immunocompetent and reproduces the typical features of human disease as closely as possible upon receiving a bio-relevant dose of challenge virus via an appropriate inoculation route (<xref rid="B54" ref-type="bibr">54</xref>).</p>
      <p>Models based on mice, which are easy to breed and handle, often represent the animal models of choice in biomedical research, and murine models would be relevant for COVID-19 vaccine research. However, wild-type mice are resistant to SARS-CoV-2 infection because murine ACE2 is significantly different from the human receptor (<xref rid="B1" ref-type="bibr">1</xref>). However, genetically modified heterozygous mice that express both the murine and the human ACE2 receptor have been developed and used for testing of novel vaccine candidates during the SARS-CoV outbreak (<xref rid="B55" ref-type="bibr">55</xref>). Compared to wild-type mice that display only mild symptoms, transgenic mice expressing the human ACE2 receptor develop clinical illness after SARS-CoV-2 infection, including weight loss and interstitial pneumonia, and viral antigens have been detected in their bronchial epithelial cells, alveolar macrophages, and alveolar epithelial cells (<xref rid="B56" ref-type="bibr">56</xref>). However, the expression of the human ACE2 receptor in transgenic mice is not physiological, and transgenic mice are currently not readily available for testing of SARS-CoV-2 vaccine candidates. ACE2 knockout mice have been used in ARDS and SARS research and may also be useful for studying ARDS associated with COVID-19 (<xref rid="B57" ref-type="bibr">57</xref>). Transmembrane serine protease 2 (TMPRSS2) knockout mice may also be useful for investigating COVID-19 pathogenesis because TMPRSS2 is involved in cellular SARS-CoV-2 entry (<xref rid="B58" ref-type="bibr">58</xref>). In addition, STAT1 knockout mice develop progressive lung disease, including diffuse interstitial pneumonia and spread to other systemic organs, hence they may be useful for studying disease pathogenesis (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B58" ref-type="bibr">58</xref>). Adaptation of SARS-CoV by serial passage in the lungs of BALB/c mice resulted in a virus (MA15) that was lethal for young mice following intranasal inoculation and was preceded by high viral titer in the lungs, viremia, and spreading of virus to other systemic organs (<xref rid="B59" ref-type="bibr">59</xref>). With the availability of mouse-adapted SARS-CoV-2 isolates, it is expected that inbred mice could be useful to study the disease and evaluate novel vaccine candidates and antiviral drugs (<xref rid="B60" ref-type="bibr">60</xref>). Young inbred mice, for example of the strains BALB/c, C57BL/6, and 129S6, support SARS-CoV replication, but without development of disease, and these strains may be useful for evaluating immune responses to COVID-19 infection and vaccines (<xref rid="B61" ref-type="bibr">61</xref>). On the other hand, old (12&#x2013;14 months) BALB/c mice exhibit patchy interstitial pneumonia following SARS-CoV infection, hence they can be used for COVID-19 research, especially to model the age-related higher mortality in humans (<xref rid="B62" ref-type="bibr">62</xref>). Aged C57BL/6 and 129S6 mice can also be used for these studies, but they exhibit lower viremia, as compared to BALB/c mice, following SARS infection (<xref rid="B63" ref-type="bibr">63</xref>). C57BL/6 mice have been used in SARS (<xref rid="B64" ref-type="bibr">64</xref>) and MERS (<xref rid="B65" ref-type="bibr">65</xref>) coronavirus-induced ARDS and can also be used for studying ARDS associated with COVID-19.</p>
      <p>Ferrets have been widely used as a model for studying several respiratory viruses (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>). Viral replication has been detected both in the upper and lower respiratory tract of ferrets after infection with influenza and SARS-CoV (<xref rid="B66" ref-type="bibr">66</xref>&#x2013;<xref rid="B68" ref-type="bibr">68</xref>). However, SARS-CoV-2 was found to replicate only in the nasal turbinate, soft palate, and tonsils of ferrets (<xref rid="B69" ref-type="bibr">69</xref>). SARS-CoV-2 can apparently also replicate in the digestive tract of ferrets, because viral RNA has been detected in the rectal swabs, but the virus was not detected in the lung lobes of ferrets, even after intratracheal inoculation (<xref rid="B69" ref-type="bibr">69</xref>). Between ferrets and humans, there is a difference of two amino acids in the segment of ACE2 to which SARS-CoV-2 first attaches (<xref rid="B69" ref-type="bibr">69</xref>), but the reason for the inability of SARS-CoV-2 to replicate in the lower respiratory tract of ferrets remains elusive. Despite this, the replication of SARS-CoV-2 in the ferret upper respiratory tract implies that ferrets represents an interesting animal model for evaluation of COVID-19 vaccine candidates.</p>
      <p>Golden Syrian hamster is another widely used experimental animal model, which supports replication of SARS-CoV (<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B70" ref-type="bibr">70</xref>) but not MERS-CoV, which uses the dipeptidyl peptidase&#x2212;4 protein for viral entry (<xref rid="B71" ref-type="bibr">71</xref>). Golden Syrian hamsters represent a suitable experimental animal model for SARS-CoV&#x2212;2 infection, because efficient viral replication takes place in the upper and lower respiratory epithelial cells, the animals display apparent clinical signs accompanied with weight loss, and high viral titers are found in the lungs and the intestine (<xref rid="B72" ref-type="bibr">72</xref>). Moreover, SARS-CoV-2 infection in Golden Syrian hamsters not only satisfies the Koch\'s postulates [(i) the pathogen must be present in every case of the disease, (ii) the pathogen must be isolated from the diseased host and grown in pure culture, (iii) the specific disease must be reproduced when a pure culture of the pathogen is inoculated into a healthy susceptible host, and (iv) the pathogen must be recoverable from the experimentally infected host] but also indicates virus transmission between challenged hamsters and na&#xEF;ve contact hamsters housed in the same cages (<xref rid="B72" ref-type="bibr">72</xref>). The differences in the susceptibility of mice and hamsters to SARS-CoV-2 infection are suggested to be related to the fact that in mice, 11 of the 29 amino acids present in the SARS-CoV-2 spike-contacting regions of ACE2 differ in the human ACE2 as compared to only four amino acids in hamster ACE2 (<xref rid="B72" ref-type="bibr">72</xref>). Nevertheless, in contrast to the large animal models and ACE2-transgenic mice, the Golden Syrian hamster model is easily available, physiologically relevant, and closely reflects COVID-19 infection, hence it represents a useful tool for studying the pathogenesis, treatment, and vaccines for COVID-19.</p>
      <p>Despite being expensive, not readily available, and difficult to handle, non-human primates (NHPs) often represent the last stage of animal testing before any drug or vaccine candidate can enter clinical trials. NHPs are the gatekeepers for clinical trials due to their close genetic relationship with humans. Among the NHPs, African greens, rhesus macaques, cynomolgus macaques, and marmosets are being studied for SARS-CoV-2 infection. In one study including eight cynomolgus macaques, four of the oldest macaques excreted virus from the nose and the throat without any clinical signs after SARS-CoV-2 infection (<xref rid="B73" ref-type="bibr">73</xref>). The virus was detected in type I and II pneumocytes and in ciliated epithelial cells of the nasal, bronchial, and bronchiolar mucosa (<xref rid="B73" ref-type="bibr">73</xref>). In another study, two rhesus macaques that recovered from SARS-CoV-2 infection were reinfected after confirmed recovery, but they did not shown any signs of COVID-19 4 weeks later (<xref rid="B74" ref-type="bibr">74</xref>). This finding suggests a possible protection following natural infection or vaccination against COVID-19. In another study, older rhesus macaques infected with SARS-CoV-2 exhibited more severe interstitial pneumonia than younger macaques (<xref rid="B75" ref-type="bibr">75</xref>). This age-related difference in the pathogenicity of SARS-CoV-2 in NHPs may be useful for evaluation of therapeutics and vaccines due to the close correlation to humans. In a recent study, rhesus macaques were rechallenged with SARS-CoV-2 and displayed a 5 log<sub>10</sub> reduction in the viral titers in the bronchoalveolar lavage and nasal mucosa, as compared to the primary infection, which suggests that the SARS-CoV-2 infection induces protective immunity against a subsequent exposure (<xref rid="B76" ref-type="bibr">76</xref>). Efforts are also underway to develop NHP models that can mimic the co-morbidities in COVID-19, e.g., hypertension and diabetes.</p>
    </sec>
    <sec id="s6">
      <title>Vaccine Platform Technologies</title>
      <p>In the past decades, a wide array of novel vaccine platform technologies has been developed, thanks to advances primarily in molecular biology and vaccinology. These platform technologies range from inactivation and targeted attenuation of live pathogens to the delivery of synthetic peptide antigens and recombinantly produced protein antigens, as well as virus-like particles (VLPs), non-replicating and replicating viral vectors, polysaccharide-protein conjugates, and nucleic acid-based (DNA and RNA) vaccines. The existing marketed vaccines against infectious diseases are based on many of these platform technologies (<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>). However, it is striking that all types of vaccine platform technologies are currently evaluated against COVID-19 in preclinical animal models (<xref ref-type="fig" rid="F3">Figure 3A</xref> and <xref rid="T1" ref-type="table">Table 1</xref>), and some of them have even progressed into clinical development (<xref ref-type="fig" rid="F3">Figure 3B</xref> and <xref rid="T2" ref-type="table">Table 2</xref>). This broad diversity increases the chances that at least a few of the candidates eventually will become approved and marketed.</p>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Examples of COVID-19 vaccine candidates in <bold>(A)</bold> preclinical (<italic>n</italic> = 62) and <bold>(B)</bold> clinical development (<italic>n</italic> = 15), grouped according to vaccine platform technology.</p>
        </caption>
        <graphic xlink:href="fimmu-11-01817-g0003"/>
      </fig>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Examples of COVID-19 vaccine candidates in preclinical development.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Vaccine platform</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Vaccine candidate/Information</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Developer</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Status</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Trial/Production site</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Link</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>Reference to the technology</bold>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" style="background-color:#bbbdc0" colspan="7" rowspan="1">
                <bold>INACTIVATED</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Formalin-inactivated</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Osaka University/BIKEN/National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing planned</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Osaka, Japan</td>
              <td valign="top" align="left" rowspan="1" colspan="1">WHO</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">SolaVAX: Chemically inactivated</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Colorado State University</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing ongoing</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Fort Collins, CO, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Colorado State University</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B81" ref-type="bibr">81</xref>&#x2013;<xref rid="B83" ref-type="bibr">83</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccine + CpG 1018 adjuvant</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Sinovac/Dynavax</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing planned</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Emeryville, CA, USA; Beijing, China</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Dynavax</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B84" ref-type="bibr">84</xref>&#x2013;<xref rid="B86" ref-type="bibr">86</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" style="background-color:#bbbdc0" colspan="7" rowspan="1">
                <bold>LIVE ATTENUATED</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Viral de-optimized live attenuated vaccine</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Codagenix/Serum Institute of India</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal test results from mice and primates in August 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Farmingdale, NY, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Codagenix</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B88" ref-type="bibr">88</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Attenuated measles virus</td>
              <td valign="top" align="left" rowspan="1" colspan="1">German Center for Infection Research (DZIF)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing in mice in Autumn 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Brunswick, Germany</td>
              <td valign="top" align="left" rowspan="1" colspan="1">DZIF</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B89" ref-type="bibr">89</xref>, <xref rid="B90" ref-type="bibr">90</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Attenuated measles virus</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Etna Biotech</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Catania, Italy</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Zydus Cadila</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B91" ref-type="bibr">91</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Codon de-optimization technology</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Griffith University/Indian Immunologicals</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Ongoing animal testing</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Brisbane, Australia; Hyderabad, India</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Indian Immunologicals</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td valign="top" align="left" style="background-color:#bbbdc0" colspan="7" rowspan="1">
                <bold>PROTEIN SUBUNIT</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Recombinant vaccine of SARS-CoV-2 S protein expressed in baculovirus system + pandemic adjuvant system (squalene, dl-&#x3B1;-tocopherol and polysorbate 80)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Sanofi Pasteur/GSK/Biomedical Advanced Research and Development Authority (BARDA)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate; clinical trial to begin between March and August 2021</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Lyon, France; Brentford, UK; Washington, DC, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Sanofi Pasteur</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B92" ref-type="bibr">92</xref>&#x2013;<xref rid="B95" ref-type="bibr">95</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Molecular clamp-stabilized S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Queensland/GSK/CSIRO/<break/>Viroclinics Xplore</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in July, 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Queensland, Australia; Brentford, UK; Canberra, Australia; Rotterdam, The Netherlands</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSK<break/> University of Queensland</td>
              <td valign="top" align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018176103">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018176103</ext-link>; (<xref rid="B96" ref-type="bibr">96</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">COVID-19 XWG-03: truncated S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSK/Xiamen Innovax Biotech Co., Ltd./Xiamen University</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Brentford, UK; Xiamen, Fujian, China</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSK</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B97" ref-type="bibr">97</xref>&#x2013;<xref rid="B99" ref-type="bibr">99</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">AJ Vaccines</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Copenhagen, Denmark</td>
              <td valign="top" align="left" rowspan="1" colspan="1">AJVaccines</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Walter Reed Army Institute of Research (WRAIR)/U Army Medical Institute of Infectious Diseases</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Ongoing animal testing</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Maryland, United States</td>
              <td valign="top" align="left" rowspan="1" colspan="1">WRAIR</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B101" ref-type="bibr">101</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">EpiVax/University of Georgia</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Providence, RI, USA; Athens, GA, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">EpiVax</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B102" ref-type="bibr">102</xref>&#x2013;<xref rid="B105" ref-type="bibr">105</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">VIDO-InterVac, University of Saskatchewan</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Ongoing animal testing</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Saskatoon, SK, Canada</td>
              <td valign="top" align="left" rowspan="1" colspan="1">VIDO-InterVac</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B106" ref-type="bibr">106</xref>, <xref rid="B107" ref-type="bibr">107</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Adjuvanted S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">National Institute of Infectious Disease</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Tokyo, Japan</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Japanese Agency for Medical Research and Development</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B108" ref-type="bibr">108</xref>, <xref rid="B109" ref-type="bibr">109</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">PittCoVacc: Microneedle arrays S1 subunit</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Pittsburgh</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in Summer, 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Pittsburgh, PA, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Pittsburgh</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B110" ref-type="bibr">110</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Recombinant protein, nanoparticles (based on S-protein and other epitopes)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Saint-Petersburg scientific research institute of vaccines and serums</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in 2021</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Saint-Petersburg, Russia</td>
              <td valign="top" align="left" rowspan="1" colspan="1">WHO</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Heat shock protein gp-96 backbone for multiple antigens</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Heat Biologics/University of Miami</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Morrisville, NC, USA; Miami, FL, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Heat Biologics</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B112" ref-type="bibr">112</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Receptor-binding domain (RBD) protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Baylor College of Medicine/Texas Children\'s Hospital</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Houston, TX, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Baylor College of Medicine</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B114" ref-type="bibr">114</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Adjuvanted RBD protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Biological E Ltd.</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Hyderabad, India</td>
              <td valign="top" align="left" rowspan="1" colspan="1">WHO</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">DPX-COVID-19: Oil-based formulation with peptides epitopes of S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">IMV Inc.</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in Summer 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Qu&#xE9;bec, Canada</td>
              <td valign="top" align="left" rowspan="1" colspan="1">IMV</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B115" ref-type="bibr">115</xref>, <xref rid="B116" ref-type="bibr">116</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Human signal peptide domain complexed with undisclosed SARS-CoV-2 protein(s) as vaccine</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Vaxil Bio Therapeutics</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate (identified by <italic>in silico</italic> analysis)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Ness Ziona, Israel</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Vaxi Bio Therapeutics</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B117" ref-type="bibr">117</xref>, <xref rid="B118" ref-type="bibr">118</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">FlowVax COVID-19: Peptide, dry powder for injection or nasal spray</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Flow Pharma Inc.</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NHP testing in April 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">East Palo Alto, CA, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Flow Pharma</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B120" ref-type="bibr">120</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Ii-Key hybrid peptide</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Generex/EpiVax</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in June, 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Toronto, Canada; Providence, RI, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">EpiVax</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B103" ref-type="bibr">103</xref>, <xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B122" ref-type="bibr">122</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Adjuvanted microsphere peptide</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Saskatchewan</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Ongoing animal testing</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Saskatoon, SK, Canada</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Saskatchewan</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B123" ref-type="bibr">123</xref>, <xref rid="B124" ref-type="bibr">124</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Synthetic long peptide vaccine candidate for S and M proteins</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OncoGen</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Timisoara, Romania</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OncoGen</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <ext-link ext-link-type="uri" xlink:href="https://www.preprints.org/manuscript/202002.0102/v1">https://www.preprints.org/manuscript/202002.0102/v1</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Recombinant <italic>Lactobacillus acidophilus</italic> expressing S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Colorado State University</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Fort Collins, CO, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Colorado State University</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B126" ref-type="bibr">126</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Drosophila S2 insect cell expression system virus-like particles (VLPs) (Split-protein conjugation system)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">ExpreS<sup>2</sup>ion/Adaptvac/<break/>University of Copenhagen</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in April, 2021</td>
              <td valign="top" align="left" rowspan="1" colspan="1">H&#xF8;rsholm, Denmark; Netherlands</td>
              <td valign="top" align="left" rowspan="1" colspan="1">ExpreS2ion/Adaptvac</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B127" ref-type="bibr">127</xref>&#x2013;<xref rid="B130" ref-type="bibr">130</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">IBIO-200: Subunit protein (Virus-Like Particle), plant produced</td>
              <td valign="top" align="left" rowspan="1" colspan="1">iBio/CC-Pharming</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Ongoing animal testing</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Bryan, TX, USA; Beijing, China</td>
              <td valign="top" align="left" rowspan="1" colspan="1">iBio</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B131" ref-type="bibr">131</xref>, <xref rid="B132" ref-type="bibr">132</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">VLP-recombinant protein administered with an adjuvant</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Osaka University/BIKEN/NIBIOHN</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Osaka, Japan</td>
              <td valign="top" align="left" rowspan="1" colspan="1">WHO</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td valign="top" align="left" style="background-color:#bbbdc0" colspan="7" rowspan="1">
                <bold>NON-REPLICATING VIRAL VECTOR</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Ad26 (alone or with MVA boost)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Janssen Pharmaceutical Companies (Johnson &amp; Johnson)/BARDA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in September 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">New Jersey, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Johnson &amp; Johnson</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B133" ref-type="bibr">133</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Modified Vaccinia Ankara encoded virus-like particles (MVA-VLP)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GeoVax/BravoVax</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Ongoing animal testing</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Atlanta, GA, United States; Wuhan, China</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GeoVax</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B134" ref-type="bibr">134</xref>, <xref rid="B135" ref-type="bibr">135</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">MVA-S encoded</td>
              <td valign="top" align="left" rowspan="1" colspan="1">DZIF&#x2014;German Center for Infection Research</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing in mice in Summer 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Brunswick, Germany</td>
              <td valign="top" align="left" rowspan="1" colspan="1">DZIF</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B136" ref-type="bibr">136</xref>, <xref rid="B137" ref-type="bibr">137</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">AdCOVID: Adenovirus-based NasoVAX expressing SARS2-CoV S protein; nasal spray</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Altimmune</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in quarter three of 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Maryland, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Altimmune</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253025/pdf/ofy209.162.pdf">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253025/pdf/ofy209.162.pdf</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Ad5 S (GREVAX&#x2122; platform)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Greffex</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing ongoing</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Houston, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Greffex</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 protein VLP produced in tobacco</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Medicago Inc.</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in Summer 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Quebec, Canada</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Medicago</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B139" ref-type="bibr">139</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Oral recombinant vaccine through adenovirus type 5 vector (Ad5)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Vaxart Inc.</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Preclinical; Phase I in second half of 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">San Francisco, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Vaxart</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B140" ref-type="bibr">140</xref>, <xref rid="B141" ref-type="bibr">141</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Adenovirus VLPs expressing SARS2-CoV S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Imophoron/University of Bristol</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing planned</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Bristol, UK</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Imophoron</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B142" ref-type="bibr">142</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Adenovirus vector expressing SARS2-CoV S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">ReiThera/LEUKOCARE/<break/>Univercells</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in Summer 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Rome, Italy; Munich, Germany; Brussels, Belgium</td>
              <td valign="top" align="left" rowspan="1" colspan="1">ReiThera</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B143" ref-type="bibr">143</xref>, <xref rid="B144" ref-type="bibr">144</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Parainfluenza virus 5 expressing S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Georgia/University of Iowa</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing ongoing</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Athens, GA, USA; Iowa City, IA, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Georgia</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B145" ref-type="bibr">145</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" style="background-color:#bbbdc0" colspan="7" rowspan="1">
                <bold>REPLICATING VIRAL VECTOR</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Measles vector</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Institute Pasteur/Themis/University of Pittsburg Center for Vaccine Research</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing planned</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Paris, France; Vienna, Austria; Pittsburgh, PA, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Themis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B146" ref-type="bibr">146</xref>, <xref rid="B147" ref-type="bibr">147</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">TNX-1800: Horsepox vector expressing S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Tonix Pharma/Southern Research</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing planned</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Birmingham, AL, USA; New York, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Tonix Pharma</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B148" ref-type="bibr">148</xref>, <xref rid="B149" ref-type="bibr">149</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Vesicular stomatitis virus (VSV) vector expressing S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">International AIDS Vaccine Initiative (IAVI)/Batavia Biosciences</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing ongoing</td>
              <td valign="top" align="left" rowspan="1" colspan="1">New York, USA; Leiden, The Netherlands</td>
              <td valign="top" align="left" rowspan="1" colspan="1">IAVI</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B150" ref-type="bibr">150</xref>, <xref rid="B151" ref-type="bibr">151</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Influenza vector expressing RBD</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Hong Kong</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in July 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Hong Kong</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Hong Kong</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B152" ref-type="bibr">152</xref>, <xref rid="B153" ref-type="bibr">153</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">CoroFlu: Influenza virus expressing S protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Wisconsin Madison/ FluGen/Bharat Biotech</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in Fall 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Madison, WI, United States; Hyderabad, India</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Wisconsin Madison</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B154" ref-type="bibr">154</xref>, <xref rid="B155" ref-type="bibr">155</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" style="background-color:#bbbdc0" colspan="7" rowspan="1">
                <bold>DNA</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">DNA plasmid vaccine (electroporation)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Zydus Cadila</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Ahmedabad, India</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Zydus Cadila</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Four linear DNA-based vaccine candidates</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Takis/Applied DNA Sciences/Evvivax</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Preclinical testing in Autumn 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Stony Brook, USA; Rome, Italy</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Evvivax</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B156" ref-type="bibr">156</xref>, <xref rid="B157" ref-type="bibr">157</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">DNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Osaka University/AnGes/Takara Bio</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing in April 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Tokyo, Japan</td>
              <td valign="top" align="left" rowspan="1" colspan="1">AnGes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B158" ref-type="bibr">158</xref>, <xref rid="B159" ref-type="bibr">159</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">DNA with electroporation</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Karolinska Institute/Cobra Biologics</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Staffordshire, UK; Stockholm, Sweden</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Cobra Biologics</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B160" ref-type="bibr">160</xref>, <xref rid="B161" ref-type="bibr">161</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Plasmid DNA, needle-free delivery</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet, Inc.</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing ongoing</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Rockville, MD, USA; Providence, RI, USA; Golden, CL, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Immunomix</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B103" ref-type="bibr">103</xref>, <xref rid="B162" ref-type="bibr">162</xref>, <xref rid="B163" ref-type="bibr">163</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">DNA, nasal delivery</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Waterloo</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Waterloo, ON, Canada</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Waterloo</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B164" ref-type="bibr">164</xref>, <xref rid="B165" ref-type="bibr">165</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" style="background-color:#bbbdc0" colspan="7" rowspan="1">
                <bold>RNA</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">RNAoptimizer&#xAE; technology</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CureVac</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in June 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Tubingen, Germany</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CureVac</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">BIOCAD</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing in April 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">St. Petersburg, Russia</td>
              <td valign="top" align="left" rowspan="1" colspan="1">BIOCAD</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Lipid nanoparticle (LNP)-encapsulated mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">China CDC/Tongji University/Stermirna Therapeutics</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in April 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Beijing, China</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Xinhuanet.com</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">LNP-encapsulated mRNA cocktail encoding VLP and LNP-encapsulated mRNA encoding RBD</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Fudan University, Shanghai JiaoTong University, and RNACure Biopharma</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing ongoing</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Shanghai, China</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Fudan University</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <ext-link ext-link-type="uri" xlink:href="http://chinaxiv.org/abs/202002.00070">http://chinaxiv.org/abs/202002.00070</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">LNP-encapsulated saRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Imperial College London</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in June 2020</td>
              <td valign="top" align="left" rowspan="1" colspan="1">UK</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Imperial College London</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B166" ref-type="bibr">166</xref>, <xref rid="B167" ref-type="bibr">167</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">LNP-encapsulated saRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Arcturus Therapeutics/Duke-National University of Singapore</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing ongoing</td>
              <td valign="top" align="left" rowspan="1" colspan="1">San Diego, USA; Singapore</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Arcturus Therapeutics</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B168" ref-type="bibr">168</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA for intranasal delivery</td>
              <td valign="top" align="left" rowspan="1" colspan="1">eTheRNA Immunotherapies/EpiVax/<break/>Nexelis, REPROCELL/Centre for the Evaluation of Vaccination</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical testing in early 2021</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Niel, Belgium</td>
              <td valign="top" align="left" rowspan="1" colspan="1">eTheRNA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B169" ref-type="bibr">169</xref>, <xref rid="B170" ref-type="bibr">170</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Sanofi Pasteur/Translate Bio</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal testing planned</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Lyon, France; Lexington, MA, United States</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Sanofi Pasteur</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B171" ref-type="bibr">171</xref>, <xref rid="B172" ref-type="bibr">172</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Replication defective SARS-CoV-2 derived RNAs</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Centro Nacional Biotecnolog&#xED;a (CNB-CSIC)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Madrid, Spain</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CNB-CSIC</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B174" ref-type="bibr">174</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">LNP-encapsulated mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Tokyo/Daiichi-Sankyo</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Advancing preclinical candidate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Tokyo, Japan</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Daiichi-Sankyo</td>
              <td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B175" ref-type="bibr">175</xref>)</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="T2" position="float">
        <label>Table 2</label>
        <caption>
          <p>COVID-19 vaccine candidates in clinical trials.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Study title</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Vaccine</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Sponsor</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Location</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Status</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>Phase</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Primary outcome</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Study identifier</bold>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection; Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA-1273</td>
              <td valign="top" align="left" rowspan="1" colspan="1">National Institute of Allergy and Infectious Diseases (NIAID)/Moderna Therapeutics</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Washington, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">I; II</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Relevant safety outcomes (12 months follow up); Adverse events (28 days post-vaccination); SARS-CoV-2-specific binding antibody (through 1 year after the final dose)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04283461; NCT04405076</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Immunity and Safety of Covid-19 Synthetic Minigene Vaccine</td>
              <td valign="top" align="left" rowspan="1" colspan="1">LV-SMENP-DC vaccine and antigen-specific CTLs</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Shenzhen Geno-Immune Medical Institute</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Guangdong, China</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">I/II</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical improvement based on a 7-point scale (28 days after randomization); Lower Murray lung injury score (7 days after randomization)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04276896</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Safety and Immunity of Covid-19 aAPC Vaccine</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Pathogen-specific aAPC</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Shenzhen Geno-Immune Medical Institute</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Guangdong, China</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">I</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Frequency of vaccine events; Frequency of serious vaccine events; Proportion of subjects with positive T cell response</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04299724</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">A Phase I Clinical Trial in 18-60 Adults (APICTH); A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV); Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CanSino Biologics Inc./Institute of Biotechnology, China</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Hubei, China; Halifax, Canada</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recruiting/Active, not recruiting; Not yet recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">I/II</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Adverse reactions 0&#x2013;7 days post-vaccination. Adverse reactions (0&#x2013;14 days post-vaccination); IgG and neutralizing antibodies (28 days post-vaccination); Adverse reactions (0&#x2013;6 and 0&#x2013;28 days and 6 months after post-vaccination)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04313127/<break/>ChiCTR2000030906; NCT04341389; NCT04398147</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">A Study of a Candidate COVID-19 Vaccine (COV001) and Investigating a Vaccine Against COVID-19</td>
              <td valign="top" align="left" rowspan="1" colspan="1">ChAdOx1 nCoV-19</td>
              <td valign="top" align="left" rowspan="1" colspan="1">University of Oxford/Advent Srl</td>
              <td valign="top" align="left" rowspan="1" colspan="1">UK</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Not yet recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">I/II and II/III</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Efficacy, safety, and immunogenicity (6 months); Efficacy and safety (6 months)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04324606 and NCT04400838</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19</td>
              <td valign="top" align="left" rowspan="1" colspan="1">bacTRL-Spike (orally)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Symvivo Corporation</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Canada</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Not yet recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">I</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Frequency of adverse events (up to 12 months post-vaccination)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04334980</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers</td>
              <td valign="top" align="left" rowspan="1" colspan="1">INO-4800 administered intradermally</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Inovio Pharmaceuticals</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Missouri and Pennsylvania, USA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">I</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Adverse events, injection site reactions, antigen-specific binding antibody titers and, IFN-&#x3B3; responses (baseline up to week 28)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04336410</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Safety and Immunogenicity Study of 2019-nCoV Vaccine (Inactivated) for Prophylaxis SARS CoV-2 Infection (COVID-19); Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Inactivated SARS-CoV-2</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Sinovac Biotech Co., Ltd.</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Jiangsu, China; Hebei, China</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recruiting; Not yet recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">I/II</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Safety indexes of adverse reactions; Immunogenicity indexes of neutralizing-antibody seroconversion rates (up to 28 days after the whole schedule vaccination) Seroconversion rates of neutralizing antibody (30th day after the 2nd dose)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04352608; NCT04383574</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults; A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults</td>
              <td valign="top" align="left" rowspan="1" colspan="1">BNT162 (BNT162a1, BNT162b1, BNT162b2) (Prime/Boost), BNT162c2 (Single Dose)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">BioNTech RNA Pharmaceuticals GmbH and Pfizer</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Mainz, Germany; Berlin, Germany</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recruiting; Recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">I/II</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Solicited local reactions at the injection; Solicited systemic reactions (up to 7 &#xB1; 1 day after each immunization); Treatment-emergent adverse event (up to 21 &#xB1; 2 day after prime immunization and 28 &#xB1; 4 days after boost immunization)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04368728; NCT04380701</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant</td>
              <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 rS and Matrix-M Adjuvant</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Novavax</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Victoria and Queensland, Australia</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Not yet recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">I</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Solicited adverse events (28 days); Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) (35 days)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04368988</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">SCB-2019 as COVID-19 Vaccine</td>
              <td valign="top" align="left" rowspan="1" colspan="1">SCB-2019 with or without AS03 or CpG 1018 + Alum</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clover Biopharmaceuticals AUS Pty Ltd.</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Australia</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Not yet recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">I</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Solicited adverse events (7 days after the first or second vaccination); Antibody Titers (Day 1 to Day 184)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04405908</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recombinant chimeric COVID-19 epitope DC vaccine</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Shenzhen Third People\'s Hospital</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Guangdong, China</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">I/II</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Duration of disease; Antipyretic rate; Severe rate</td>
              <td valign="top" align="left" rowspan="1" colspan="1">ChiCTR2000030750</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Adenovirus type 5 vector vaccine</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Jiangsu Provincial Center for Disease Control and Prevention</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Jiangsu, China</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Not yet recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">II</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Adverse reactions 0&#x2013;14 days post-vaccination; Anti-SARS-CoV-2 neutralizing antibody titer on day 28 post-vaccination</td>
              <td valign="top" align="left" rowspan="1" colspan="1">ChiCTR2000031781</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Inactivated</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Wuhan Institute of Biological Products Co., Ltd.</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Wuhan, Hubei, China</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Not yet recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">I/II</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Incidence of adverse reactions/events (up to 7 days); Four-fold growth rate and antibody level, and cellular immunity (up to 90, 180, and 360 days)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">ChiCTR2000031809</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">A phase I/II clinical trial for inactivated novel coronavirus (2019-CoV) vaccine (Vero cells)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Inactivated</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Beijing Institute of Biological Products Co., Ltd.</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Beijing, China</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td>
              <td valign="top" align="center" rowspan="1" colspan="1">I/II</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Incidence of adverse reactions/events (up to 7 days); Four-fold growth rate and antibody level (up to 28 days); Cellular immunity (Up to 28, 180, and 360 days)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">ChiCTR2000032459</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p><italic>aAPC, artificial antigen-presenting cell; COVID-19, coronavirus disease 2019; CTLs, cytotoxic T lymphocytes; DC, dendritic cell; LNP, lipid nanoparticle; mRNA, messenger RNA; nCoV, novel coronavirus; SARS-CoV-2, SARS coronavirus 2; S protein, SARS-CoV-2 spike protein. Sources: Chinese Clinical Trial Register website (<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn">www.chictr.org.cn</ext-link>); <ext-link ext-link-type="uri" xlink:href="https://www.ClinicalTrials.gov">ClinicalTrials.gov</ext-link> website (<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>); EU Clinical Trials Register (<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrialsregister.eu">www.clinicaltrialsregister.eu</ext-link>)</italic>.</p>
        </table-wrap-foot>
      </table-wrap>
      <sec>
        <title>Inactivated Vaccines</title>
        <p>Many approved vaccines are so-called inactivated vaccines based on inactivated pathogens, including the vaccines against polio, typhoid, cholera, plague, pertussis, and influenza. A few COVID-19 vaccine candidates based on this well-established technology are evaluated in preclinical studies [(<xref rid="B79" ref-type="bibr">79</xref>&#x2013;<xref rid="B81" ref-type="bibr">81</xref>); <xref rid="T1" ref-type="table">Table 1</xref>]. This includes a formalin-inactivated COVID-19 vaccine candidate developed by Osaka University, Japan similar to their previous formalin-inactivated West Nile virus vaccine (<xref rid="B79" ref-type="bibr">79</xref>), which was found to be protective in mice and immunogenic in NHPs (<xref rid="B80" ref-type="bibr">80</xref>). Researchers at Colorado State University (Fort Collins, CO, USA) are developing an inactivated virus vaccine for COVID-19 (SolaVAX), which is based on an existing technology platform for pathogen inactivation in blood products including the use of ultraviolet light and riboflavin to inactivate the virus by targeted damage of nucleic acids while preserving the integrity of proteins and viral antigens (<xref rid="B81" ref-type="bibr">81</xref>, <xref rid="B82" ref-type="bibr">82</xref>). This strategy has been shown to be efficient for inactivating MERS-CoV (<xref rid="B83" ref-type="bibr">83</xref>). Sinovac Biotech (Beijing, China) in collaboration with Dynavax (Emeryville, CA, USA) will evaluate the combination of Sinovac\'s chemically inactivated COVID-19 vaccine candidate (<xref rid="B86" ref-type="bibr">86</xref>) with Dynavax\'s advanced adjuvant CpG 1018 (<xref rid="B84" ref-type="bibr">84</xref>, <xref rid="B85" ref-type="bibr">85</xref>). Sinovac is also testing their chemically-inactivated whole SARS-CoV-2 virus particles (PiCoVacc) developed in VERO monkey cells and the adjuvant alum (<xref rid="B86" ref-type="bibr">86</xref>) in phase I/II clinical trials (<xref rid="T2" ref-type="table">Table 2</xref>). PiCoVacc induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and NHPs and conferred complete protection in NHPs against SARS-CoV-2 (<xref rid="B86" ref-type="bibr">86</xref>). Using the same platform technology, candidate vaccines against influenza (<xref rid="B176" ref-type="bibr">176</xref>) and SARS (<xref rid="B177" ref-type="bibr">177</xref>) where shown to be safe and immunogenicity in phase I clinical trials. Wuhan Institute of Biological Products (Wuhan, China) and Beijing Institute of Biological Products (Beijing, China) are testing their vaccine candidates, which have been prepared by growing the SARS-CoV-2 in the VERO monkey cell line and inactivated with chemicals [(<xref rid="B19" ref-type="bibr">19</xref>); <xref rid="T2" ref-type="table">Table 2</xref>]. The development of conventional inactivated vaccines requires the cultivation of high titers of infectious virus, which in the case of SARS-CoV-2 has to take place in biosafety level 3 facilities, which is of major safety concern. Moreover, incomplete virus inactivation constitutes a potential risk to vaccine production workers and may also cause disease outbreaks in vaccinated populations and induce harmful immune or inflammatory responses.</p>
      </sec>
      <sec>
        <title>Live Attenuated Vaccines</title>
        <p>Live attenuation of pathogens is yet another conventional vaccine technology, which is exploited for at least four novel COVID-19 vaccine candidates (<xref rid="T1" ref-type="table">Table 1</xref>). Live attenuated vaccines against several viruses have been commercialized, including influenza virus, rotavirus, polio virus, yellow fever virus, and measles virus. A live-attenuated vaccine has several advantages, including inducing an immune response against several different antigens of the virus and the possibility for scale-up for mass production. Codagenix (Farmingdale, NY, USA) and the Serum Institute of India (Pune, India) are co-developing a live-attenuated vaccine candidate against SARS-CoV-2 using rational, computer-aided gene design and chemical synthesis through a process referred to as <italic>viral gene deoptimization</italic> (<xref rid="B87" ref-type="bibr">87</xref>). A vaccine against respiratory syncytial virus designed using this technique has previously been shown to induce protective immunity in NHPs (<xref rid="B88" ref-type="bibr">88</xref>). The German Center for Infection Research (DZIF, Braunschweig, Germany) and Zydus Cadila (Etna Biotech, Ahmedabad, India) are developing a live attenuated recombinant measles virus (rMV) vectored vaccine against COVID-19. Using rMV, Etna Biotech has demonstrated the ability of a live attenuated human papillomavirus virus (HPV) vaccine to induce nAbs in NHPs (<xref rid="B91" ref-type="bibr">91</xref>), while DZIF has shown protection against infection with MERS-CoV (<xref rid="B89" ref-type="bibr">89</xref>) and Zika virus (<xref rid="B90" ref-type="bibr">90</xref>) in mice using this platform. Indian Immunologicals (Hyderabad, India) in collaboration with Griffith University (Brisbane, Australia) is exploiting the codon de-optimization technology to develop a live attenuated COVID-19 vaccine. Although live attenuated vaccines that target respiratory viral infections have been approved for use in humans, the fact that the virus is excreted in the feces of SARS-CoV-2-infected individuals (<xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B179" ref-type="bibr">179</xref>) generate concern that a live attenuated SARS-CoV-2 vaccine strain may also be excreted in the feces and can potentially transmit to unvaccinated individuals. Yet another potential matter of concern is the risk of recombination of a live attenuated vaccine virus with wild-type CoV.</p>
      </sec>
      <sec>
        <title>Subunit Vaccines</title>
        <p>Subunit vaccines are based on synthetic peptide(s) or recombinant protein(s) of the target pathogen. Several approved vaccines are subunit vaccines, for example vaccines against HPV, hepatitis B virus and influenza virus. Unlike inactivated viruses, live attenuated viruses, and virus-vectored vaccines, subunit vaccines only contain specific viral antigenic fragments and do not include any additional components of the pathogenic viruses. Therefore, this approach eliminates the concerns of incomplete viral inactivation, virulence recovery, and pre-existing anti-vector immunity (<xref rid="B180" ref-type="bibr">180</xref>). Hence, subunit vaccines are generally considered very safe. In addition, subunit vaccines can specifically target well-characterized neutralizing antigenic epitopes and, in combination with adjuvants, improve immunogenicity, and/or efficacy (<xref rid="B180" ref-type="bibr">180</xref>). Because the S protein of SARS-CoV-2 plays a vital role in receptor binding and membrane fusion, vaccines targeting the S protein are suggested to be capable of inducing antibodies that can neutralize virus infection by blocking virus binding and fusion (<xref rid="B181" ref-type="bibr">181</xref>). Therefore, the S protein constitutes a major target antigen for SARS-CoV-2 subunit vaccine candidates (<xref rid="T1" ref-type="table">Table 1</xref>). However, in addition to the full-length S protein and its antigenic fragments, the S1 subunit, NTD, RBD, and the S2 subunit may also be important antigen targets for the development of subunit vaccines (<xref rid="B20" ref-type="bibr">20</xref>). Sanofi Pasteur (Lyon, France) and GlaxoSmithKline (GSK, London, UK) are developing a COVID-19 subunit vaccine candidate, where Sanofi contributes with an S-protein antigen, which is based on recombinant DNA technology using a baculovirus expression platform (<xref rid="B92" ref-type="bibr">92</xref>, <xref rid="B93" ref-type="bibr">93</xref>). Using this platform, Sanofi has licensed a recombinant influenza vaccine in the USA (<xref rid="B93" ref-type="bibr">93</xref>). GSK contributes with a pandemic adjuvant technology based on the Adjuvant System 03 (AS03) comprising of squalene, dl-&#x3B1;-tocopherol, and polysorbate 80 (<xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B95" ref-type="bibr">95</xref>). GSK is also testing their adjuvant in collaboration with Clover Biopharmaceuticals, University of Queensland (Brisbane, Australia), and Xiamen Innovax Biotech (Xiamen, China). Utilizing its patented Trimer-Tag&#xA9; technology, Clover Biopharmaceuticals has developed a SARS-CoV-2 S-Trimer subunit vaccine candidate SCB-2019 that resembles the native trimeric viral spike (<xref rid="B182" ref-type="bibr">182</xref>, <xref rid="B183" ref-type="bibr">183</xref>). SCB-2019 is in phase I clinical testing with AS03 (<xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B95" ref-type="bibr">95</xref>) or CpG 1018 and alum adjuvants [(<xref rid="B84" ref-type="bibr">84</xref>, <xref rid="B85" ref-type="bibr">85</xref>); <xref rid="T2" ref-type="table">Table 2</xref>]. Researchers at the University of Queensland are using the patented <italic>molecular clamp</italic> technology, which involves synthesizing a protein and subsequently clamping it onto virus-infected cells (<xref rid="B184" ref-type="bibr">184</xref>) as shown previously against flaviviruses (<xref rid="B96" ref-type="bibr">96</xref>). Molecular clamp-stabilized S protein will be combined with GSK adjuvants. COVID-19 XWG-03 is a preclinical vaccine candidate developed by Xiamen University (Xiamen, China) and Xiamen Innovax Biotech using the GSK adjuvant AS04 (monophosphoryl lipid A and aluminum hydroxide) (<xref rid="B97" ref-type="bibr">97</xref>). COVID-19 XWG-03 is based on a series of truncated S proteins, which will be screened in combination with AS04. Xiamen Innovax Biotech has previously developed similar <italic>Escherichia coli</italic>-produced subunit vaccines against HPV (<xref rid="B98" ref-type="bibr">98</xref>) and hepatitis E (<xref rid="B99" ref-type="bibr">99</xref>) in humans. The Walter Reed Army Institute of Research (Silver Spring, MD, USA) is also targeting the S protein and has previously demonstrated efficacy of a MERS-CoV S1-protein subunit vaccine in mice and NHPs (<xref rid="B100" ref-type="bibr">100</xref>), as well as in camels and alpacas (<xref rid="B101" ref-type="bibr">101</xref>). EpiVax (Providence, RI, USA) is exploiting the proprietary iVAX toolkit that comprises a suite of immunoinformatics algorithms for sorting candidate antigens, selecting immunogenic and conserved T cell epitopes, and eliminating regulatory T-cell epitopes (<xref rid="B102" ref-type="bibr">102</xref>&#x2013;<xref rid="B104" ref-type="bibr">104</xref>). The optimized S-protein antigens will be tested for immunogenicity and protection against a SARS-CoV-2 challenge in collaboration with University of Georgia (Athens, GA, USA), which has previously tested the platform against influenza (<xref rid="B105" ref-type="bibr">105</xref>). Vaccine and Infectious Disease Organization&#x2014;International Vaccine Centre (VIDO-InterVac, University of Saskatchewan, Saskatoon, Canada) is developing an S protein subunit vaccine based on prior experience with testing of a MERS-CoV vaccine candidate in NHPs (<xref rid="B106" ref-type="bibr">106</xref>, <xref rid="B107" ref-type="bibr">107</xref>). The National Institute of Infectious Disease (Tokyo, Japan) is aiming at developing a new vaccine by combining an undisclosed adjuvant and an antigen using recombinant protein synthesis as previously demonstrated against influenza virus H5N1 (<xref rid="B108" ref-type="bibr">108</xref>, <xref rid="B109" ref-type="bibr">109</xref>). PittCoVacc is a subunit vaccine candidate from University of Pittsburgh (Pittsburgh, PA, USA) that is based on a microneedle array (MNA) embedded SARS-CoV-2 S1 protein, which was recently found to elicit strong antigen-specific antibody responses for up to 2 weeks in mice (<xref rid="B110" ref-type="bibr">110</xref>). This MNA platform is currently tested in clinical trials against cutaneous T-cell lymphoma (<italic>ClinicalTrials.gov Identifier: NCT02192021</italic>). The COVID-19 vaccine candidate of Heat Biologics (Morrisville, NC, USA) is based on its secreted heat shock protein chaperone gp96 platform and has been shown to induce protection against simian immunodeficiency virus (SIV) in NHPs (<xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B112" ref-type="bibr">112</xref>). Vaccine researchers at Baylor College of Medicine and Texas Children\'s Hospital (both Houston, TX, USA) are using their experience with developing a SARS vaccine antigen consisting of the RBD of the SARS-CoV S protein to develop a similar vaccine against SARS-CoV-2 (<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B114" ref-type="bibr">114</xref>).</p>
        <p>In addition to vaccines based on full protein, several vaccine developers are investigating peptides antigens as vaccine candidates against COVID-19. IMV Inc. (Qu&#xE9;bec, Canada) is developing a vaccine candidate based on the IMV\'s DPX delivery technology and incorporating peptides targeting S protein epitopes of SARS-Cov-2 as shown previously for respiratory syncytial virus (RSV) (<xref rid="B115" ref-type="bibr">115</xref>) and anthrax (<xref rid="B116" ref-type="bibr">116</xref>). Vaxil Bio Therapeutics (Toronto, Ontario, Canada) is using the proprietary bioinformatic approach VaxHit&#x2122; to identify signal peptide domains of SARS-CoV-2 proteins as shown for mucin 1 tumor-associated antigen in mice (<xref rid="B117" ref-type="bibr">117</xref>) and in multiple myeloma patients (<xref rid="B118" ref-type="bibr">118</xref>). FlowVax COVID-19 is a candidate vaccine from Flow Pharma (Palo Alto, CA, USA) consisting of an adjuvanted, thermostable, and biodegradable peptide-loaded microsphere vaccine targeting the SARS-CoV-2 nucleocapsid. Flow Pharma has developed and tested a Zika virus vaccine candidate that induces cytotoxic T cell (CTL) responses in mice (<xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B120" ref-type="bibr">120</xref>). Generex Biotechnology (Toronto, Canada) is using EpiVax\'s computational tools to predict epitopes that can be used to generate peptide-based COVID-19 vaccines using the patented NuGenerex Immuno-Oncology Ii-Key technology (NGIO). NGIO technology has been used to develop peptide-based vaccine candidates, which have been tested against a HPV16+ cancer model in mice (<xref rid="B121" ref-type="bibr">121</xref>) and prostate cancer in humans (<xref rid="B122" ref-type="bibr">122</xref>). University of Saskatchewan\'s VIDO-InterVac is developing a peptide-based, microsphere-adjuvanted COVID-19 vaccine candidate using a combination adjuvant platform (TriAdj) (<xref rid="B123" ref-type="bibr">123</xref>) comprising of a TLR agonist (either polyinosinic-polycytidylic acid or CpG oligodeoxynucleotides), a host defense peptide, and polyphosphazene. TriAdj has been used to generate vaccine-induced protective immunity against several infectious diseases in animals and humans (<xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B185" ref-type="bibr">185</xref>). Colorado State University is developing a novel oral COVID-19 vaccine candidate using recombinant <italic>Lactobacillus acidophilus</italic> expressing the viral S protein. This platform has been shown to induce Th1 and Th17 responses against HIV-1 epitopes in mice after oral administration (<xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B126" ref-type="bibr">126</xref>). ExpreS<sup>2</sup>ion Biotechnology (H&#xF8;rsholm, Denmark), Adaptvac (H&#xF8;rsholm, Denmark), and University of Copenhagen is applying a <italic>Drosophila melanogaster</italic> Schneider 2 stable cell line expression system expressing VLPs to generate a novel vaccine candidate as previously used for malaria in human clinical trials (<xref rid="B127" ref-type="bibr">127</xref>, <xref rid="B128" ref-type="bibr">128</xref>). They are utilizing this split-protein conjugation technology to generate stable isopeptide-bound antigen-VLP complexes by mixing antigen and VLP components. The technology has been demonstrated to induce broadly nAbs specific for HIV-1 V3 glycan in mice and macaques (<xref rid="B129" ref-type="bibr">129</xref>), and it has been used to develop a combinatorial HPV and placental malaria vaccine (<xref rid="B130" ref-type="bibr">130</xref>). iBio (Newark, DE, USA) in partnership with CC-Pharming (Beijing, China) is working on iBIO-200, which is a COVID-19 candidate vaccine based on Agrobacterium-mediated transient protein production in tobacco (Nicotiana benthamiana) plants and has been used for delivering recombinant proteins into mammalian cells (<xref rid="B131" ref-type="bibr">131</xref>) and for generating strong virus-specific nAb responses in animals (<xref rid="B132" ref-type="bibr">132</xref>).</p>
        <p>Novavax (Gaithersburg, MD, USA) with support from the Coalition for Epidemic Preparedness Innovations (CEPI, Oslo, Norway), is clinically testing their COVID-19 subunit vaccine candidate prepared using the proprietary Sf9/baculovirus recombinant technology platform to generate S protein antigens as done previously for an RSV vaccine candidate (<xref rid="B186" ref-type="bibr">186</xref>). The protein antigens have been combined with a saponin-based Matrix-M&#x2122; adjuvant [(<xref rid="B187" ref-type="bibr">187</xref>); <xref rid="T2" ref-type="table">Table 2</xref>]. A subunit-based vaccine candidate from Shenzhen Third People\'s Hospital (Guangdong, China) in phase I/II testing is aimed at evaluating the effectiveness and safety of the recombinant chimeric COVID-19 epitope DC vaccine in the treatment of SARS-CoV-2-induced pneumonia.</p>
      </sec>
      <sec>
        <title>Non-replicating Viral Vector Vaccines</title>
        <p>Viral vectors are used to deliver vaccine antigens to the target cells or tissues. A wide variety of replicating and non-replicating viral vectors are available. Adenoviruses and poxviruses represent examples of viral vectors, of which both replicating and non-replicating forms are available. Vectors designed primarily as replication-defective or non-replicating viral vectors include adeno-associated virus, alphavirus, and herpesvirus, while replicating vectors include measles virus, vesicular stomatitis virus, poliovirus, and yellow fever virus. Several of the non-replicating viral vector-based COVID-19 vaccine candidates in preclinical testing are based on adenovirus vectors (<xref rid="T1" ref-type="table">Table 1</xref>). Janssen (Johnson &amp; Johnson, Leiden, The Netherlands) is using the AdVac&#xAE; technology (based on adenovirus type 26) alone or in combination with the MVA-BN&#xAE; technology based on a Modified Vaccinia Ankara (MVA) virus from Bavarian Nordic A/S (Hellerup, Denmark) as a prime-boost immunization approach against COVID-19. The adenovirus type 26 vector was demonstrated to mediate protection against SIV in NHPs (<xref rid="B76" ref-type="bibr">76</xref>) and immunogenicity against Ebola virus in clinical phase I testing (<xref rid="B133" ref-type="bibr">133</xref>). Vaxart (South San Francisco, CA, USA) initiated a project to develop a COVID-19 vaccine based on the VAAST<sup>TM</sup> platform, which contains an adenovirus 5 vector and a TLR3 adjuvant, and it is designed as enteric-coated vaccine tablets that release the vector in the small intestine for targeted immune activation, as previously shown for an oral influenza candidate vaccine (<xref rid="B140" ref-type="bibr">140</xref>, <xref rid="B141" ref-type="bibr">141</xref>). Imophoron\'s (Bristol, UK) in collaboration with University of Bristol (Bristol, UK) is using the ADDomer vaccine platform, which is an adenovirus-derived multimeric protein-based self-assembling nanoparticle scaffold engineered to facilitate plug-and-play display of multiple immunogenic epitopes from pathogens, and it has been tested against Chikungunya infection (<xref rid="B142" ref-type="bibr">142</xref>). ReiThera (Rome, Italy), LEUKOCARE (Munich, Germany), and Univercells (Brussels, Belgium) are developing a vaccine candidate based on ReiThera\'s simian adenoviral vector with strong immunological potency (<xref rid="B143" ref-type="bibr">143</xref>, <xref rid="B144" ref-type="bibr">144</xref>) and Univercells\'s NevoLine&#x2122; biomanufacturing platform for scale up. GeoVax\'s (Atlanta, GE, USA) MVA platform technology has the advantage of being a live replication-competent vector in avian cells for manufacturing, yet replication-deficient in mammalian cells upon vaccination, and it was found to protect against Lassa fever virus in mice (<xref rid="B134" ref-type="bibr">134</xref>) and Ebola virus in NHPs (<xref rid="B135" ref-type="bibr">135</xref>). The DZIF is also developing a COVID-19 vaccine candidate based on MVA as a viral vector for the SARS-CoV-2 S protein, and protective efficacy against MERS infection has previously been demonstrated in mice (<xref rid="B136" ref-type="bibr">136</xref>) and camels (<xref rid="B137" ref-type="bibr">137</xref>). Medicago (Uppsala, Sweden) is using SARS-CoV-2 protein VLPs produced in tobacco (<italic>Nicotiana Benthamiana</italic>) to generate cellular and humoral immunity, as shown previously against influenza in clinical testing (<xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B139" ref-type="bibr">139</xref>). University of Georgia (Athens, GA, USA) in collaboration with University of Iowa (Iowa city, IA, USA) is developing a vaccine candidate using a parainfluenza virus 5 vector that encodes the S protein of SARS-CoV-2. Using this vector, a similar vaccine has been developed against MERS-CoV, which was protective in mice (<xref rid="B145" ref-type="bibr">145</xref>).</p>
        <p>LV-SMENP-DC and pathogen-specific artificial antigen-presenting cell (aAPC) are the two lentiviral vector-based vaccine candidates in clinical trials from Shenzhen Geno-Immune Medical Institute (Guangdong, China) (<xref rid="T2" ref-type="table">Table 2</xref>). For the LV-SMENP-DC vaccine, an efficient lentiviral vector system (NHP/TYF) is used to express SARS-CoV-2 minigenes, engineered based on multiple viral genes, into viral proteins and immune-modulatory genes to modify DCs and to activate T cells (<xref rid="B188" ref-type="bibr">188</xref>, <xref rid="B189" ref-type="bibr">189</xref>). In a similar strategy, a lentiviral vector system is used to express viral proteins and immune modulatory proteins to modify aAPC and to activate T cells (<xref rid="B190" ref-type="bibr">190</xref>). ChAdOx1 nCoV-19, developed by University of Oxford (Oxford, UK) and manufactured by Advent Srl (Pomezia, Italy), consists of an attenuated chimpanzee adenovirus capable of producing the S protein of SARS-CoV-2, and it is expected to induce antibodies against these proteins in SARS-CoV-2. The ChAdOx1 viral vector was shown to elicit nAbs and cellular immune responses in mice against human MERS-CoV (<xref rid="B191" ref-type="bibr">191</xref>). Another non-replicating viral vector-based vaccine candidate in clinical trials has been developed by CanSino Biologics (Hubei, China) and is based on a recombinant adenovirus type 5 vector (<xref rid="B192" ref-type="bibr">192</xref>).</p>
      </sec>
      <sec>
        <title>Replicating Viral Vector Vaccines</title>
        <p>Measles virus, influenza virus, vesicular stomatitis virus, and horse pox virus, respectively, are used as replicating viral vector platforms to develop novel COVID-19 vaccine candidates (<xref rid="T1" ref-type="table">Table 1</xref>). Institut Pasteur (Paris, France) is exploiting their measles vaccine vector technology and has developed vaccine candidates against chikungunya (<xref rid="B146" ref-type="bibr">146</xref>) and MERS (<xref rid="B147" ref-type="bibr">147</xref>) based on this technology. Tonix Pharmaceuticals (New York, NY, USA) in collaboration with Southern Research (Birmingham, Alabama, USA) is developing TNX-1800, which is a live modified horsepox virus designed to express the S protein of SARS-CoV-2, and it is based on Tonix\'s biodefense vaccines against small pox and monkey pox (<xref rid="B148" ref-type="bibr">148</xref>, <xref rid="B149" ref-type="bibr">149</xref>). The International AIDS Vaccine Initiative (IAVI, New York, NY, USA) is exploiting a recombinant vesicular stomatitis virus (rVSV) vector against COVID-19 and has demonstrated efficacy of rVSV-vectored vaccines against SIV in NHPs (<xref rid="B150" ref-type="bibr">150</xref>) and Ebola virus in humans (<xref rid="B151" ref-type="bibr">151</xref>). CEPI is partnering with The University of Hong Kong (Hong Kong, China) to develop a COVID-19 vaccine candidate based on a live-attenuated influenza vaccine platform (<xref rid="B152" ref-type="bibr">152</xref>, <xref rid="B153" ref-type="bibr">153</xref>). The University of Wisconsin&#x2013;Madison (Madison, WI, USA) and the vaccine companies FluGen (Madison, WI, USA) and Bharat Biotech (Hyderabad, India) have initiated the development and testing of the vaccine candidate CoroFlu that builds on the backbone of FluGen\'s flu vaccine candidate known as M2SR, which is a self-limiting version of the influenza virus in which gene sequences of SARS-CoV-2 are inserted to induce additional immunity against coronavirus (<xref rid="B154" ref-type="bibr">154</xref>, <xref rid="B155" ref-type="bibr">155</xref>). Although several viral vector-based COVID-19 vaccine candidates are in preclinical as well as clinical development, several drawbacks are associated with the use of viral vectors to deliver genetic material to cells. First, the viral vector itself can induce an immune response in the body (<xref rid="B193" ref-type="bibr">193</xref>). Second, if a vaccine fails during clinical testing, the same viral vector cannot be reused in the patient because it can induce an immune response. Third, pre-existing immunity against the viral vector can render a vaccine ineffective (<xref rid="B193" ref-type="bibr">193</xref>). However, pre-existing immunity can be challenged by priming with a non-viral DNA vaccine (<xref rid="B194" ref-type="bibr">194</xref>) or by increasing the vaccine dose or changing the administration route (<xref rid="B195" ref-type="bibr">195</xref>). Other potential issues with viral vectors, e.g., low transgenic expression and genetic toxicity, can be overcome by using hybrid viral vectors (<xref rid="B196" ref-type="bibr">196</xref>).</p>
      </sec>
      <sec>
        <title>DNA Vaccines</title>
        <p>This type of vaccine contains selected gene(s) of the virus in the form of DNA. Upon injection, the DNA is used as template for <italic>in situ</italic> expression of potentially harmless viral protein(s), which induces a protective immune response. One of the greatest advantage of this type of vaccine is the safety and scalability for mass production. DNA-based viral vaccines have been shown to induce strong immune responses in animal models, especially in mice (<xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B197" ref-type="bibr">197</xref>&#x2013;<xref rid="B199" ref-type="bibr">199</xref>). However, there is limited positive clinical data on DNA-based viral vaccines in humans, and no commercial DNA vaccine against any disease has yet been approved. Nevertheless, several DNA vaccine candidates are tested preclinically (<xref ref-type="fig" rid="F3">Figure 3A</xref>) and two candidates have progressed into phase I clinical testing (<xref ref-type="fig" rid="F3">Figure 3B</xref>). Zydus Cadila (Ahmedabad, India) is developing a DNA vaccine against the S protein of SARS-CoV-2 based on an indigenously developed plasmid DNA delivery technology (<xref rid="B19" ref-type="bibr">19</xref>). Evvivax (Rome, Italy) collaborates with Applied DNA Sciences (Stony Brook, NY, USA) and Takis Biotech (Rome, Italy) to develop four linear DNA-based vaccine candidates. Evvivax utilizes viral or plasmid DNA vectors for <italic>in vivo</italic> delivery of an expression cassette carrying the coding region of the target gene in combination with the electro-gene-transfer technology from Takis Biotech (heterologous prime/boost) (<xref rid="B156" ref-type="bibr">156</xref>, <xref rid="B157" ref-type="bibr">157</xref>). AnGes Inc. (Osaka, Japan) in partnership with Osaka University is developing a DNA-based COVID-19 vaccine candidate based on a hepatocyte growth factor plasmid, which has been used to develop a therapeutic DNA vaccine against hypertension (<xref rid="B158" ref-type="bibr">158</xref>, <xref rid="B159" ref-type="bibr">159</xref>). Cobra Biologics (Newcastle, UK) and Karolinska Institutet (Stockholm, Sweden) are developing a DNA vaccine candidate, which is based on Cobra\'s ORT&#xAE; (Operator-Repressor Titration) technology for producing plasmid DNA without antibiotics, antibiotic resistance genes or any other selectable marker genes (<xref rid="B160" ref-type="bibr">160</xref>, <xref rid="B161" ref-type="bibr">161</xref>). These vaccine strategies all involve DNA administration by conventional intramuscular immunization. However, Immunomic Therapeutics (Rockville, MD, USA) is working with EpiVax and PharmaJet (Golden, CO, USA) to develop a DNA vaccine that is delivered intradermally using a needle-free injection system. This partnership will combine platform technologies from all three companies: Immunomic\'s (Rockville, MD, USA) UNiversal Intracellular Targeted Expression (UNITE) platform (<xref rid="B162" ref-type="bibr">162</xref>), EpiVax\'s <italic>in silico</italic> T-cell epitope prediction tool (<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B103" ref-type="bibr">103</xref>), and PharmaJet\'s Tropis&#xAE; needle-free injection system that accurately targets delivery to the intradermal tissue layer (<xref rid="B163" ref-type="bibr">163</xref>). Immunomic\'s UNITE platform involves fusing pathogenic antigens with lysosomal-associated membrane protein, which is an endogenous protein in humans, for enhanced MHC-II processing and MHC-I cross presentation and subsequent induction of both Th1 and CD8<sup>+</sup> T cell responses (<xref rid="B162" ref-type="bibr">162</xref>). Researchers at the University of Waterloo (Waterloo, ON, Canada) are developing a DNA-based vaccine that is administered using a nasal spray. They will use a lambda bacteriophage system for delivering DNA into target cells (<xref rid="B164" ref-type="bibr">164</xref>, <xref rid="B165" ref-type="bibr">165</xref>), which them produce SARS-CoV-2 VLPs that stimulate an immune response.</p>
        <p>Among DNA vaccine candidates in clinical testing, bacTRL-Spike developed by Symvivo Corporation (Burnaby, Canada) is based on the bacTRL platform technology, which is a genetically modified live cell probiotic bacteria-based gene delivery platform (<xref rid="B200" ref-type="bibr">200</xref>). Each oral dose of bacTRL-Spike contains live <italic>Bifidobacterium longum</italic>, which has been genetically engineered to deliver plasmids containing synthetic DNA encoding the S protein of SARS-CoV-2. INO-4800 developed by Inovio Pharmaceuticals (Pennsylvania, USA) involves intradermal plasmid delivery directly into cells using INOVIO\'s proprietary hand-held device called CELLECTRA&#xAE; 2000 (<xref rid="B201" ref-type="bibr">201</xref>, <xref rid="B202" ref-type="bibr">202</xref>). The principle of CELLECTRA&#xAE; 2000 is to use a brief electrical pulse to reversibly open small pores in the cell membrane to allow plasmid entry (<xref rid="B203" ref-type="bibr">203</xref>).</p>
      </sec>
      <sec>
        <title>RNA Vaccines</title>
        <p>Similar to DNA vaccines, RNA vaccines contain selected genes of the virus in the form of mRNA, and following cytosolic delivery, these genes are translated into viral proteins. The mRNA-1273 from Moderna Therapeutics (Cambridge, MA, USA) is the first candidate vaccine that entered into Phase I clinical testing just 42 days after the sequencing of the full SARS-CoV-2 genome (<italic>ClinicalTrials.gov identifier NCT04283461</italic>) (<xref rid="T2" ref-type="table">Table 2</xref>). The mRNA-1273 has recently entered into phase II clinical testing (<italic>ClinicalTrials.gov identifier NCT04405076</italic>). mRNA-1273 is a novel LNP-encapsulated, mRNA-based vaccine that encodes the full-length, prefusion-stabilized S protein of SARS-CoV-2. This LNP-based technology platform has previously been shown to induce strong immune responses and protection against a number of different pathogens in preclinical studies (<xref rid="B204" ref-type="bibr">204</xref>, <xref rid="B205" ref-type="bibr">205</xref>). In addition, the LNP technology was approved in 2018 for siRNA delivery as part of the product Patisiran (Onpattro, Alnylam Pharmaceuticals, Cambridge, MA, USA), which inhibits hepatocyte expression of transthyretin in patients with hereditary transthyretin-mediated amyloidosis (<xref rid="B206" ref-type="bibr">206</xref>). The mRNA-based vaccine candidate program BNT162 of BioNTech\'s (Mainz, Germany), which is developed jointly with Pfizer, is based on BioNTech\'s extensive experience with developing mRNA-based therapeutics, in particular against cancer, using customized mRNA molecules and intracellular delivery systems (<xref rid="B207" ref-type="bibr">207</xref>&#x2013;<xref rid="B209" ref-type="bibr">209</xref>). BNT162 comprises of four vaccine candidates, each of which represent different mRNA formats and target antigens (S and RBD), and they are formulated using the LNP delivery system. Two candidates include nucleoside-modified mRNA (modRNA), one includes a uridine-containing mRNA (uRNA), and the fourth vaccine candidate is based on saRNA. CureVac (T&#xFC;bingen, Germany) is exploiting the propriety RNAoptimizer&#xAE; platform technology for developing a novel COVID-19 vaccine candidate (<xref rid="T1" ref-type="table">Table 1</xref>). BIOCAD (Saint-Petersburg, Russia) is designing an mRNA vaccine against SARS-COV-2 based on previous experience with mRNA-based cancer vaccines (<xref rid="B19" ref-type="bibr">19</xref>). The mRNA COVID-19 vaccine candidate co-developed by the Chinese Center for Disease Control and Prevention (Beijing, China), Tongji University School of Medicine (Shanghai, China), and Stermirna Therapeutics (Shanghai, China) is based on Stermirna\'s mRNA synthesis and lipopolyplex nano-delivery platform (<xref rid="B19" ref-type="bibr">19</xref>). Fudan University (Fudan, China), in cooperation with Shanghai JiaoTong University (Shanghai, China), and RNACure Biopharma (Shanghai, China), is pursuing two different strategies to develop mRNA vaccines against COVID-19. The first strategy includes an mRNA encoding the RBD of the S protein to induce nAbs (<xref rid="B19" ref-type="bibr">19</xref>), while the second strategy includes an mRNA that instructs the host to produce VLPs (<xref rid="B19" ref-type="bibr">19</xref>). Imperial College London (London, UK) is developing an mRNA COVID-19 vaccine based on prior work with lipid nanoparticle (LNP)-encapsulated self-amplifying RNA, which has previously been shown to induce antibodies against the HIV-1 Env gp140 (<xref rid="B166" ref-type="bibr">166</xref>, <xref rid="B167" ref-type="bibr">167</xref>). Arcturus Therapeutics (San Diego, CA, USA) in collaboration with Duke National University of Singapore (Singapore) is developing a vaccine candidate using its STARR&#x2122; (self-transcribing and replicating RNA) technology platform that combines self-replicating RNA with the nanoparticle delivery system LUNAR&#xAE; into a single solution for <italic>in situ</italic> expression of SARS-CoV-2 proteins that induce an anti-viral immune response (<xref rid="B168" ref-type="bibr">168</xref>). eTheRNA Immunotherapies (Niel, Belgium) is developing a novel vaccine using the proprietary TriMix technology platform (<xref rid="B169" ref-type="bibr">169</xref>, <xref rid="B170" ref-type="bibr">170</xref>). The TriMix platform comprises three different mRNAs encoding proteins (caTLR4, CD40L, and CD70) that stimulates dendritic cells (DCs) to activate strong CD4<sup>+</sup> and CD8 T<sup>+</sup> cell responses, and it was shown to induce immunogenic responses in preclinical (<xref rid="B169" ref-type="bibr">169</xref>) and clinical studies (<xref rid="B170" ref-type="bibr">170</xref>) of an mRNA-based melanoma vaccine. Sanofi Pasteur and Translate Bio (Lexington, MA, USA) are collaborating to develop a novel mRNA vaccine based on Translate Bio\'s proprietary mRNA therapeutic platform (MRT<sup>TM</sup>). This platform includes the design of the desired mRNA sequences and then packaging them into delivery systems (<xref rid="B171" ref-type="bibr">171</xref>), and it has been shown to induce therapeutic antibodies against human epidermal growth factor receptor 2-positive tumors in humanized mice (<xref rid="B172" ref-type="bibr">172</xref>). Centro Nacional de Biotecnolog&#xED;a (Madrid, Spain) is developing an mRNA COVID-19 vaccine candidate based on the highly attenuated poxvirus vector MVA expressing the S protein, which has previously been tested as a vector for vaccine candidates against Zika and Ebola viruses (<xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B174" ref-type="bibr">174</xref>). Daiichi Sankyo (Tokyo, Japan) is developing an mRNA vaccine encoding the S protein using their novel nucleic acid delivery technology based on LNPs, and the protective effects of the vaccine will be verified in animal models in partnership with University of Tokyo (Tokyo, Japan) (<xref rid="B175" ref-type="bibr">175</xref>).</p>
      </sec>
      <sec>
        <title>Repurposed Vaccines</title>
        <p>Bacillus Calmette&#x2013;Gu&#xE9;rin (BCG), which is a live attenuated vaccine that was developed against tuberculosis, has been reported to decrease the susceptibility to respiratory tract infections (<xref rid="B210" ref-type="bibr">210</xref>, <xref rid="B211" ref-type="bibr">211</xref>) through reprogramming of innate immunity (<xref rid="B212" ref-type="bibr">212</xref>). Currently, there is no evidence that the BCG vaccine affords protection against COVID-19. However, several phase III and IV clinical trials are investigating if the BCG vaccine can help to boost the immune system and reduce the infection rate of SARS-CoV-2 (<italic>ClinicalTrials.gov identifier NCT04327206, NCT04348370, NCT04350931, NCT04362124, NCT04369794</italic>, and <italic>EU Clinical Trials Register 2020-001591-15, 020-001678-31</italic>) or reduce absenteeism among healthcare workers involved in COVID-19 patient care (<italic>NCT04328441</italic> and <italic>NCT04373291</italic>). One phase I trial in China is testing the effect of inhalation of inactivated <italic>Mycobacterium vaccae</italic> on protection against COVID-19 (<italic>Chinese Clinical Trials Register ChiCTR2000030016</italic>).</p>
      </sec>
    </sec>
    <sec id="s7">
      <title>Vaccine Manufacture</title>
      <p>Vaccine development and manufacture of sufficient doses to induce herd immunity is one of the most challenging tasks within biopharmaceutical enterprises due to the complexity of the products. The most basic requirements for manufacturing vaccines in a way that is safe, effective yet consistent from batch to batch are difficult to implement. A number of variables dictate the outcome of vaccine production processes, including (i) the biological variability of the starting material, (ii) the pathogen, (iii) the environmental conditions during culture, (iv) the expertise of the manufacturing personnel, and (v) multiple steps during the purification process. In addition to these variables, the analytical methods used and the antigens produced during manufacturing often have high intrinsic variability. Scale up and safety of vaccine formulations are equally important for maintaining a successful production process. Therefore, improved technologies to streamline vaccine development and manufacturing are crucial. During the past decades, multiple novel platforms have been developed for producing vaccines at pandemic speed, including VLPs, viral vector-based vaccines, and nucleic acid-based vaccines. Each platform has its own advantages and challenges related to its ability to induce potent immune responses, manufacturing capacity, and safety for clinical use (<xref rid="T3" ref-type="table">Table 3</xref>). Therefore, it is unlikely that any single platform on its own will constitute a solution for the ongoing COVID-19 pandemic or a pandemic situation in the future (<xref rid="B213" ref-type="bibr">213</xref>).</p>
      <table-wrap id="T3" position="float">
        <label>Table 3</label>
        <caption>
          <p>Vaccine platform technologies used for developing vaccines against COVID-19.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Platform</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Antigen type</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Immune response</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Advantages</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Disadvantages</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Response time in pandemics</bold>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Inactivated (egg-based)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Inactivated pathogen</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Humoral Cellular</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Over 70 years of experience<break/> Potent<break/> Simple formulation</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Labor-intensive<break/> Difficult to manufacture in a short time<break/> Stringent quality control</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Low</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Live attenuated</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Attenuated pathogen</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Humoral<break/> Cellular</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Potent<break/> Multivalent by nature<break/> Simple formulation<break/> No adjuvants required</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Labor-intensive<break/> Difficult to manufacture in a short time<break/> Stringent quality control<break/> Risk for infection</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Low</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Subunit/Recombinant protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Humoral</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Non-infectious<break/> Less side effects</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Labor-intensive<break/> New production process and stability assays for each new antigen<break/> Quality control<break/> Cold chain transfer and storage<break/> Need for adjuvants</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Medium</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Virus-like particles (VLPs)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Humoral</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Non-infectious<break/> Potent</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Stability<break/> Quality control<break/> Potential contaminants<break/> Assembly into stable particles<break/> Heterogeneity<break/> Cold chain transfer and storage</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Medium</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Viral vectors</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Nucleic acid</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Humoral<break/> Cellular</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Potent<break/> No need for an adjuvant<break/> Antigens are expressed natively</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recombination of virus during production<break/> Contaminants from human- or animal-derived material<break/> Pre-existing immunity against the vector</td>
              <td valign="top" align="left" rowspan="1" colspan="1">High</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Nucleic acid</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Humoral<break/> Cellular</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Room temperature storage<break/> Rapid large-scale production<break/> Options for multivalency<break/> Cell-free<break/> No contaminants<break/> Non-infectious</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Weak immunogenicity in humans<break/> Risk of carcinogenesis due to potential genetic integration<break/> Difficult to scale up to g-kg scale<break/> Purity<break/> High concentration</td>
              <td valign="top" align="left" rowspan="1" colspan="1">High</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Nucleic acid</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Humoral<break/> Cellular</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Room temperature storage<break/> Ease of large-scale production Options for multivalency<break/> Cell free<break/> No contaminants<break/> Non-infectious<break/> No genome integration risk<break/> No anti-vector immunity</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Scale up of mRNA synthesis<break/> Stability<break/> Stringent RNase-free environment<break/> Relatively higher cost<break/> Risk of adverse reaction<break/> Inflammation</td>
              <td valign="top" align="left" rowspan="1" colspan="1">High</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="s8">
      <title>Concluding Remarks</title>
      <p>Currently, SARS-CoV-2 is spreading and posing a considerable economic and public health concern globally. It is urgent to design and develop safe and efficacious vaccines to prevent further spread of COVID-19 and establish vaccine-induced herd immunity. The development of transforming vaccine technology platforms over the past few decades has broadened the scope and shortened the time from pathogen identification to the deployment of vaccine candidates for clinical testing. The global COVID-19 vaccine pipeline is currently expanding on a daily basis, and radical rethinking of vaccine development and manufacturing processes may substantially improve our responses to the COVID-19 pandemic. The knowledge generated through vaccine development efforts for closely related coronavirus strains, e.g., SARS and MERS, are used to direct the vaccine development efforts for COVID-19. Although inducing nAbs against the S proteins represents the main target for the majority of the vaccine candidates, the prospects of exploiting T and B cell responses for COVID-19 vaccination should also be considered, because these responses have been found to be persistent and protective in animal models. In addition, strategies worth further investigation include (i) vaccine potentiation with adjuvants, (ii) tailoring of S protein, (iii) targeting RBD and N proteins, (iv) mucosal immunization, and (v) the employment of unchartered vaccine platforms for reducing vaccine development time and costs, and/or for improving vaccine safety and efficacy. The lack of naturally acquired immunity against SARS-CoV-2 should not be considered a bottleneck in developing efficacious vaccines against COVID-19, because this was disproved for vaccination against now eradicated smallpox. Also, research efforts should be directed toward studying SARS-CoV-2 infection in appropriate animal models to analyze (i) viral replication, (ii) transmission, (iii) pathogenesis, and (iv) host immune responses, as well as (v) the effect of serious underlying medical conditions like hypertension and diabetes. To date, no mRNA vaccines have been licensed for human use. However, important lessons from the current advancement of the mRNA vaccine platform technology for COVID-19, which takes place at an unprecedented pace, may benefit the development of any target vaccine in the future, because the technology implies a significantly reduced overall time from target identification to regulatory approval and deployment of the vaccine. Collectively, the broad array of platform technologies under investigation in the development and manufacture of novel vaccines against SARS-CoV-2 will hopefully result in one or a few safe and efficacious novel COVID-19 vaccines that can bring us closer to the goal of COVID-19 herd immunity.</p>
    </sec>
    <sec id="s9">
      <title>Author Contributions</title>
      <p>LF, YZ, and AT wrote the review article. CF and AT critically revised all versions of the article. All authors contributed to the article and approved the submitted version.</p>
    </sec>
    <sec id="s10">
      <title>Conflict of Interest</title>
      <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="financial-disclosure">
        <p><bold>Funding.</bold> We gratefully acknowledge the financial support from the Independent Research Fund, Denmark, Technology and Production Sciences (Grant No. 9041-00198B). The funder had no role in literature search, decision to publish, or preparation of the article.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>XG</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source>Nature.</source> (<year>2020</year>) <volume>579</volume>:<fpage>270</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munster</surname><given-names>VJ</given-names></name><name><surname>Koopmans</surname><given-names>M</given-names></name><name><surname>van Doremalen</surname><given-names>N</given-names></name><name><surname>van Riel</surname><given-names>D</given-names></name><name><surname>de Wit</surname><given-names>E</given-names></name></person-group>. <article-title>A novel coronavirus emerging in China - key questions for impact assessment</article-title>. <source>N Engl J Med.</source> (<year>2020</year>) <volume>382</volume>:<fpage>692</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMp2000929</pub-id><pub-id pub-id-type="pmid">31978293</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group>. <source>Coronavirus Disease 2019 (COVID-19): Situation Report, 155. 2020</source>. (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200623-covid-19-sitrep-155.pdf?sfvrsn=ca01ebe_2">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200623-covid-19-sitrep-155.pdf?sfvrsn=ca01ebe_2</ext-link> (accessed June 23, 2020).</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>DS</given-names></name><name><surname>Azhar</surname><given-names>EI</given-names></name><name><surname>Madani</surname><given-names>TA</given-names></name><name><surname>Ntoumi</surname><given-names>F</given-names></name><name><surname>Kock</surname><given-names>R</given-names></name><name><surname>Dar</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China</article-title>. <source>Int J Infect Dis.</source> (<year>2020</year>) <volume>91</volume>:<fpage>264</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.01.009</pub-id><pub-id pub-id-type="pmid">31953166</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwood</surname><given-names>B</given-names></name></person-group>. <article-title>The contribution of vaccination to global health: past, present and future</article-title>. <source>Philos Trans R Soc Lond B Biol Sci.</source> (<year>2014</year>) <volume>369</volume>:<fpage>20130433</fpage>. <pub-id pub-id-type="doi">10.1098/rstb.2013.0433</pub-id><pub-id pub-id-type="pmid">24821919</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group>
<source>Immunization Coverage</source>. (<year>2019</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/en/news-room/fact-sheets/detail/immunization-coverage">https://www.who.int/en/news-room/fact-sheets/detail/immunization-coverage</ext-link> (accessed June 23, 2020).</mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallory</surname><given-names>ML</given-names></name><name><surname>Lindesmith</surname><given-names>LC</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group>. <article-title>Vaccination-induced herd immunity: successes and challenges</article-title>. <source>J Allergy Clin Immunol.</source> (<year>2018</year>) <volume>142</volume>:<fpage>64</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2018.05.007</pub-id><pub-id pub-id-type="pmid">29803799</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plans</surname><given-names>P</given-names></name><name><surname>Torner</surname><given-names>N</given-names></name><name><surname>Godoy</surname><given-names>P</given-names></name><name><surname>Jane</surname><given-names>M</given-names></name></person-group>. <article-title>Lack of herd immunity against measles in individuals aged &lt;35 years could explain re-emergence of measles in Catalonia (Spain)</article-title>. <source>Int J Infect Dis.</source> (<year>2014</year>) <volume>18</volume>:<fpage>81</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2013.09.015</pub-id><pub-id pub-id-type="pmid">24211476</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwok</surname><given-names>KO</given-names></name><name><surname>Lai</surname><given-names>F</given-names></name><name><surname>Wei</surname><given-names>WI</given-names></name><name><surname>Wong</surname><given-names>SYS</given-names></name><name><surname>Tang</surname><given-names>JWT</given-names></name></person-group>. <article-title>Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries</article-title>. <source>J Infect.</source> (<year>2020</year>) <volume>80</volume>:<fpage>e32</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.027</pub-id><pub-id pub-id-type="pmid">32209383</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>TS</given-names></name><name><surname>Liu</surname><given-names>DX</given-names></name></person-group>. <article-title>Human coronavirus: host-pathogen interaction</article-title>. <source>Annu Rev Microbiol.</source> (<year>2019</year>) <volume>73</volume>:<fpage>529</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-micro-020518-115759</pub-id><pub-id pub-id-type="pmid">31226023</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlman</surname><given-names>S</given-names></name><name><surname>Netland</surname><given-names>J</given-names></name></person-group>. <article-title>Coronaviruses post-SARS: update on replication and pathogenesis</article-title>. <source>Nat Rev Microbiol.</source> (<year>2009</year>) <volume>7</volume>:<fpage>439</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2147</pub-id><pub-id pub-id-type="pmid">19430490</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shereen</surname><given-names>MA</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Kazmi</surname><given-names>A</given-names></name><name><surname>Bashir</surname><given-names>N</given-names></name><name><surname>Siddique</surname><given-names>R</given-names></name></person-group>. <article-title>COVID-19 infection: origin, transmission, and characteristics of human coronaviruses</article-title>. <source>J Adv Res.</source> (<year>2020</year>) <volume>24</volume>:<fpage>91</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jare.2020.03.005</pub-id><pub-id pub-id-type="pmid">32257431</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehr</surname><given-names>AR</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group>. <article-title>Coronaviruses: an overview of their replication and pathogenesis</article-title>. <source>Methods Mol Biol.</source> (<year>2015</year>) <volume>1282</volume>:<fpage>1</fpage>&#x2013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-2438-7_1</pub-id><pub-id pub-id-type="pmid">25720466</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopecky-Bromberg</surname><given-names>SA</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L</given-names></name><name><surname>Frieman</surname><given-names>M</given-names></name><name><surname>Baric</surname><given-names>RA</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group>. <article-title>Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists</article-title>. <source>J Virol.</source> (<year>2007</year>) <volume>81</volume>:<fpage>548</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01782-06</pub-id><pub-id pub-id-type="pmid">17108024</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birra</surname><given-names>D</given-names></name><name><surname>Benucci</surname><given-names>M</given-names></name><name><surname>Landolfi</surname><given-names>L</given-names></name><name><surname>Merchionda</surname><given-names>A</given-names></name><name><surname>Loi</surname><given-names>G</given-names></name><name><surname>Amato</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>COVID 19: a clue from innate immunity</article-title>. <source>Immunol Res.</source> (<year>2020</year>) <volume>10</volume>:<fpage>1</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s12026-020-09137-5</pub-id><pub-id pub-id-type="pmid">32524333</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Park</surname><given-names>YJ</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Wall</surname><given-names>A</given-names></name><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name></person-group>. <article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title>. <source>Cell.</source> (<year>2020</year>) <volume>181</volume>:<fpage>281</fpage>&#x2013;<lpage>92.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmid">32155444</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lai</surname><given-names>ACK</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Epidemiology, genetic recombination, and pathogenesis of coronaviruses</article-title>. <source>Trends Microbiol.</source> (<year>2016</year>) <volume>24</volume>:<fpage>490</fpage>&#x2013;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1016/j.tim.2016.03.003</pub-id><pub-id pub-id-type="pmid">27012512</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Ji</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Virology, epidemiology, pathogenesis, and control of COVID-19</article-title>. <source>Viruses.</source> (<year>2020</year>) <volume>12</volume>:<fpage>372</fpage>. <pub-id pub-id-type="doi">10.3390/v12040372</pub-id><pub-id pub-id-type="pmid">32230900</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group>
<source>DRAFT Landscape of COVID-19 Candidate Vaccines</source>. (<year>2020</year>) Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link> (accessed July 13, 2020).</mixed-citation>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>Q</given-names></name></person-group>. <article-title>Progress and prospects on vaccine development against SARS-CoV-2</article-title>. <source>Vaccines (Basel).</source> (<year>2020</year>) <volume>8</volume>:<fpage>E153</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines8020153</pub-id><pub-id pub-id-type="pmid">32235387</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Nguyen</surname><given-names>VG</given-names></name><name><surname>Park</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>BK</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name></person-group>. <article-title>A novel synonymous mutation of SARS-CoV-2: is this possible to affect their antigenicity and immunogenicity?</article-title>
<source>Vaccines.</source> (<year>2020</year>) <volume>8</volume>:<fpage>E220</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines8020220</pub-id><pub-id pub-id-type="pmid">32422894</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group>
<article-title>Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak</article-title>. <source>Curr Biol.</source> (<year>2020</year>) <volume>30</volume>:<fpage>1346</fpage>&#x2013;<lpage>51.e2</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2020.03.022</pub-id><pub-id pub-id-type="pmid">32197085</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>KG</given-names></name><name><surname>Rambaut</surname><given-names>A</given-names></name><name><surname>Lipkin</surname><given-names>WI</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name><name><surname>Garry</surname><given-names>RF</given-names></name></person-group>. <article-title>The proximal origin of SARS-CoV-2</article-title>. <source>Nat Med.</source> (<year>2020</year>) <volume>26</volume>:<fpage>450</fpage>&#x2013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0820-9</pub-id><pub-id pub-id-type="pmid">32284615</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedford</surname><given-names>J</given-names></name><name><surname>Enria</surname><given-names>D</given-names></name><name><surname>Giesecke</surname><given-names>J</given-names></name><name><surname>Heymann</surname><given-names>DL</given-names></name><name><surname>Ihekweazu</surname><given-names>C</given-names></name><name><surname>Kobinger</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>COVID-19: towards controlling of a pandemic</article-title>. <source>Lancet.</source> (<year>2020</year>) <volume>395</volume>:<fpage>1015</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30673-5</pub-id><pub-id pub-id-type="pmid">32197103</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Doremalen</surname><given-names>N</given-names></name><name><surname>Bushmaker</surname><given-names>T</given-names></name><name><surname>Morris</surname><given-names>DH</given-names></name><name><surname>Holbrook</surname><given-names>MG</given-names></name><name><surname>Gamble</surname><given-names>A</given-names></name><name><surname>Williamson</surname><given-names>BN</given-names></name><etal/></person-group>. <article-title>Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1</article-title>. <source>N Engl J Med.</source> (<year>2020</year>) <volume>382</volume>:<fpage>1564</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2004973</pub-id><pub-id pub-id-type="pmid">32182409</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfel</surname><given-names>R</given-names></name><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Guggemos</surname><given-names>W</given-names></name><name><surname>Seilmaier</surname><given-names>M</given-names></name><name><surname>Zange</surname><given-names>S</given-names></name><name><surname>Muller</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Virological assessment of hospitalized patients with COVID-2019</article-title>. <source>Nature.</source> (<year>2020</year>) <volume>581</volume>:<fpage>465</fpage>&#x2013;<lpage>469</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2196-x</pub-id><pub-id pub-id-type="pmid">32235945</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>NHL</given-names></name><name><surname>Chu</surname><given-names>DKW</given-names></name><name><surname>Shiu</surname><given-names>EYC</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>McDevitt</surname><given-names>JJ</given-names></name><name><surname>Hau</surname><given-names>BJP</given-names></name><etal/></person-group>
<article-title>Respiratory virus shedding in exhaled breath and efficacy of face masks</article-title>. <source>Nat Med.</source> (<year>2020</year>) <volume>26</volume>:<fpage>676</fpage>&#x2013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.21203/rs.3.rs-16836/v1</pub-id><pub-id pub-id-type="pmid">32371934</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Hong</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Prolonged presence of SARS-CoV-2 viral RNA in faecal samples</article-title>. <source>Lancet Gastroenterol Hepatol.</source> (<year>2020</year>) <volume>5</volume>:<fpage>434</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/S2468-1253(20)30083-2</pub-id><pub-id pub-id-type="pmid">32199469</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>C</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding</article-title>. <source>Nat Med.</source> (<year>2020</year>) <volume>26</volume>:<fpage>502</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0817-4</pub-id><pub-id pub-id-type="pmid">32284613</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothan</surname><given-names>HA</given-names></name><name><surname>Byrareddy</surname><given-names>SN</given-names></name></person-group>. <article-title>The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak</article-title>. <source>J Autoimmun.</source> (<year>2020</year>) <volume>109</volume>:<fpage>102433</fpage>. <pub-id pub-id-type="doi">10.1016/j.jaut.2020.102433</pub-id><pub-id pub-id-type="pmid">32113704</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauer</surname><given-names>SA</given-names></name><name><surname>Grantz</surname><given-names>KH</given-names></name><name><surname>Bi</surname><given-names>Q</given-names></name><name><surname>Jones</surname><given-names>FK</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Meredith</surname><given-names>HR</given-names></name><etal/></person-group>. <article-title>The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application</article-title>. <source>Ann Intern Med.</source> (<year>2020</year>) <volume>10</volume>:<fpage>M20</fpage>-<lpage>0504</lpage>. <pub-id pub-id-type="doi">10.7326/M20-0504</pub-id><pub-id pub-id-type="pmid">32150748</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>F</given-names></name></person-group>. <article-title>Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China</article-title>. <source>J Med Virol.</source> (<year>2020</year>) <volume>92</volume>:<fpage>441</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25689</pub-id><pub-id pub-id-type="pmid">31994742</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <label>33.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Niu</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title>. <source>Lancet.</source> (<year>2020</year>) <volume>395</volume>:<fpage>565</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id><pub-id pub-id-type="pmid">32007145</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>YY</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>SARS-CoV-2 infection in children</article-title>. <source>N Engl J Med.</source> (<year>2020</year>) <volume>382</volume>:<fpage>1663</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2005073</pub-id><pub-id pub-id-type="pmid">32187458</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <label>35.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagunas-Rangel</surname><given-names>FA</given-names></name></person-group>. <article-title>Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis</article-title>. <source>J Med Virol.</source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1002/jmv.25819</pub-id>. [Epub ahead of print].<pub-id pub-id-type="pmid">32242950</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <label>36.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Functional exhaustion of antiviral lymphocytes in COVID-19 patients</article-title>. <source>Cell Mol Immunol.</source> (<year>2020</year>) <volume>17</volume>:<fpage>533</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-020-0402-2</pub-id><pub-id pub-id-type="pmid">32203188</pub-id></mixed-citation>
      </ref>
      <ref id="B37">
        <label>37.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source>Lancet.</source> (<year>2020</year>) <volume>395</volume>:<fpage>497</fpage>&#x2013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation>
      </ref>
      <ref id="B38">
        <label>38.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>BJB</given-names></name><name><surname>June</surname><given-names>CH</given-names></name></person-group>. <article-title>Cytokine release syndrome in severe COVID-19</article-title>. <source>Science.</source> (<year>2020</year>) <volume>368</volume>:<fpage>473</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb8925</pub-id><pub-id pub-id-type="pmid">32303591</pub-id></mixed-citation>
      </ref>
      <ref id="B39">
        <label>39.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>van Doremalen</surname><given-names>N</given-names></name><name><surname>Falzarano</surname><given-names>D</given-names></name><name><surname>Munster</surname><given-names>VJ</given-names></name></person-group>. <article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title>. <source>Nat Rev Microbiol.</source> (<year>2016</year>) <volume>14</volume>:<fpage>523</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro.2016.81</pub-id><pub-id pub-id-type="pmid">27344959</pub-id></mixed-citation>
      </ref>
      <ref id="B40">
        <label>40.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantlo</surname><given-names>E</given-names></name><name><surname>Bukreyeva</surname><given-names>N</given-names></name><name><surname>Maruyama</surname><given-names>J</given-names></name><name><surname>Paessler</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name></person-group>. <article-title>Antiviral activities of type I interferons to SARS-CoV-2 infection</article-title>. <source>Antiviral Res.</source> (<year>2020</year>) <volume>179</volume>:<fpage>104811</fpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104811</pub-id><pub-id pub-id-type="pmid">32360182</pub-id></mixed-citation>
      </ref>
      <ref id="B41">
        <label>41.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acharya</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Gack</surname><given-names>MU</given-names></name></person-group>. <article-title>Dysregulation of type I interferon responses in COVID-19</article-title>. <source>Nat Rev Immunol.</source> (<year>2020</year>) <volume>20</volume>:<fpage>397</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-020-0346-x</pub-id><pub-id pub-id-type="pmid">32457522</pub-id></mixed-citation>
      </ref>
      <ref id="B42">
        <label>42.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolich-Zugich</surname><given-names>J</given-names></name><name><surname>Knox</surname><given-names>KS</given-names></name><name><surname>Rios</surname><given-names>CT</given-names></name><name><surname>Natt</surname><given-names>B</given-names></name><name><surname>Bhattacharya</surname><given-names>D</given-names></name><name><surname>Fain</surname><given-names>MJ</given-names></name></person-group>
<article-title>SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes</article-title>. <source>Geroscience.</source> (<year>2020</year>) <volume>42</volume>:<fpage>505</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-020-00186-0</pub-id><pub-id pub-id-type="pmid">32274617</pub-id></mixed-citation>
      </ref>
      <ref id="B43">
        <label>43.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zust</surname><given-names>R</given-names></name><name><surname>Cervantes-Barragan</surname><given-names>L</given-names></name><name><surname>Habjan</surname><given-names>M</given-names></name><name><surname>Maier</surname><given-names>R</given-names></name><name><surname>Neuman</surname><given-names>BW</given-names></name><name><surname>Ziebuhr</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Ribose 2\'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5</article-title>. <source>Nat Immunol.</source> (<year>2011</year>) <volume>12</volume>:<fpage>137</fpage>&#x2013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1979</pub-id><pub-id pub-id-type="pmid">21217758</pub-id></mixed-citation>
      </ref>
      <ref id="B44">
        <label>44.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Nichols</surname><given-names>DB</given-names></name><etal/></person-group>. <article-title>Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling</article-title>. <source>PLoS ONE.</source> (<year>2012</year>) <volume>7</volume>:<fpage>e30802</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0030802</pub-id><pub-id pub-id-type="pmid">22312431</pub-id></mixed-citation>
      </ref>
      <ref id="B45">
        <label>45.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Hillyer</surname><given-names>C</given-names></name><name><surname>Du</surname><given-names>L</given-names></name></person-group>
<article-title>Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses</article-title>. <source>Trends Immunol.</source> (<year>2020</year>) <volume>14</volume>:<fpage>355</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2020.04.008</pub-id></mixed-citation>
      </ref>
      <ref id="B46">
        <label>46.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name></person-group>. <article-title>An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies</article-title>. <source>Emerg Microbes Infect.</source> (<year>2020</year>) <volume>9</volume>:<fpage>275</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1080/22221751.2020.1723441</pub-id><pub-id pub-id-type="pmid">32005086</pub-id></mixed-citation>
      </ref>
      <ref id="B47">
        <label>47.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Kruger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>. <source>Cell.</source> (<year>2020</year>) <volume>181</volume>:<fpage>271</fpage>&#x2013;<lpage>80.e8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation>
      </ref>
      <ref id="B48">
        <label>48.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janice Oh</surname><given-names>HL</given-names></name><name><surname>Ken-En Gan</surname><given-names>S</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>YJ</given-names></name></person-group>. <article-title>Understanding the T cell immune response in SARS coronavirus infection</article-title>. <source>Emerg Microbes Infect.</source> (<year>2012</year>) <volume>1</volume>:<fpage>e23</fpage>. <pub-id pub-id-type="doi">10.1038/emi.2012.26</pub-id><pub-id pub-id-type="pmid">26038429</pub-id></mixed-citation>
      </ref>
      <ref id="B49">
        <label>49.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>HY</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>CX</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>XC</given-names></name><name><surname>Yang</surname><given-names>XP</given-names></name><etal/></person-group>. <article-title>Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients</article-title>. <source>Cell Mol Immunol.</source> (<year>2020</year>) <volume>17</volume>:<fpage>541</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-020-0401-3</pub-id><pub-id pub-id-type="pmid">32203186</pub-id></mixed-citation>
      </ref>
      <ref id="B50">
        <label>50.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Down-regulated gene expression spectrum and immune responses changed during the disease progression in COVID-19 patients</article-title>. <source>Clin Infect Dis.</source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1093/cid/ciaa462</pub-id>. [Epub ahead of print].<pub-id pub-id-type="pmid">32307550</pub-id></mixed-citation>
      </ref>
      <ref id="B51">
        <label>51.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CK</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>T cell responses to whole SARS coronavirus in humans</article-title>. <source>J Immunol.</source> (<year>2008</year>) <volume>181</volume>:<fpage>5490</fpage>&#x2013;<lpage>500</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.181.8.5490</pub-id><pub-id pub-id-type="pmid">18832706</pub-id></mixed-citation>
      </ref>
      <ref id="B52">
        <label>52.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Moderbacher</surname><given-names>CR</given-names></name><etal/></person-group>. <article-title>Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title>. <source>Cell.</source> (<year>2020</year>) <volume>181</volume>:<fpage>1489</fpage>&#x2013;<lpage>1501.e15</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.05.015</pub-id><pub-id pub-id-type="pmid">32473127</pub-id></mixed-citation>
      </ref>
      <ref id="B53">
        <label>53.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belzung</surname><given-names>C</given-names></name><name><surname>Lemoine</surname><given-names>M</given-names></name></person-group>. <article-title>Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression</article-title>. <source>Biol Mood Anxiety Disord.</source> (<year>2011</year>) <volume>1</volume>:<fpage>9</fpage>. <pub-id pub-id-type="doi">10.1186/2045-5380-1-9</pub-id><pub-id pub-id-type="pmid">22738250</pub-id></mixed-citation>
      </ref>
      <ref id="B54">
        <label>54.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safronetz</surname><given-names>D</given-names></name><name><surname>Geisbert</surname><given-names>TW</given-names></name><name><surname>Feldmann</surname><given-names>H</given-names></name></person-group>. <article-title>Animal models for highly pathogenic emerging viruses</article-title>. <source>Curr Opin Virol.</source> (<year>2013</year>) <volume>3</volume>:<fpage>205</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2013.01.001</pub-id><pub-id pub-id-type="pmid">23403208</pub-id></mixed-citation>
      </ref>
      <ref id="B55">
        <label>55.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCray</surname><given-names>PB</given-names><suffix>Jr</suffix></name><name><surname>Pewe</surname><given-names>L</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C</given-names></name><name><surname>Hickey</surname><given-names>M</given-names></name><name><surname>Manzel</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus</article-title>. <source>J Virol.</source> (<year>2007</year>) <volume>81</volume>:<fpage>813</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02012-06</pub-id><pub-id pub-id-type="pmid">17079315</pub-id></mixed-citation>
      </ref>
      <ref id="B56">
        <label>56.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice</article-title>. <source>Nature.</source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1038/s41586-020-2312-y</pub-id>. [Epub ahead of print].</mixed-citation>
      </ref>
      <ref id="B57">
        <label>57.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Kuba</surname><given-names>K</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Huan</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Guan</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Angiotensin-converting enzyme 2 protects from severe acute lung failure</article-title>. <source>Nature.</source> (<year>2005</year>) <volume>436</volume>:<fpage>112</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/nature03712</pub-id><pub-id pub-id-type="pmid">16001071</pub-id></mixed-citation>
      </ref>
      <ref id="B58">
        <label>58.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>RL</given-names></name><name><surname>Becker</surname><given-names>MM</given-names></name><name><surname>Eckerle</surname><given-names>LD</given-names></name><name><surname>Bolles</surname><given-names>M</given-names></name><name><surname>Denison</surname><given-names>MR</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group>. <article-title>A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease</article-title>. <source>Nat Med.</source> (<year>2012</year>) <volume>18</volume>:<fpage>1820</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2972</pub-id><pub-id pub-id-type="pmid">23142821</pub-id></mixed-citation>
      </ref>
      <ref id="B59">
        <label>59.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Deming</surname><given-names>D</given-names></name><name><surname>Paddock</surname><given-names>CD</given-names></name><name><surname>Cheng</surname><given-names>A</given-names></name><name><surname>Yount</surname><given-names>B</given-names></name><name><surname>Vogel</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice</article-title>. <source>PLoS Pathog.</source> (<year>2007</year>) <volume>3</volume>:<fpage>e5</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.0030005</pub-id><pub-id pub-id-type="pmid">17222058</pub-id></mixed-citation>
      </ref>
      <ref id="B60">
        <label>60.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>CW</given-names></name><name><surname>Baric</surname><given-names>R</given-names></name><name><surname>Cai</surname><given-names>SX</given-names></name><name><surname>Frieman</surname><given-names>M</given-names></name><name><surname>Kumaki</surname><given-names>Y</given-names></name><name><surname>Morrey</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents <italic>in vitro</italic> and <italic>in vivo</italic></article-title>. <source>Virology.</source> (<year>2009</year>) <volume>395</volume>:<fpage>210</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2009.09.023</pub-id><pub-id pub-id-type="pmid">19853271</pub-id></mixed-citation>
      </ref>
      <ref id="B61">
        <label>61.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>Roberts</surname><given-names>A</given-names></name></person-group>. <article-title>Is there an ideal animal model for SARS?</article-title>
<source>Trends Microbiol.</source> (<year>2006</year>) <volume>14</volume>:<fpage>299</fpage>&#x2013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1016/j.tim.2006.05.007</pub-id><pub-id pub-id-type="pmid">16759866</pub-id></mixed-citation>
      </ref>
      <ref id="B62">
        <label>62.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Paddock</surname><given-names>C</given-names></name><name><surname>Vogel</surname><given-names>L</given-names></name><name><surname>Butler</surname><given-names>E</given-names></name><name><surname>Zaki</surname><given-names>S</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name></person-group>. <article-title>Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans</article-title>. <source>J Virol.</source> (<year>2005</year>) <volume>79</volume>:<fpage>5833</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.9.5833-5838.2005</pub-id><pub-id pub-id-type="pmid">15827197</pub-id></mixed-citation>
      </ref>
      <ref id="B63">
        <label>63.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Lamirande</surname><given-names>EW</given-names></name><name><surname>Vogel</surname><given-names>L</given-names></name><name><surname>Jackson</surname><given-names>JP</given-names></name><name><surname>Paddock</surname><given-names>CD</given-names></name><name><surname>Guarner</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Animal models and vaccines for SARS-CoV infection</article-title>. <source>Virus Res.</source> (<year>2008</year>) <volume>133</volume>:<fpage>20</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2007.03.025</pub-id><pub-id pub-id-type="pmid">17499378</pub-id></mixed-citation>
      </ref>
      <ref id="B64">
        <label>64.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>WG</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>Murphy</surname><given-names>B</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name></person-group>. <article-title>Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice</article-title>. <source>J Immunol.</source> (<year>2004</year>) <volume>173</volume>:<fpage>4030</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.173.6.4030</pub-id><pub-id pub-id-type="pmid">15356152</pub-id></mixed-citation>
      </ref>
      <ref id="B65">
        <label>65.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cockrell</surname><given-names>AS</given-names></name><name><surname>Yount</surname><given-names>BL</given-names></name><name><surname>Scobey</surname><given-names>T</given-names></name><name><surname>Jensen</surname><given-names>K</given-names></name><name><surname>Douglas</surname><given-names>M</given-names></name><name><surname>Beall</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A mouse model for MERS coronavirus-induced acute respiratory distress syndrome</article-title>. <source>Nat Microbiol.</source> (<year>2016</year>) <volume>2</volume>:<fpage>16226</fpage>. <pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.226</pub-id><pub-id pub-id-type="pmid">27892925</pub-id></mixed-citation>
      </ref>
      <ref id="B66">
        <label>66.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>H7N9 influenza viruses are transmissible in ferrets by respiratory droplet</article-title>. <source>Science.</source> (<year>2013</year>) <volume>341</volume>:<fpage>410</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1126/science.1240532</pub-id><pub-id pub-id-type="pmid">23868922</pub-id></mixed-citation>
      </ref>
      <ref id="B67">
        <label>67.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Hatta</surname><given-names>M</given-names></name><name><surname>Das</surname><given-names>SC</given-names></name><name><surname>Ozawa</surname><given-names>M</given-names></name><name><surname>Shinya</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets</article-title>. <source>Nature.</source> (<year>2012</year>) <volume>486</volume>:<fpage>420</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/nature10831</pub-id><pub-id pub-id-type="pmid">22722205</pub-id></mixed-citation>
      </ref>
      <ref id="B68">
        <label>68.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>YK</given-names></name><name><surname>Ali</surname><given-names>GD</given-names></name><name><surname>Jia</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Kelvin</surname><given-names>D</given-names></name><name><surname>Couch</surname><given-names>RC</given-names></name><etal/></person-group>. <article-title>The SARS-CoV ferret model in an infection-challenge study</article-title>. <source>Virology.</source> (<year>2008</year>) <volume>374</volume>:<fpage>151</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2007.12.032</pub-id><pub-id pub-id-type="pmid">18234270</pub-id></mixed-citation>
      </ref>
      <ref id="B69">
        <label>69.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2</article-title>. <source>Science.</source> (<year>2020</year>) <volume>368</volume>:<fpage>1016</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb7015</pub-id><pub-id pub-id-type="pmid">32269068</pub-id></mixed-citation>
      </ref>
      <ref id="B70">
        <label>70.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Vogel</surname><given-names>L</given-names></name><name><surname>Guarner</surname><given-names>J</given-names></name><name><surname>Hayes</surname><given-names>N</given-names></name><name><surname>Murphy</surname><given-names>B</given-names></name><name><surname>Zaki</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters</article-title>. <source>J Virol.</source> (<year>2005</year>) <volume>79</volume>:<fpage>503</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.1.503-511.2005</pub-id><pub-id pub-id-type="pmid">15596843</pub-id></mixed-citation>
      </ref>
      <ref id="B71">
        <label>71.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>Prescott</surname><given-names>J</given-names></name><name><surname>Baseler</surname><given-names>L</given-names></name><name><surname>Bushmaker</surname><given-names>T</given-names></name><name><surname>Thomas</surname><given-names>T</given-names></name><name><surname>Lackemeyer</surname><given-names>MG</given-names></name><etal/></person-group>. <article-title>The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters</article-title>. <source>PLoS ONE.</source> (<year>2013</year>) <volume>8</volume>:<fpage>e69127</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0069127</pub-id><pub-id pub-id-type="pmid">23844250</pub-id></mixed-citation>
      </ref>
      <ref id="B72">
        <label>72.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JF</given-names></name><name><surname>Zhang</surname><given-names>AJ</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Poon</surname><given-names>VK</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>AC</given-names></name><etal/></person-group>. <article-title>Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility</article-title>. <source>Clin Infect Dis.</source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1093/cid/ciaa325</pub-id>. [Epub ahead of print].<pub-id pub-id-type="pmid">32215622</pub-id></mixed-citation>
      </ref>
      <ref id="B73">
        <label>73.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockx</surname><given-names>B</given-names></name><name><surname>Kuiken</surname><given-names>T</given-names></name><name><surname>Herfst</surname><given-names>S</given-names></name><name><surname>Bestebroer</surname><given-names>T</given-names></name><name><surname>Lamers</surname><given-names>MM</given-names></name><name><surname>Oude Munnink</surname><given-names>BB</given-names></name><etal/></person-group>. <article-title>Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model</article-title>. <source>Science.</source> (<year>2020</year>) <volume>368</volume>:<fpage>1012</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1101/2020.03.17.995639</pub-id><pub-id pub-id-type="pmid">32303590</pub-id></mixed-citation>
      </ref>
      <ref id="B74">
        <label>74.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ota</surname><given-names>M</given-names></name></person-group>
<article-title>Will we see protection or reinfection in COVID-19?</article-title>
<source>Nat Rev Immunol.</source> (<year>2020</year>) <volume>17</volume>:<fpage>1</fpage>
<pub-id pub-id-type="doi">10.1038/s41577-020-0316-3</pub-id></mixed-citation>
      </ref>
      <ref id="B75">
        <label>75.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Qi</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Age-related rhesus macaque models of COVID-19</article-title>. <source>Animal Model Exp Med.</source> (<year>2020</year>) <volume>3</volume>:<fpage>93</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/ame2.12108</pub-id><pub-id pub-id-type="pmid">32318665</pub-id></mixed-citation>
      </ref>
      <ref id="B76">
        <label>76.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barouch</surname><given-names>DH</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Broge</surname><given-names>T</given-names></name><name><surname>Linde</surname><given-names>C</given-names></name><name><surname>Ackerman</surname><given-names>ME</given-names></name><name><surname>Brown</surname><given-names>EP</given-names></name><etal/></person-group>. <article-title>Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys</article-title>. <source>Science.</source> (<year>2015</year>) <volume>349</volume>:<fpage>320</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1126/science.aab3886</pub-id><pub-id pub-id-type="pmid">26138104</pub-id></mixed-citation>
      </ref>
      <ref id="B77">
        <label>77.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rappuoli</surname><given-names>R</given-names></name><name><surname>Santoni</surname><given-names>A</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group>. <article-title>Vaccines: an achievement of civilization, a human right, our health insurance for the future</article-title>. <source>J Exp Med.</source> (<year>2018</year>) <volume>216</volume>:<fpage>7</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20182160</pub-id><pub-id pub-id-type="pmid">30510147</pub-id></mixed-citation>
      </ref>
      <ref id="B78">
        <label>78.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delany</surname><given-names>I</given-names></name><name><surname>Rappuoli</surname><given-names>R</given-names></name><name><surname>De Gregorio</surname><given-names>E</given-names></name></person-group>. <article-title>Vaccines for the 21st century</article-title>. <source>EMBO Mol Med.</source> (<year>2014</year>) <volume>6</volume>:<fpage>708</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1002/emmm.201403876</pub-id><pub-id pub-id-type="pmid">24803000</pub-id></mixed-citation>
      </ref>
      <ref id="B79">
        <label>79.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posadas-Herrera</surname><given-names>G</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name><name><surname>Fuke</surname><given-names>I</given-names></name><name><surname>Muraki</surname><given-names>Y</given-names></name><name><surname>Mapua</surname><given-names>CA</given-names></name><name><surname>Khan</surname><given-names>AH</given-names></name><etal/></person-group>. <article-title>Development and evaluation of a formalin-inactivated West Nile virus vaccine (WN-VAX) for a human vaccine candidate</article-title>. <source>Vaccine.</source> (<year>2010</year>) <volume>28</volume>:<fpage>7939</fpage>&#x2013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.09.076</pub-id><pub-id pub-id-type="pmid">20933564</pub-id></mixed-citation>
      </ref>
      <ref id="B80">
        <label>80.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muraki</surname><given-names>Y</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Matsuura</surname><given-names>M</given-names></name><name><surname>Fuke</surname><given-names>I</given-names></name><name><surname>Manabe</surname><given-names>S</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>The efficacy of inactivated west Nile vaccine (WN-VAX) in mice and monkeys</article-title>. <source>Virol J.</source> (<year>2015</year>) <volume>12</volume>:<fpage>54</fpage>. <pub-id pub-id-type="doi">10.1186/s12985-015-0282-8</pub-id><pub-id pub-id-type="pmid">25889682</pub-id></mixed-citation>
      </ref>
      <ref id="B81">
        <label>81.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanlandingham</surname><given-names>DL</given-names></name><name><surname>Keil</surname><given-names>SD</given-names></name><name><surname>Horne</surname><given-names>KM</given-names></name><name><surname>Pyles</surname><given-names>R</given-names></name><name><surname>Goodrich</surname><given-names>RP</given-names></name><name><surname>Higgs</surname><given-names>S</given-names></name></person-group>. <article-title>Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system</article-title>. <source>Transfusion.</source> (<year>2013</year>) <volume>53</volume>:<fpage>284</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1111/j.1537-2995.2012.03717.x</pub-id><pub-id pub-id-type="pmid">22626525</pub-id></mixed-citation>
      </ref>
      <ref id="B82">
        <label>82.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faddy</surname><given-names>HM</given-names></name><name><surname>Prow</surname><given-names>NA</given-names></name><name><surname>Fryk</surname><given-names>JJ</given-names></name><name><surname>Hall</surname><given-names>RA</given-names></name><name><surname>Keil</surname><given-names>SD</given-names></name><name><surname>Goodrich</surname><given-names>RP</given-names></name><etal/></person-group>. <article-title>The effect of riboflavin and ultraviolet light on the infectivity of arboviruses</article-title>. <source>Transfusion.</source> (<year>2015</year>) <volume>55</volume>:<fpage>824</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1111/trf.12899</pub-id><pub-id pub-id-type="pmid">25370822</pub-id></mixed-citation>
      </ref>
      <ref id="B83">
        <label>83.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keil</surname><given-names>SD</given-names></name><name><surname>Bowen</surname><given-names>R</given-names></name><name><surname>Marschner</surname><given-names>S</given-names></name></person-group>. <article-title>Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment</article-title>. <source>Transfusion.</source> (<year>2016</year>) <volume>56</volume>:<fpage>2948</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1111/trf.13860</pub-id><pub-id pub-id-type="pmid">27805261</pub-id></mixed-citation>
      </ref>
      <ref id="B84">
        <label>84.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyer</surname><given-names>R</given-names></name><name><surname>McGuire</surname><given-names>DK</given-names></name><name><surname>Xing</surname><given-names>B</given-names></name><name><surname>Jackson</surname><given-names>S</given-names></name><name><surname>Janssen</surname><given-names>R</given-names></name></person-group>. <article-title>Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults</article-title>. <source>Vaccine.</source> (<year>2018</year>) <volume>36</volume>:<fpage>2604</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.03.067</pub-id><pub-id pub-id-type="pmid">29628151</pub-id></mixed-citation>
      </ref>
      <ref id="B85">
        <label>85.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyer</surname><given-names>RN</given-names></name><name><surname>Janssen</surname><given-names>RS</given-names></name></person-group>. <article-title>Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60-70years</article-title>. <source>Vaccine.</source> (<year>2019</year>) <volume>37</volume>:<fpage>5854</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2019.08.005</pub-id><pub-id pub-id-type="pmid">31431412</pub-id></mixed-citation>
      </ref>
      <ref id="B86">
        <label>86.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Mao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Rapid development of an inactivated vaccine candidate for SARS-CoV-2</article-title>. <source>Science</source>. (<year>2020</year>) <volume>6</volume>:<fpage>eabc1932</fpage>. <pub-id pub-id-type="doi">10.1126/science.abc1932</pub-id><pub-id pub-id-type="pmid">32376603</pub-id></mixed-citation>
      </ref>
      <ref id="B87">
        <label>87.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stauft</surname><given-names>CB</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Coleman</surname><given-names>JR</given-names></name><name><surname>Boltz</surname><given-names>D</given-names></name><name><surname>Chin</surname><given-names>C</given-names></name><name><surname>Kushnir</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Live-attenuated H1N1 influenza vaccine candidate displays potent efficacy in mice and ferrets</article-title>. <source>PLoS ONE.</source> (<year>2019</year>) <volume>14</volume>:<fpage>e0223784</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0223784</pub-id><pub-id pub-id-type="pmid">31609986</pub-id></mixed-citation>
      </ref>
      <ref id="B88">
        <label>88.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>S</given-names></name><name><surname>Stauft</surname><given-names>CB</given-names></name><name><surname>Kalkeri</surname><given-names>R</given-names></name><name><surname>Koidei</surname><given-names>F</given-names></name><name><surname>Kushnir</surname><given-names>A</given-names></name><name><surname>Tasker</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates</article-title>. <source>Vaccine.</source> (<year>2020</year>) <volume>38</volume>:<fpage>2943</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2020.02.056</pub-id><pub-id pub-id-type="pmid">32107060</pub-id></mixed-citation>
      </ref>
      <ref id="B89">
        <label>89.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malczyk</surname><given-names>AH</given-names></name><name><surname>Kupke</surname><given-names>A</given-names></name><name><surname>Prufer</surname><given-names>S</given-names></name><name><surname>Scheuplein</surname><given-names>VA</given-names></name><name><surname>Hutzler</surname><given-names>S</given-names></name><name><surname>Kreuz</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform</article-title>. <source>J Virol.</source> (<year>2015</year>) <volume>89</volume>:<fpage>11654</fpage>&#x2013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01815-15</pub-id><pub-id pub-id-type="pmid">26355094</pub-id></mixed-citation>
      </ref>
      <ref id="B90">
        <label>90.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nurnberger</surname><given-names>C</given-names></name><name><surname>Bodmer</surname><given-names>BS</given-names></name><name><surname>Fiedler</surname><given-names>AH</given-names></name><name><surname>Gabriel</surname><given-names>G</given-names></name><name><surname>Muhlebach</surname><given-names>MD</given-names></name></person-group>
<article-title>A measles virus-based vaccine candidate mediates protection against zika virus in an allogeneic mouse pregnancy model</article-title>. <source>J Virol.</source> (<year>2019</year>) <volume>93</volume>:<fpage>e01485</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01485-18</pub-id><pub-id pub-id-type="pmid">30429338</pub-id></mixed-citation>
      </ref>
      <ref id="B91">
        <label>91.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>G</given-names></name><name><surname>Giannino</surname><given-names>V</given-names></name><name><surname>Rishi</surname><given-names>N</given-names></name><name><surname>Glueck</surname><given-names>R</given-names></name></person-group>. <article-title>Immunogenicity of next-generation HPV vaccines in non-human primates: measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine</article-title>. <source>Vaccine.</source> (<year>2016</year>) <volume>34</volume>:<fpage>4724</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.07.051</pub-id><pub-id pub-id-type="pmid">27523740</pub-id></mixed-citation>
      </ref>
      <ref id="B92">
        <label>92.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palomares</surname><given-names>LA</given-names></name><name><surname>Srivastava</surname><given-names>IK</given-names></name><name><surname>Ramirez</surname><given-names>OT</given-names></name><name><surname>Cox</surname><given-names>MMJ</given-names></name></person-group>. <article-title>Glycobiotechnology of the insect cell-baculovirus expression system technology</article-title>. <source>Adv Biochem Eng Biotechnol.</source> (<year>2018</year>). <pub-id pub-id-type="doi">10.1007/10_2018_61</pub-id>. [Epub ahead of print].<pub-id pub-id-type="pmid">29886511</pub-id></mixed-citation>
      </ref>
      <ref id="B93">
        <label>93.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunkle</surname><given-names>LM</given-names></name><name><surname>Izikson</surname><given-names>R</given-names></name><name><surname>Patriarca</surname><given-names>PA</given-names></name><name><surname>Goldenthal</surname><given-names>KL</given-names></name><name><surname>Muse</surname><given-names>D</given-names></name><name><surname>Cox</surname><given-names>MMJ</given-names></name></person-group>. <article-title>Randomized comparison of immunogenicity and safety of quadrivalent recombinant versus inactivated influenza vaccine in healthy adults 18-49 years of age</article-title>. <source>J Infect Dis.</source> (<year>2017</year>) <volume>216</volume>:<fpage>1219</fpage>&#x2013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jix478</pub-id><pub-id pub-id-type="pmid">28968871</pub-id></mixed-citation>
      </ref>
      <ref id="B94">
        <label>94.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madan</surname><given-names>A</given-names></name><name><surname>Ferguson</surname><given-names>M</given-names></name><name><surname>Rheault</surname><given-names>P</given-names></name><name><surname>Seiden</surname><given-names>D</given-names></name><name><surname>Toma</surname><given-names>A</given-names></name><name><surname>Friel</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: a phase II, observer-blind, randomized, controlled trial</article-title>. <source>Vaccine.</source> (<year>2017</year>) <volume>35</volume>:<fpage>1865</fpage>&#x2013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.02.057</pub-id><pub-id pub-id-type="pmid">28302407</pub-id></mixed-citation>
      </ref>
      <ref id="B95">
        <label>95.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodaya</surname><given-names>RN</given-names></name><name><surname>Kanitkar</surname><given-names>AP</given-names></name><name><surname>Friedrich</surname><given-names>K</given-names></name><name><surname>Henson</surname><given-names>D</given-names></name><name><surname>Yamagata</surname><given-names>R</given-names></name><name><surname>Nuti</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Formulation design, optimization and <italic>in vivo</italic> evaluations of an alpha-tocopherol-containing self-emulsified adjuvant system using inactivated influenza vaccine</article-title>. <source>J Control Release.</source> (<year>2019</year>) <volume>316</volume>:<fpage>12</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2019.10.042</pub-id><pub-id pub-id-type="pmid">31678654</pub-id></mixed-citation>
      </ref>
      <ref id="B96">
        <label>96.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobson-Peters</surname><given-names>J</given-names></name><name><surname>Harrison</surname><given-names>JJ</given-names></name><name><surname>Watterson</surname><given-names>D</given-names></name><name><surname>Hazlewood</surname><given-names>JE</given-names></name><name><surname>Vet</surname><given-names>LJ</given-names></name><name><surname>Newton</surname><given-names>ND</given-names></name><etal/></person-group>. <article-title>A recombinant platform for flavivirus vaccines and diagnostics using chimeras of a new insect-specific virus</article-title>. <source>Sci Transl Med.</source> (<year>2019</year>) <volume>11</volume>:<fpage>eaax7888</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aax7888</pub-id><pub-id pub-id-type="pmid">31826984</pub-id></mixed-citation>
      </ref>
      <ref id="B97">
        <label>97.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>TF</given-names></name><name><surname>Huang</surname><given-names>LM</given-names></name><name><surname>Valencia</surname><given-names>A</given-names></name><name><surname>Panzer</surname><given-names>F</given-names></name><name><surname>Chiu</surname><given-names>CH</given-names></name><name><surname>Decreux</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years</article-title>. <source>Hum Vaccin Immunother.</source> (<year>2019</year>) <volume>15</volume>:<fpage>1970</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2019.1625644</pub-id><pub-id pub-id-type="pmid">31268383</pub-id></mixed-citation>
      </ref>
      <ref id="B98">
        <label>98.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>YL</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>RC</given-names></name><name><surname>Hu</surname><given-names>YM</given-names></name><name><surname>Wei</surname><given-names>LH</given-names></name><name><surname>Li</surname><given-names>CG</given-names></name><etal/></person-group>. <article-title>Efficacy, safety, and immunogenicity of an <italic>Escherichia coli</italic>-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial</article-title>. <source>J Natl Cancer Inst.</source> (<year>2020</year>) <volume>112</volume>:<fpage>145</fpage>&#x2013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djz074</pub-id><pub-id pub-id-type="pmid">31086947</pub-id></mixed-citation>
      </ref>
      <ref id="B99">
        <label>99.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>XF</given-names></name><name><surname>Huang</surname><given-names>SJ</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>YM</given-names></name><name><surname>Wang</surname><given-names>ZZ</given-names></name><etal/></person-group>
<article-title>Long-term efficacy of a hepatitis E vaccine</article-title>. <source>N Engl J Med.</source> (<year>2015</year>) <volume>372</volume>:<fpage>914</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1406011</pub-id><pub-id pub-id-type="pmid">25738667</pub-id></mixed-citation>
      </ref>
      <ref id="B100">
        <label>100.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Joyce</surname><given-names>MG</given-names></name><name><surname>Modjarrad</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Leung</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Evaluation of candidate vaccine approaches for MERS-CoV</article-title>. <source>Nat Commun.</source> (<year>2015</year>) <volume>6</volume>:<fpage>7712</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms8712</pub-id><pub-id pub-id-type="pmid">26218507</pub-id></mixed-citation>
      </ref>
      <ref id="B101">
        <label>101.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adney</surname><given-names>DR</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>van Doremalen</surname><given-names>N</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Kong</surname><given-names>WP</given-names></name><etal/></person-group>. <article-title>Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas</article-title>. <source>Viruses.</source> (<year>2019</year>) <volume>11</volume>:<fpage>212</fpage>. <pub-id pub-id-type="doi">10.3390/v11030212</pub-id><pub-id pub-id-type="pmid">30832356</pub-id></mixed-citation>
      </ref>
      <ref id="B102">
        <label>102.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moise</surname><given-names>L</given-names></name><name><surname>De Groot</surname><given-names>A</given-names></name><name><surname>Marcello</surname><given-names>A</given-names></name><name><surname>Tassone</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>W</given-names></name><name><surname>Cousens</surname><given-names>L</given-names></name></person-group>. <article-title>Building better biotherapeutics and vaccines by design: EpiVax, Inc., an immunology company</article-title>. <source>R I Med J.</source> (<year>2013</year>) <volume>96</volume>:<fpage>19</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="pmid">23641421</pub-id></mixed-citation>
      </ref>
      <ref id="B103">
        <label>103.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moise</surname><given-names>L</given-names></name><name><surname>Cousens</surname><given-names>L</given-names></name><name><surname>Fueyo</surname><given-names>J</given-names></name><name><surname>De Groot</surname><given-names>AS</given-names></name></person-group>. <article-title>Harnessing the power of genomics and immunoinformatics to produce improved vaccines</article-title>. <source>Expert Opin Drug Discov.</source> (<year>2011</year>) <volume>6</volume>:<fpage>9</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1517/17460441.2011.534454</pub-id><pub-id pub-id-type="pmid">22646824</pub-id></mixed-citation>
      </ref>
      <ref id="B104">
        <label>104.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moise</surname><given-names>L</given-names></name><name><surname>Gutierrez</surname><given-names>A</given-names></name><name><surname>Kibria</surname><given-names>F</given-names></name><name><surname>Martin</surname><given-names>R</given-names></name><name><surname>Tassone</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines</article-title>. <source>Hum Vaccin Immunother.</source> (<year>2015</year>) <volume>11</volume>:<fpage>2312</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2015.1061159</pub-id><pub-id pub-id-type="pmid">26155959</pub-id></mixed-citation>
      </ref>
      <ref id="B105">
        <label>105.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sautto</surname><given-names>GA</given-names></name><name><surname>Kirchenbaum</surname><given-names>GA</given-names></name><name><surname>Abreu</surname><given-names>RB</given-names></name><name><surname>Ecker</surname><given-names>JW</given-names></name><name><surname>Pierce</surname><given-names>SR</given-names></name><name><surname>Kleanthous</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>A computationally optimized broadly reactive antigen subtype-specific influenza vaccine strategy elicits unique potent broadly neutralizing antibodies against hemagglutinin</article-title>. <source>J Immunol.</source> (<year>2020</year>) <volume>204</volume>:<fpage>375</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1900379</pub-id><pub-id pub-id-type="pmid">31811019</pub-id></mixed-citation>
      </ref>
      <ref id="B106">
        <label>106.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muthumani</surname><given-names>K</given-names></name><name><surname>Falzarano</surname><given-names>D</given-names></name><name><surname>Reuschel</surname><given-names>EL</given-names></name><name><surname>Tingey</surname><given-names>C</given-names></name><name><surname>Flingai</surname><given-names>S</given-names></name><name><surname>Villarreal</surname><given-names>DO</given-names></name><etal/></person-group>. <article-title>A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates</article-title>. <source>Sci Transl Med.</source> (<year>2015</year>) <volume>7</volume>:<fpage>301ra132</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aac7462</pub-id><pub-id pub-id-type="pmid">26290414</pub-id></mixed-citation>
      </ref>
      <ref id="B107">
        <label>107.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prescott</surname><given-names>J</given-names></name><name><surname>Falzarano</surname><given-names>D</given-names></name><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>Hardcastle</surname><given-names>K</given-names></name><name><surname>Feldmann</surname><given-names>F</given-names></name><name><surname>Haddock</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Pathogenicity and viral shedding of MERS-CoV in immunocompromised rhesus macaques</article-title>. <source>Front Immunol.</source> (<year>2018</year>) <volume>9</volume>:<fpage>205</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00205</pub-id><pub-id pub-id-type="pmid">29483914</pub-id></mixed-citation>
      </ref>
      <ref id="B108">
        <label>108.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichinohe</surname><given-names>T</given-names></name><name><surname>Ainai</surname><given-names>A</given-names></name><name><surname>Ami</surname><given-names>Y</given-names></name><name><surname>Nagata</surname><given-names>N</given-names></name><name><surname>Iwata</surname><given-names>N</given-names></name><name><surname>Kawaguchi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus</article-title>. <source>J Med Virol.</source> (<year>2010</year>) <volume>82</volume>:<fpage>1754</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.21824</pub-id><pub-id pub-id-type="pmid">20827774</pub-id></mixed-citation>
      </ref>
      <ref id="B109">
        <label>109.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asahi-Ozaki</surname><given-names>Y</given-names></name><name><surname>Itamura</surname><given-names>S</given-names></name><name><surname>Ichinohe</surname><given-names>T</given-names></name><name><surname>Strong</surname><given-names>P</given-names></name><name><surname>Tamura</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection</article-title>. <source>Microbes Infect.</source> (<year>2006</year>) <volume>8</volume>:<fpage>2706</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2006.07.018</pub-id><pub-id pub-id-type="pmid">16968669</pub-id></mixed-citation>
      </ref>
      <ref id="B110">
        <label>110.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Erdos</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Kenniston</surname><given-names>TW</given-names></name><name><surname>Balmert</surname><given-names>SC</given-names></name><name><surname>Carey</surname><given-names>CD</given-names></name><etal/></person-group>. <article-title>Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development</article-title>. <source>EBioMedicine.</source> (<year>2020</year>) <volume>55</volume>:<fpage>102743</fpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102743</pub-id><pub-id pub-id-type="pmid">32249203</pub-id></mixed-citation>
      </ref>
      <ref id="B111">
        <label>111.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strbo</surname><given-names>N</given-names></name><name><surname>Vaccari</surname><given-names>M</given-names></name><name><surname>Pahwa</surname><given-names>S</given-names></name><name><surname>Kolber</surname><given-names>MA</given-names></name><name><surname>Doster</surname><given-names>MN</given-names></name><name><surname>Fisher</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus</article-title>. <source>J Immunol.</source> (<year>2013</year>) <volume>190</volume>:<fpage>2495</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1202655</pub-id><pub-id pub-id-type="pmid">23401588</pub-id></mixed-citation>
      </ref>
      <ref id="B112">
        <label>112.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strbo</surname><given-names>N</given-names></name><name><surname>Garcia-Soto</surname><given-names>A</given-names></name><name><surname>Schreiber</surname><given-names>TH</given-names></name><name><surname>Podack</surname><given-names>ER</given-names></name></person-group>. <article-title>Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases</article-title>. <source>Immunol Res.</source> (<year>2013</year>) <volume>57</volume>:<fpage>311</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1007/s12026-013-8468-x</pub-id><pub-id pub-id-type="pmid">24254084</pub-id></mixed-citation>
      </ref>
      <ref id="B113">
        <label>113.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WH</given-names></name><name><surname>Chag</surname><given-names>SM</given-names></name><name><surname>Poongavanam</surname><given-names>MV</given-names></name><name><surname>Biter</surname><given-names>AB</given-names></name><name><surname>Ewere</surname><given-names>EA</given-names></name><name><surname>Rezende</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Optimization of the production process and characterization of the yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1), a SARS vaccine candidate</article-title>. <source>J Pharm Sci.</source> (<year>2017</year>) <volume>106</volume>:<fpage>1961</fpage>&#x2013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.xphs.2017.04.037</pub-id><pub-id pub-id-type="pmid">28456726</pub-id></mixed-citation>
      </ref>
      <ref id="B114">
        <label>114.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WH</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Chag</surname><given-names>SM</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Tricoche</surname><given-names>N</given-names></name><name><surname>Tao</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate</article-title>. <source>Hum Vaccin Immunother.</source> (<year>2014</year>) <volume>10</volume>:<fpage>648</fpage>&#x2013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.4161/hv.27464</pub-id><pub-id pub-id-type="pmid">24355931</pub-id></mixed-citation>
      </ref>
      <ref id="B115">
        <label>115.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langley</surname><given-names>JM</given-names></name><name><surname>MacDonald</surname><given-names>LD</given-names></name><name><surname>Weir</surname><given-names>GM</given-names></name><name><surname>MacKinnon-Cameron</surname><given-names>D</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>McNeil</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A respiratory syncytial virus vaccine based on the small hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study</article-title>. <source>J Infect Dis.</source> (<year>2018</year>) <volume>218</volume>:<fpage>378</fpage>&#x2013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiy177</pub-id><pub-id pub-id-type="pmid">29617814</pub-id></mixed-citation>
      </ref>
      <ref id="B116">
        <label>116.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weir</surname><given-names>GM</given-names></name><name><surname>MacDonald</surname><given-names>LD</given-names></name><name><surname>Rajagopalan</surname><given-names>R</given-names></name><name><surname>Sivko</surname><given-names>GS</given-names></name><name><surname>Valderas</surname><given-names>MW</given-names></name><name><surname>Rayner</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal bacillus anthracis spore inhalation challenge</article-title>. <source>NPJ Vaccines.</source> (<year>2019</year>) <volume>4</volume>:<fpage>6</fpage>. <pub-id pub-id-type="doi">10.1038/s41541-019-0102-z</pub-id><pub-id pub-id-type="pmid">30774997</pub-id></mixed-citation>
      </ref>
      <ref id="B117">
        <label>117.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovjazin</surname><given-names>R</given-names></name><name><surname>Volovitz</surname><given-names>I</given-names></name><name><surname>Kundel</surname><given-names>Y</given-names></name><name><surname>Rosenbaum</surname><given-names>E</given-names></name><name><surname>Medalia</surname><given-names>G</given-names></name><name><surname>Horn</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors</article-title>. <source>Vaccine.</source> (<year>2011</year>) <volume>29</volume>:<fpage>4676</fpage>&#x2013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.04.103</pub-id><pub-id pub-id-type="pmid">21570434</pub-id></mixed-citation>
      </ref>
      <ref id="B118">
        <label>118.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmon</surname><given-names>L</given-names></name><name><surname>Avivi</surname><given-names>I</given-names></name><name><surname>Kovjazin</surname><given-names>R</given-names></name><name><surname>Zuckerman</surname><given-names>T</given-names></name><name><surname>Dray</surname><given-names>L</given-names></name><name><surname>Gatt</surname><given-names>ME</given-names></name><etal/></person-group>. <article-title>Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients</article-title>. <source>Br J Haematol.</source> (<year>2015</year>) <volume>169</volume>:<fpage>44</fpage>&#x2013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1111/bjh.13245</pub-id><pub-id pub-id-type="pmid">25496030</pub-id></mixed-citation>
      </ref>
      <ref id="B119">
        <label>119.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha-Neto</surname><given-names>E</given-names></name><name><surname>Rosa</surname><given-names>DS</given-names></name><name><surname>Harris</surname><given-names>PE</given-names></name><name><surname>Olson</surname><given-names>T</given-names></name><name><surname>Morrow</surname><given-names>A</given-names></name><name><surname>Ciotlos</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>An approach for a synthetic CTL vaccine design against zika flavivirus using class I and class II epitopes identified by computer modeling</article-title>. <source>Front Immunol.</source> (<year>2017</year>) <volume>8</volume>:<fpage>640</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.00640</pub-id><pub-id pub-id-type="pmid">28649242</pub-id></mixed-citation>
      </ref>
      <ref id="B120">
        <label>120.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubsamen</surname><given-names>RM</given-names></name><name><surname>Herst</surname><given-names>CV</given-names></name><name><surname>Lloyd</surname><given-names>PM</given-names></name><name><surname>Heckerman</surname><given-names>DE</given-names></name></person-group>. <article-title>Eliciting cytotoxic T-lymphocyte responses from synthetic vectors containing one or two epitopes in a C57BL/6 mouse model using peptide-containing biodegradable microspheres and adjuvants</article-title>. <source>Vaccine.</source> (<year>2014</year>) <volume>32</volume>:<fpage>4111</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.05.071</pub-id><pub-id pub-id-type="pmid">24912025</pub-id></mixed-citation>
      </ref>
      <ref id="B121">
        <label>121.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Sposato</surname><given-names>M</given-names></name><name><surname>Zinckgraf</surname><given-names>JW</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>von Hofe</surname><given-names>E</given-names></name></person-group>. <article-title>Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers</article-title>. <source>Vaccine.</source> (<year>2009</year>) <volume>27</volume>:<fpage>4641</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.05.054</pub-id><pub-id pub-id-type="pmid">19520206</pub-id></mixed-citation>
      </ref>
      <ref id="B122">
        <label>122.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>SA</given-names></name><name><surname>Kallinteris</surname><given-names>NL</given-names></name><name><surname>Bisias</surname><given-names>S</given-names></name><name><surname>Tzonis</surname><given-names>PK</given-names></name><name><surname>Georgakopoulou</surname><given-names>K</given-names></name><name><surname>Varla-Leftherioti</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer</article-title>. <source>Clin Cancer Res.</source> (<year>2010</year>) <volume>16</volume>:<fpage>3495</fpage>&#x2013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-0085</pub-id><pub-id pub-id-type="pmid">20466887</pub-id></mixed-citation>
      </ref>
      <ref id="B123">
        <label>123.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>R</given-names></name><name><surname>Babiuk</surname><given-names>L</given-names></name><name><surname>van Drunen</surname><given-names>Littel-van den Hurk S</given-names></name><name><surname>Gerdts</surname><given-names>V</given-names></name></person-group>. <article-title>A novel combination adjuvant platform for human and animal vaccines</article-title>. <source>Vaccine.</source> (<year>2017</year>) <volume>35</volume>(<issue>35 Pt A</issue>):<fpage>4486</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.067</pub-id><pub-id pub-id-type="pmid">28599794</pub-id></mixed-citation>
      </ref>
      <ref id="B124">
        <label>124.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garlapati</surname><given-names>S</given-names></name><name><surname>Eng</surname><given-names>NF</given-names></name><name><surname>Kiros</surname><given-names>TG</given-names></name><name><surname>Kindrachuk</surname><given-names>J</given-names></name><name><surname>Mutwiri</surname><given-names>GK</given-names></name><name><surname>Hancock</surname><given-names>RE</given-names></name><etal/></person-group>
<article-title>Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis</article-title>. <source>Vaccine.</source> (<year>2011</year>) <volume>29</volume>:<fpage>6540</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.07.009</pub-id><pub-id pub-id-type="pmid">21771625</pub-id></mixed-citation>
      </ref>
      <ref id="B125">
        <label>125.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kajikawa</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>LaVoy</surname><given-names>A</given-names></name><name><surname>Bumgardner</surname><given-names>S</given-names></name><name><surname>Klaenhammer</surname><given-names>TR</given-names></name><name><surname>Dean</surname><given-names>GA</given-names></name></person-group>. <article-title>Mucosal immunogenicity of genetically modified lactobacillus acidophilus expressing an HIV-1 epitope within the surface layer protein</article-title>. <source>PLoS ONE.</source> (<year>2015</year>) <volume>10</volume>:<fpage>e0141713</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0141713</pub-id><pub-id pub-id-type="pmid">26509697</pub-id></mixed-citation>
      </ref>
      <ref id="B126">
        <label>126.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bumgardner</surname><given-names>SA</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>LaVoy</surname><given-names>AS</given-names></name><name><surname>Andre</surname><given-names>B</given-names></name><name><surname>Frank</surname><given-names>CB</given-names></name><name><surname>Kajikawa</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Nod2 is required for antigen-specific humoral responses against antigens orally delivered using a recombinant lactobacillus vaccine platform</article-title>. <source>PLoS ONE.</source> (<year>2018</year>) <volume>13</volume>:<fpage>e0196950</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0196950</pub-id><pub-id pub-id-type="pmid">29734365</pub-id></mixed-citation>
      </ref>
      <ref id="B127">
        <label>127.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hjerrild</surname><given-names>KA</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Wright</surname><given-names>KE</given-names></name><name><surname>Brown</surname><given-names>RE</given-names></name><name><surname>Marshall</surname><given-names>JM</given-names></name><name><surname>Labbe</surname><given-names>GM</given-names></name><etal/></person-group>. <article-title>Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a drosophila melanogaster Schneider 2 stable cell line system</article-title>. <source>Sci Rep.</source> (<year>2016</year>) <volume>6</volume>:<fpage>30357</fpage>. <pub-id pub-id-type="doi">10.1038/srep30357</pub-id><pub-id pub-id-type="pmid">27457156</pub-id></mixed-citation>
      </ref>
      <ref id="B128">
        <label>128.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mordmuller</surname><given-names>B</given-names></name><name><surname>Sulyok</surname><given-names>M</given-names></name><name><surname>Egger-Adam</surname><given-names>D</given-names></name><name><surname>Resende</surname><given-names>M</given-names></name><name><surname>de Jongh</surname><given-names>WA</given-names></name><name><surname>Jensen</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a vaccine candidate to prevent pregnancy-associated malaria</article-title>. <source>Clin Infect Dis.</source> (<year>2019</year>) <volume>69</volume>:<fpage>1509</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciy1140</pub-id><pub-id pub-id-type="pmid">30629148</pub-id></mixed-citation>
      </ref>
      <ref id="B129">
        <label>129.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escolano</surname><given-names>A</given-names></name><name><surname>Gristick</surname><given-names>HB</given-names></name><name><surname>Abernathy</surname><given-names>ME</given-names></name><name><surname>Merkenschlager</surname><given-names>J</given-names></name><name><surname>Gautam</surname><given-names>R</given-names></name><name><surname>Oliveira</surname><given-names>TY</given-names></name><etal/></person-group>. <article-title>Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques</article-title>. <source>Nature.</source> (<year>2019</year>) <volume>570</volume>:<fpage>468</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1250-z</pub-id><pub-id pub-id-type="pmid">31142836</pub-id></mixed-citation>
      </ref>
      <ref id="B130">
        <label>130.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janitzek</surname><given-names>CM</given-names></name><name><surname>Peabody</surname><given-names>J</given-names></name><name><surname>Thrane</surname><given-names>S</given-names></name><name><surname>P</surname><given-names>HRC</given-names></name><name><surname>T</surname><given-names>GT</given-names></name><name><surname>Salanti</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine</article-title>. <source>Sci Rep.</source> (<year>2019</year>) <volume>9</volume>:<fpage>5260</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-41522-5</pub-id><pub-id pub-id-type="pmid">30918267</pub-id></mixed-citation>
      </ref>
      <ref id="B131">
        <label>131.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwestka</surname><given-names>J</given-names></name><name><surname>Tschofen</surname><given-names>M</given-names></name><name><surname>Vogt</surname><given-names>S</given-names></name><name><surname>Marcel</surname><given-names>S</given-names></name><name><surname>Grillari</surname><given-names>J</given-names></name><name><surname>Raith</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Plant-derived protein bodies as delivery vehicles for recombinant proteins into mammalian cells</article-title>. <source>Biotechnol Bioeng.</source> (<year>2020</year>) <volume>117</volume>:<fpage>1037</fpage>&#x2013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1002/bit.27273</pub-id><pub-id pub-id-type="pmid">31956981</pub-id></mixed-citation>
      </ref>
      <ref id="B132">
        <label>132.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laughlin</surname><given-names>RC</given-names></name><name><surname>Madera</surname><given-names>R</given-names></name><name><surname>Peres</surname><given-names>Y</given-names></name><name><surname>Berquist</surname><given-names>BR</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Buist</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Plant-made E2 glycoprotein single-dose vaccine protects pigs against classical swine fever</article-title>. <source>Plant Biotechnol J.</source> (<year>2019</year>) <volume>17</volume>:<fpage>410</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1111/pbi.12986</pub-id><pub-id pub-id-type="pmid">29993179</pub-id></mixed-citation>
      </ref>
      <ref id="B133">
        <label>133.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milligan</surname><given-names>ID</given-names></name><name><surname>Gibani</surname><given-names>MM</given-names></name><name><surname>Sewell</surname><given-names>R</given-names></name><name><surname>Clutterbuck</surname><given-names>EA</given-names></name><name><surname>Campbell</surname><given-names>D</given-names></name><name><surname>Plested</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial</article-title>. <source>JAMA.</source> (<year>2016</year>) <volume>315</volume>:<fpage>1610</fpage>&#x2013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2016.4218</pub-id><pub-id pub-id-type="pmid">27092831</pub-id></mixed-citation>
      </ref>
      <ref id="B134">
        <label>134.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvato</surname><given-names>MS</given-names></name><name><surname>Domi</surname><given-names>A</given-names></name><name><surname>Guzman-Cardozo</surname><given-names>C</given-names></name><name><surname>Medina-Moreno</surname><given-names>S</given-names></name><name><surname>Zapata</surname><given-names>JC</given-names></name><name><surname>Hsu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>A single dose of modified vaccinia Ankara expressing Lassa virus-like particles protects mice from lethal intra-cerebral virus challenge</article-title>. <source>Pathogens.</source> (<year>2019</year>) <volume>8</volume>:<fpage>33</fpage>. <pub-id pub-id-type="doi">10.3390/pathogens8030133</pub-id><pub-id pub-id-type="pmid">31466243</pub-id></mixed-citation>
      </ref>
      <ref id="B135">
        <label>135.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domi</surname><given-names>A</given-names></name><name><surname>Feldmann</surname><given-names>F</given-names></name><name><surname>Basu</surname><given-names>R</given-names></name><name><surname>McCurley</surname><given-names>N</given-names></name><name><surname>Shifflett</surname><given-names>K</given-names></name><name><surname>Emanuel</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>A single dose of modified vaccinia Ankara expressing Ebola virus like particles protects nonhuman primates from lethal Ebola virus challenge</article-title>. <source>Sci Rep.</source> (<year>2018</year>) <volume>8</volume>:<fpage>864</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-19041-y</pub-id><pub-id pub-id-type="pmid">29339750</pub-id></mixed-citation>
      </ref>
      <ref id="B136">
        <label>136.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volz</surname><given-names>A</given-names></name><name><surname>Kupke</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>F</given-names></name><name><surname>Jany</surname><given-names>S</given-names></name><name><surname>Fux</surname><given-names>R</given-names></name><name><surname>Shams-Eldin</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein</article-title>. <source>J Virol.</source> (<year>2015</year>) <volume>89</volume>:<fpage>8651</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00614-15</pub-id><pub-id pub-id-type="pmid">26018172</pub-id></mixed-citation>
      </ref>
      <ref id="B137">
        <label>137.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haagmans</surname><given-names>BL</given-names></name><name><surname>van den Brand</surname><given-names>JM</given-names></name><name><surname>Raj</surname><given-names>VS</given-names></name><name><surname>Volz</surname><given-names>A</given-names></name><name><surname>Wohlsein</surname><given-names>P</given-names></name><name><surname>Smits</surname><given-names>SL</given-names></name><etal/></person-group>. <article-title>An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels</article-title>. <source>Science.</source> (<year>2016</year>) <volume>351</volume>:<fpage>77</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1126/science.aad1283</pub-id><pub-id pub-id-type="pmid">26678878</pub-id></mixed-citation>
      </ref>
      <ref id="B138">
        <label>138.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>N</given-names></name><name><surname>Pillet</surname><given-names>S</given-names></name><name><surname>Favre</surname><given-names>D</given-names></name><name><surname>Poulin</surname><given-names>JF</given-names></name><name><surname>Trepanier</surname><given-names>S</given-names></name><name><surname>Yassine-Diab</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Influenza virus-like particle vaccines made in nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens</article-title>. <source>Clin Immunol.</source> (<year>2014</year>) <volume>154</volume>:<fpage>164</fpage>&#x2013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2014.08.003</pub-id><pub-id pub-id-type="pmid">25128897</pub-id></mixed-citation>
      </ref>
      <ref id="B139">
        <label>139.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillet</surname><given-names>S</given-names></name><name><surname>Couillard</surname><given-names>J</given-names></name><name><surname>Trepanier</surname><given-names>S</given-names></name><name><surname>Poulin</surname><given-names>JF</given-names></name><name><surname>Yassine-Diab</surname><given-names>B</given-names></name><name><surname>Guy</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-two randomized Phase II clinical trials in 18 to 49 and &gt;/=50 years old adults</article-title>. <source>PLoS ONE.</source> (<year>2019</year>) <volume>14</volume>:<fpage>e0216533</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0216533</pub-id><pub-id pub-id-type="pmid">31166987</pub-id></mixed-citation>
      </ref>
      <ref id="B140">
        <label>140.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scallan</surname><given-names>CD</given-names></name><name><surname>Tingley</surname><given-names>DW</given-names></name><name><surname>Lindbloom</surname><given-names>JD</given-names></name><name><surname>Toomey</surname><given-names>JS</given-names></name><name><surname>Tucker</surname><given-names>SN</given-names></name></person-group>. <article-title>An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models</article-title>. <source>Clin Vaccine Immunol.</source> (<year>2013</year>) <volume>20</volume>:<fpage>85</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00552-12</pub-id><pub-id pub-id-type="pmid">23155123</pub-id></mixed-citation>
      </ref>
      <ref id="B141">
        <label>141.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liebowitz</surname><given-names>D</given-names></name><name><surname>Gottlieb</surname><given-names>K</given-names></name><name><surname>Kolhatkar</surname><given-names>NS</given-names></name><name><surname>Garg</surname><given-names>SJ</given-names></name><name><surname>Asher</surname><given-names>JM</given-names></name><name><surname>Nazareno</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study</article-title>. <source>Lancet Infect Dis.</source> (<year>2020</year>) <volume>20</volume>:<fpage>435</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(19)30584-5</pub-id><pub-id pub-id-type="pmid">31978354</pub-id></mixed-citation>
      </ref>
      <ref id="B142">
        <label>142.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vragniau</surname><given-names>C</given-names></name><name><surname>Bufton</surname><given-names>JC</given-names></name><name><surname>Garzoni</surname><given-names>F</given-names></name><name><surname>Stermann</surname><given-names>E</given-names></name><name><surname>Rabi</surname><given-names>F</given-names></name><name><surname>Terrat</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Synthetic self-assembling ADDomer platform for highly efficient vaccination by genetically encoded multiepitope display</article-title>. <source>Sci Adv.</source> (<year>2019</year>) <volume>5</volume>:<fpage>eaaw2853</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.aaw2853</pub-id><pub-id pub-id-type="pmid">31620562</pub-id></mixed-citation>
      </ref>
      <ref id="B143">
        <label>143.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>CA</given-names></name><name><surname>Sande</surname><given-names>CJ</given-names></name><name><surname>Scarselli</surname><given-names>E</given-names></name><name><surname>Capone</surname><given-names>S</given-names></name><name><surname>Vitelli</surname><given-names>A</given-names></name><name><surname>Nicosia</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults</article-title>. <source>J Infect.</source> (<year>2019</year>) <volume>78</volume>:<fpage>382</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2019.02.003</pub-id><pub-id pub-id-type="pmid">30742894</pub-id></mixed-citation>
      </ref>
      <ref id="B144">
        <label>144.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>DA</given-names></name><name><surname>Honko</surname><given-names>AN</given-names></name><name><surname>Asiedu</surname><given-names>C</given-names></name><name><surname>Trefry</surname><given-names>JC</given-names></name><name><surname>Lau-Kilby</surname><given-names>AW</given-names></name><name><surname>Johnson</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge</article-title>. <source>Nat Med.</source> (<year>2014</year>) <volume>20</volume>:<fpage>1126</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3702</pub-id><pub-id pub-id-type="pmid">25194571</pub-id></mixed-citation>
      </ref>
      <ref id="B145">
        <label>145.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>An</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Single-dose, intranasal immunization with recombinant parainfluenza virus 5 expressing Middle East respiratory syndrome coronavirus (MERS-CoV) spike protein protects mice from fatal MERS-CoV infection</article-title>. <source>mBio.</source> (<year>2020</year>) <volume>11</volume>:<fpage>e00554</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.00554-20</pub-id><pub-id pub-id-type="pmid">32265331</pub-id></mixed-citation>
      </ref>
      <ref id="B146">
        <label>146.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsauer</surname><given-names>K</given-names></name><name><surname>Schwameis</surname><given-names>M</given-names></name><name><surname>Firbas</surname><given-names>C</given-names></name><name><surname>Mullner</surname><given-names>M</given-names></name><name><surname>Putnak</surname><given-names>RJ</given-names></name><name><surname>Thomas</surname><given-names>SJ</given-names></name><etal/></person-group>. <article-title>Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial</article-title>. <source>Lancet Infect Dis.</source> (<year>2015</year>) <volume>15</volume>:<fpage>519</fpage>&#x2013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(15)70043-5</pub-id><pub-id pub-id-type="pmid">25739878</pub-id></mixed-citation>
      </ref>
      <ref id="B147">
        <label>147.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escriou</surname><given-names>N</given-names></name><name><surname>Callendret</surname><given-names>B</given-names></name><name><surname>Lorin</surname><given-names>V</given-names></name><name><surname>Combredet</surname><given-names>C</given-names></name><name><surname>Marianneau</surname><given-names>P</given-names></name><name><surname>Fevrier</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein</article-title>. <source>Virology.</source> (<year>2014</year>) <volume>452-453</volume>:<fpage>32</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2014.01.002</pub-id><pub-id pub-id-type="pmid">24606680</pub-id></mixed-citation>
      </ref>
      <ref id="B148">
        <label>148.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noyce</surname><given-names>RS</given-names></name><name><surname>Lederman</surname><given-names>S</given-names></name><name><surname>Evans</surname><given-names>DH</given-names></name></person-group>. <article-title>Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments</article-title>. <source>PLoS ONE.</source> (<year>2018</year>) <volume>13</volume>:<fpage>e0188453</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0188453</pub-id><pub-id pub-id-type="pmid">29351298</pub-id></mixed-citation>
      </ref>
      <ref id="B149">
        <label>149.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tulman</surname><given-names>ER</given-names></name><name><surname>Delhon</surname><given-names>G</given-names></name><name><surname>Afonso</surname><given-names>CL</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Zsak</surname><given-names>L</given-names></name><name><surname>Sandybaev</surname><given-names>NT</given-names></name><etal/></person-group>. <article-title>Genome of horsepox virus</article-title>. <source>J Virol.</source> (<year>2006</year>) <volume>80</volume>:<fpage>9244</fpage>&#x2013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00945-06</pub-id><pub-id pub-id-type="pmid">16940536</pub-id></mixed-citation>
      </ref>
      <ref id="B150">
        <label>150.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>DK</given-names></name><name><surname>Nasar</surname><given-names>F</given-names></name><name><surname>Chong</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>JE</given-names></name><name><surname>Coleman</surname><given-names>JW</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates</article-title>. <source>J Virol.</source> (<year>2014</year>) <volume>88</volume>:<fpage>6690</fpage>&#x2013;<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.03441-13</pub-id><pub-id pub-id-type="pmid">24696472</pub-id></mixed-citation>
      </ref>
      <ref id="B151">
        <label>151.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henao-Restrepo</surname><given-names>AM</given-names></name><name><surname>Camacho</surname><given-names>A</given-names></name><name><surname>Longini</surname><given-names>IM</given-names></name><name><surname>Watson</surname><given-names>CH</given-names></name><name><surname>Edmunds</surname><given-names>WJ</given-names></name><name><surname>Egger</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)</article-title>. <source>Lancet.</source> (<year>2017</year>) <volume>389</volume>:<fpage>505</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)32621-6</pub-id><pub-id pub-id-type="pmid">28017403</pub-id></mixed-citation>
      </ref>
      <ref id="B152">
        <label>152.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Lau</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Mok</surname><given-names>BW</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Generation of DelNS1 influenza viruses: a strategy for optimizing live attenuated influenza vaccines</article-title>. <source>mBio.</source> (<year>2019</year>) <volume>10</volume>:<fpage>e02180</fpage>&#x2013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.02180-19</pub-id><pub-id pub-id-type="pmid">31530680</pub-id></mixed-citation>
      </ref>
      <ref id="B153">
        <label>153.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Lau</surname><given-names>SY</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>An A14U substitution in the 3\' noncoding region of the M segment of viral RNA supports replication of influenza virus with an NS1 deletion by modulating alternative splicing of M segment mRNAs</article-title>. <source>J Virol.</source> (<year>2015</year>) <volume>89</volume>:<fpage>10273</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00919-15</pub-id><pub-id pub-id-type="pmid">26223635</pub-id></mixed-citation>
      </ref>
      <ref id="B154">
        <label>154.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatta</surname><given-names>Y</given-names></name><name><surname>Boltz</surname><given-names>D</given-names></name><name><surname>Sarawar</surname><given-names>S</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name><name><surname>Neumann</surname><given-names>G</given-names></name><name><surname>Bilsel</surname><given-names>P</given-names></name></person-group>. <article-title>M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza</article-title>. <source>Vaccine.</source> (<year>2017</year>) <volume>35</volume>:<fpage>4177</fpage>&#x2013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.06.039</pub-id><pub-id pub-id-type="pmid">28668565</pub-id></mixed-citation>
      </ref>
      <ref id="B155">
        <label>155.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatta</surname><given-names>Y</given-names></name><name><surname>Boltz</surname><given-names>D</given-names></name><name><surname>Sarawar</surname><given-names>S</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name><name><surname>Neumann</surname><given-names>G</given-names></name><name><surname>Bilsel</surname><given-names>P</given-names></name></person-group>. <article-title>Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity</article-title>. <source>Vaccine.</source> (<year>2018</year>) <volume>36</volume>:<fpage>5097</fpage>&#x2013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.06.053</pub-id><pub-id pub-id-type="pmid">30007825</pub-id></mixed-citation>
      </ref>
      <ref id="B156">
        <label>156.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurisicchio</surname><given-names>L</given-names></name><name><surname>Peruzzi</surname><given-names>D</given-names></name><name><surname>Koo</surname><given-names>G</given-names></name><name><surname>Wei</surname><given-names>WZ</given-names></name><name><surname>La Monica</surname><given-names>N</given-names></name><name><surname>Ciliberto</surname><given-names>G</given-names></name></person-group>. <article-title>Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models</article-title>. <source>Hum Gene Ther.</source> (<year>2014</year>) <volume>25</volume>:<fpage>121</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1089/hum.2013.103</pub-id><pub-id pub-id-type="pmid">24195644</pub-id></mixed-citation>
      </ref>
      <ref id="B157">
        <label>157.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurisicchio</surname><given-names>L</given-names></name><name><surname>Fridman</surname><given-names>A</given-names></name><name><surname>Bagchi</surname><given-names>A</given-names></name><name><surname>Scarselli</surname><given-names>E</given-names></name><name><surname>La Monica</surname><given-names>N</given-names></name><name><surname>Ciliberto</surname><given-names>G</given-names></name></person-group>. <article-title>A novel minigene scaffold for therapeutic cancer vaccines</article-title>. <source>Oncoimmunology.</source> (<year>2014</year>) <volume>3</volume>:<fpage>e27529</fpage>. <pub-id pub-id-type="doi">10.4161/onci.27529</pub-id><pub-id pub-id-type="pmid">24790791</pub-id></mixed-citation>
      </ref>
      <ref id="B158">
        <label>158.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shigematsu</surname><given-names>H</given-names></name><name><surname>Yasuda</surname><given-names>K</given-names></name><name><surname>Sasajima</surname><given-names>T</given-names></name><name><surname>Takano</surname><given-names>T</given-names></name><name><surname>Miyata</surname><given-names>T</given-names></name><name><surname>Ohta</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Transfection of human HGF plasmid DNA improves limb salvage in buerger\'s disease patients with critical limb ischemia</article-title>. <source>Int Angiol.</source> (<year>2011</year>) <volume>30</volume>:<fpage>140</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="pmid">21427651</pub-id></mixed-citation>
      </ref>
      <ref id="B159">
        <label>159.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koriyama</surname><given-names>H</given-names></name><name><surname>Nakagami</surname><given-names>H</given-names></name><name><surname>Nakagami</surname><given-names>F</given-names></name><name><surname>Osako</surname><given-names>MK</given-names></name><name><surname>Kyutoku</surname><given-names>M</given-names></name><name><surname>Shimamura</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Long-term reduction of high blood pressure by angiotensin II DNA vaccine in spontaneously hypertensive rats</article-title>. <source>Hypertension.</source> (<year>2015</year>) <volume>66</volume>:<fpage>167</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.114.04534</pub-id><pub-id pub-id-type="pmid">26015450</pub-id></mixed-citation>
      </ref>
      <ref id="B160">
        <label>160.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leckenby</surname><given-names>MW</given-names></name><name><surname>Spear</surname><given-names>AM</given-names></name><name><surname>Neeson</surname><given-names>BN</given-names></name><name><surname>Williamson</surname><given-names>ED</given-names></name><name><surname>Cranenburgh</surname><given-names>RM</given-names></name><name><surname>Atkins</surname><given-names>HS</given-names></name></person-group>. <article-title>Enhanced vaccine antigen delivery by Salmonella using antibiotic-free operator-repressor titration-based plasmid stabilisation compared to chromosomal integration</article-title>. <source>Microb Pathog.</source> (<year>2009</year>) <volume>46</volume>:<fpage>201</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2009.01.001</pub-id><pub-id pub-id-type="pmid">19490834</pub-id></mixed-citation>
      </ref>
      <ref id="B161">
        <label>161.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>JM</given-names></name><name><surname>Sali</surname><given-names>M</given-names></name><name><surname>Leckenby</surname><given-names>MW</given-names></name><name><surname>Radford</surname><given-names>DS</given-names></name><name><surname>Huynh</surname><given-names>HA</given-names></name><name><surname>Delogu</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Oral delivery of a DNA vaccine against tuberculosis using operator-repressor titration in a salmonella enterica vector</article-title>. <source>Vaccine.</source> (<year>2010</year>) <volume>28</volume>:<fpage>7523</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.09.001</pub-id><pub-id pub-id-type="pmid">20851079</pub-id></mixed-citation>
      </ref>
      <ref id="B162">
        <label>162.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Connolly</surname><given-names>M</given-names></name><name><surname>Marketon</surname><given-names>A</given-names></name><name><surname>Heiland</surname><given-names>T</given-names></name></person-group>. <article-title>CryJ-LAMP DNA vaccines for Japanese red cedar allergy induce robust Th1-type immune responses in murine model</article-title>. <source>J Immunol Res.</source> (<year>2016</year>) <volume>2016</volume>:<fpage>4857869</fpage>. <pub-id pub-id-type="doi">10.1155/2016/4857869</pub-id><pub-id pub-id-type="pmid">27239481</pub-id></mixed-citation>
      </ref>
      <ref id="B163">
        <label>163.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Resik</surname><given-names>S</given-names></name><name><surname>Tejeda</surname><given-names>A</given-names></name><name><surname>Mach</surname><given-names>O</given-names></name><name><surname>Sein</surname><given-names>C</given-names></name><name><surname>Molodecky</surname><given-names>N</given-names></name><name><surname>Jarrahian</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: association between injection quality and immunogenicity</article-title>. <source>Vaccine.</source> (<year>2015</year>) <volume>33</volume>:<fpage>5873</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.06.071</pub-id><pub-id pub-id-type="pmid">26192350</pub-id></mixed-citation>
      </ref>
      <ref id="B164">
        <label>164.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barati</surname><given-names>N</given-names></name><name><surname>Razazan</surname><given-names>A</given-names></name><name><surname>Nicastro</surname><given-names>J</given-names></name><name><surname>Slavcev</surname><given-names>R</given-names></name><name><surname>Arab</surname><given-names>A</given-names></name><name><surname>Mosaffa</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Immunogenicity and antitumor activity of the superlytic lambdaF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice</article-title>. <source>Cancer Lett.</source> (<year>2018</year>) <volume>424</volume>:<fpage>109</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2018.03.030</pub-id><pub-id pub-id-type="pmid">29580807</pub-id></mixed-citation>
      </ref>
      <ref id="B165">
        <label>165.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razazan</surname><given-names>A</given-names></name><name><surname>Nicastro</surname><given-names>J</given-names></name><name><surname>Slavcev</surname><given-names>R</given-names></name><name><surname>Barati</surname><given-names>N</given-names></name><name><surname>Arab</surname><given-names>A</given-names></name><name><surname>Mosaffa</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice</article-title>. <source>Sci Rep.</source> (<year>2019</year>) <volume>9</volume>:<fpage>2221</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-38371-z</pub-id><pub-id pub-id-type="pmid">30778090</pub-id></mixed-citation>
      </ref>
      <ref id="B166">
        <label>166.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blakney</surname><given-names>AK</given-names></name><name><surname>McKay</surname><given-names>PF</given-names></name><name><surname>Yus</surname><given-names>BI</given-names></name><name><surname>Aldon</surname><given-names>Y</given-names></name><name><surname>Shattock</surname><given-names>RJ</given-names></name></person-group>. <article-title>Inside out: optimization of lipid nanoparticle formulations for exterior complexation and <italic>in vivo</italic> delivery of saRNA</article-title>. <source>Gene Ther.</source> (<year>2019</year>) <volume>26</volume>:<fpage>363</fpage>&#x2013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1038/s41434-019-0095-2</pub-id><pub-id pub-id-type="pmid">31300730</pub-id></mixed-citation>
      </ref>
      <ref id="B167">
        <label>167.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blakney</surname><given-names>AK</given-names></name><name><surname>Yilmaz</surname><given-names>G</given-names></name><name><surname>McKay</surname><given-names>PF</given-names></name><name><surname>Becer</surname><given-names>CR</given-names></name><name><surname>Shattock</surname><given-names>RJ</given-names></name></person-group>. <article-title>One size does not fit all: the effect of chain length and charge density of poly(ethylene imine) based copolymers on delivery of pDNA, mRNA, and RepRNA polyplexes</article-title>. <source>Biomacromolecules.</source> (<year>2018</year>) <volume>19</volume>:<fpage>2870</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1021/acs.biomac.8b00429</pub-id><pub-id pub-id-type="pmid">29698602</pub-id></mixed-citation>
      </ref>
      <ref id="B168">
        <label>168.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaswamy</surname><given-names>S</given-names></name><name><surname>Tonnu</surname><given-names>N</given-names></name><name><surname>Tachikawa</surname><given-names>K</given-names></name><name><surname>Limphong</surname><given-names>P</given-names></name><name><surname>Vega</surname><given-names>JB</given-names></name><name><surname>Karmali</surname><given-names>PP</given-names></name><etal/></person-group>. <article-title>Systemic delivery of factor IX messenger RNA for protein replacement therapy</article-title>. <source>Proc Natl Acad Sci U S A.</source> (<year>2017</year>) <volume>114</volume>:<fpage>E1941</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1619653114</pub-id><pub-id pub-id-type="pmid">28202722</pub-id></mixed-citation>
      </ref>
      <ref id="B169">
        <label>169.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Lint</surname><given-names>S</given-names></name><name><surname>Goyvaerts</surname><given-names>C</given-names></name><name><surname>Maenhout</surname><given-names>S</given-names></name><name><surname>Goethals</surname><given-names>L</given-names></name><name><surname>Disy</surname><given-names>A</given-names></name><name><surname>Benteyn</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy</article-title>. <source>Cancer Res.</source> (<year>2012</year>) <volume>72</volume>:<fpage>1661</fpage>&#x2013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-2957</pub-id><pub-id pub-id-type="pmid">22337996</pub-id></mixed-citation>
      </ref>
      <ref id="B170">
        <label>170.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilgenhof</surname><given-names>S</given-names></name><name><surname>Van Nuffel</surname><given-names>AM</given-names></name><name><surname>Benteyn</surname><given-names>D</given-names></name><name><surname>Corthals</surname><given-names>J</given-names></name><name><surname>Aerts</surname><given-names>C</given-names></name><name><surname>Heirman</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients</article-title>. <source>Ann Oncol.</source> (<year>2013</year>) <volume>24</volume>:<fpage>2686</fpage>&#x2013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdt245</pub-id><pub-id pub-id-type="pmid">23904461</pub-id></mixed-citation>
      </ref>
      <ref id="B171">
        <label>171.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kauffman</surname><given-names>KJ</given-names></name><name><surname>Dorkin</surname><given-names>JR</given-names></name><name><surname>Yang</surname><given-names>JH</given-names></name><name><surname>Heartlein</surname><given-names>MW</given-names></name><name><surname>DeRosa</surname><given-names>F</given-names></name><name><surname>Mir</surname><given-names>FF</given-names></name><etal/></person-group>. <article-title>Optimization of lipid nanoparticle formulations for mRNA delivery <italic>in vivo</italic> with fractional factorial and definitive screening designs</article-title>. <source>Nano Lett.</source> (<year>2015</year>) <volume>15</volume>:<fpage>7300</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.5b02497</pub-id><pub-id pub-id-type="pmid">26469188</pub-id></mixed-citation>
      </ref>
      <ref id="B172">
        <label>172.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rybakova</surname><given-names>Y</given-names></name><name><surname>Kowalski</surname><given-names>PS</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Gonzalez</surname><given-names>JT</given-names></name><name><surname>Heartlein</surname><given-names>MW</given-names></name><name><surname>DeRosa</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>mRNA delivery for therapeutic anti-HER2 antibody expression <italic>in vivo</italic></article-title>. <source>Mol Ther.</source> (<year>2019</year>) <volume>27</volume>:<fpage>1415</fpage>&#x2013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2019.05.012</pub-id><pub-id pub-id-type="pmid">31160223</pub-id></mixed-citation>
      </ref>
      <ref id="B173">
        <label>173.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>P</given-names></name><name><surname>M</surname><given-names>QM</given-names></name><name><surname>Lazaro-Frias</surname><given-names>A</given-names></name><name><surname>Jimenez de Oya</surname><given-names>N</given-names></name><name><surname>Blazquez</surname><given-names>AB</given-names></name><name><surname>Escribano-Romero</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>A vaccine based on a modified vaccinia virus Ankara vector expressing zika virus structural proteins controls zika virus replication in mice</article-title>. <source>Sci Rep.</source> (<year>2018</year>) <volume>8</volume>:<fpage>17385</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-35724-6</pub-id><pub-id pub-id-type="pmid">30478418</pub-id></mixed-citation>
      </ref>
      <ref id="B174">
        <label>174.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazaro-Frias</surname><given-names>A</given-names></name><name><surname>Gomez-Medina</surname><given-names>S</given-names></name><name><surname>Sanchez-Sampedro</surname><given-names>L</given-names></name><name><surname>Ljungberg</surname><given-names>K</given-names></name><name><surname>Ustav</surname><given-names>M</given-names></name><name><surname>Liljestrom</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Distinct immunogenicity and efficacy of poxvirus-based vaccine candidates against Ebola virus expressing GP and VP40 proteins</article-title>. <source>J Virol.</source> (<year>2018</year>) <volume>92</volume>:<fpage>e00363</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00363-18</pub-id><pub-id pub-id-type="pmid">29514907</pub-id></mixed-citation>
      </ref>
      <ref id="B175">
        <label>175.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzi</surname><given-names>A</given-names></name><name><surname>Halfmann</surname><given-names>P</given-names></name><name><surname>Hill-Batorski</surname><given-names>L</given-names></name><name><surname>Feldmann</surname><given-names>F</given-names></name><name><surname>Shupert</surname><given-names>WL</given-names></name><name><surname>Neumann</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates</article-title>. <source>Science.</source> (<year>2015</year>) <volume>348</volume>:<fpage>439</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaa4919</pub-id><pub-id pub-id-type="pmid">25814063</pub-id></mixed-citation>
      </ref>
      <ref id="B176">
        <label>176.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>F</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu(R)</article-title>. <source>Hum Vaccin Immunother.</source> (<year>2016</year>) <volume>12</volume>:<fpage>1229</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2015.1123357</pub-id><pub-id pub-id-type="pmid">26934750</pub-id></mixed-citation>
      </ref>
      <ref id="B177">
        <label>177.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JT</given-names></name><name><surname>Zhang</surname><given-names>JS</given-names></name><name><surname>Su</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>JG</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>JT</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine</article-title>. <source>Antivir Ther.</source> (<year>2007</year>) <volume>12</volume>:<fpage>1107</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="pmid">18018769</pub-id></mixed-citation>
      </ref>
      <ref id="B178">
        <label>178.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group>. <article-title>SARS-CoV-2: virus dynamics and host response</article-title>. <source>Lancet Infect Dis.</source> (<year>2020</year>) <volume>20</volume>:<fpage>515</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30235-8</pub-id><pub-id pub-id-type="pmid">32213336</pub-id></mixed-citation>
      </ref>
      <ref id="B179">
        <label>179.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>YH</given-names></name><name><surname>Ni</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>WJ</given-names></name><name><surname>Li</surname><given-names>GJ</given-names></name><name><surname>Wang</surname><given-names>WD</given-names></name><etal/></person-group>. <article-title>Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019</article-title>. <source>J Microbiol Immunol Infect.</source> (<year>2020</year>) <volume>53</volume>:<fpage>473</fpage>&#x2013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmii.2020.03.021</pub-id><pub-id pub-id-type="pmid">32276848</pub-id></mixed-citation>
      </ref>
      <ref id="B180">
        <label>180.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Zheng</surname><given-names>BJ</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>L</given-names></name></person-group>. <article-title>Advancements in the development of subunit influenza vaccines</article-title>. <source>Microbes Infect.</source> (<year>2015</year>) <volume>17</volume>:<fpage>123</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2014.12.006</pub-id><pub-id pub-id-type="pmid">25529753</pub-id></mixed-citation>
      </ref>
      <ref id="B181">
        <label>181.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Mi</surname><given-names>D</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV</article-title>. <source>Nat Commun.</source> (<year>2020</year>) <volume>11</volume>:<fpage>1620</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-15562-9</pub-id><pub-id pub-id-type="pmid">32221306</pub-id></mixed-citation>
      </ref>
      <ref id="B182">
        <label>182.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Improvement of pharmacokinetic profile of TRAIL via Trimer-Tag enhances its antitumor activity <italic>in vivo</italic></article-title>. <source>Sci Rep.</source> (<year>2017</year>) <volume>7</volume>:<fpage>8953</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-09518-1</pub-id><pub-id pub-id-type="pmid">28827692</pub-id></mixed-citation>
      </ref>
      <ref id="B183">
        <label>183.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Trivalent soluble TNF receptor, a potent TNF-alpha antagonist for the treatment collagen-induced arthritis</article-title>. <source>Sci Rep.</source> (<year>2018</year>) <volume>8</volume>:<fpage>7327</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-25652-w</pub-id><pub-id pub-id-type="pmid">29743640</pub-id></mixed-citation>
      </ref>
      <ref id="B184">
        <label>184.</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Chappell</surname><given-names>KJ</given-names></name><name><surname>Watterson</surname><given-names>D</given-names></name><name><surname>Young</surname><given-names>PR</given-names></name></person-group>
<source>Inventors Chimeric Molecules and Uses Thereof.</source> U.S. Patent No. WO/2018/176103. St. <publisher-loc>Lucia, QLD</publisher-loc>: <publisher-name>The University of Queensland</publisher-name> (<year>2018</year>).</mixed-citation>
      </ref>
      <ref id="B185">
        <label>185.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>R</given-names></name><name><surname>Brownlie</surname><given-names>R</given-names></name><name><surname>Latimer</surname><given-names>L</given-names></name><name><surname>Gerdts</surname><given-names>V</given-names></name><name><surname>Potter</surname><given-names>A</given-names></name><name><surname>van Drunen</surname><given-names>Littel-van den Hurk S</given-names></name></person-group>. <article-title>A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3</article-title>. <source>Antiviral Res.</source> (<year>2018</year>) <volume>158</volume>:<fpage>78</fpage>&#x2013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2018.07.021</pub-id><pub-id pub-id-type="pmid">30071204</pub-id></mixed-citation>
      </ref>
      <ref id="B186">
        <label>186.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghunandan</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Xabier</surname><given-names>MG</given-names></name><name><surname>Massare</surname><given-names>MJ</given-names></name><name><surname>Flyer</surname><given-names>DC</given-names></name><etal/></person-group>. <article-title>An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization</article-title>. <source>Vaccine.</source> (<year>2014</year>) <volume>32</volume>:<fpage>6485</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.09.030</pub-id><pub-id pub-id-type="pmid">25269094</pub-id></mixed-citation>
      </ref>
      <ref id="B187">
        <label>187.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magnusson</surname><given-names>SE</given-names></name><name><surname>Reimer</surname><given-names>JM</given-names></name><name><surname>Karlsson</surname><given-names>KH</given-names></name><name><surname>Lilja</surname><given-names>L</given-names></name><name><surname>Bengtsson</surname><given-names>KL</given-names></name><name><surname>Stertman</surname><given-names>L</given-names></name></person-group>. <article-title>Immune enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice</article-title>. <source>Vaccine.</source> (<year>2013</year>) <volume>31</volume>:<fpage>1725</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.01.039</pub-id><pub-id pub-id-type="pmid">23384754</pub-id></mixed-citation>
      </ref>
      <ref id="B188">
        <label>188.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>LJ</given-names></name></person-group>. <article-title>Lentiviral vector transduction of dendritic cells for novel vaccine strategies</article-title>. <source>Methods Mol Biol.</source> (<year>2010</year>) <volume>614</volume>:<fpage>161</fpage>&#x2013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-60761-533-0_11</pub-id><pub-id pub-id-type="pmid">20225043</pub-id></mixed-citation>
      </ref>
      <ref id="B189">
        <label>189.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>LJ</given-names></name></person-group>. <article-title>An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens</article-title>. <source>Vaccine.</source> (<year>2006</year>) <volume>24</volume>:<fpage>3477</fpage>&#x2013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2006.02.025</pub-id><pub-id pub-id-type="pmid">16530303</pub-id></mixed-citation>
      </ref>
      <ref id="B190">
        <label>190.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>LJ</given-names></name></person-group>. <article-title>Immunity of lentiviral vector-modified dendritic cells</article-title>. <source>Methods Mol Biol.</source> (<year>2009</year>) <volume>542</volume>:<fpage>245</fpage>&#x2013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-59745-561-9_13</pub-id><pub-id pub-id-type="pmid">19565906</pub-id></mixed-citation>
      </ref>
      <ref id="B191">
        <label>191.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alharbi</surname><given-names>NK</given-names></name><name><surname>Padron-Regalado</surname><given-names>E</given-names></name><name><surname>Thompson</surname><given-names>CP</given-names></name><name><surname>Kupke</surname><given-names>A</given-names></name><name><surname>Wells</surname><given-names>D</given-names></name><name><surname>Sloan</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice</article-title>. <source>Vaccine.</source> (<year>2017</year>) <volume>35</volume>:<fpage>3780</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.032</pub-id><pub-id pub-id-type="pmid">28579232</pub-id></mixed-citation>
      </ref>
      <ref id="B192">
        <label>192.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>FC</given-names></name><name><surname>Wurie</surname><given-names>AH</given-names></name><name><surname>Hou</surname><given-names>LH</given-names></name><name><surname>Liang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Russell</surname><given-names>JB</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial</article-title>. <source>Lancet.</source> (<year>2017</year>) <volume>389</volume>:<fpage>621</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)32617-4</pub-id><pub-id pub-id-type="pmid">28017399</pub-id></mixed-citation>
      </ref>
      <ref id="B193">
        <label>193.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nayak</surname><given-names>S</given-names></name><name><surname>Herzog</surname><given-names>RW</given-names></name></person-group>. <article-title>Progress and prospects: immune responses to viral vectors</article-title>. <source>Gene Ther.</source> (<year>2010</year>) <volume>17</volume>:<fpage>295</fpage>&#x2013;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1038/gt.2009.148</pub-id><pub-id pub-id-type="pmid">19907498</pub-id></mixed-citation>
      </ref>
      <ref id="B194">
        <label>194.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ZY</given-names></name><name><surname>Wyatt</surname><given-names>LS</given-names></name><name><surname>Kong</surname><given-names>WP</given-names></name><name><surname>Moodie</surname><given-names>Z</given-names></name><name><surname>Moss</surname><given-names>B</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name></person-group>. <article-title>Overcoming immunity to a viral vaccine by DNA priming before vector boosting</article-title>. <source>J Virol.</source> (<year>2003</year>) <volume>77</volume>:<fpage>799</fpage>&#x2013;<lpage>803</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.77.1.799-803.2003</pub-id><pub-id pub-id-type="pmid">12477888</pub-id></mixed-citation>
      </ref>
      <ref id="B195">
        <label>195.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Vemula</surname><given-names>SV</given-names></name><name><surname>Couetil</surname><given-names>L</given-names></name><name><surname>Katz</surname><given-names>JM</given-names></name><name><surname>Donis</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine</article-title>. <source>PLoS ONE.</source> (<year>2012</year>) <volume>7</volume>:<fpage>e33428</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0033428</pub-id><pub-id pub-id-type="pmid">22432020</pub-id></mixed-citation>
      </ref>
      <ref id="B196">
        <label>196.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Kamihira</surname><given-names>M</given-names></name></person-group>. <article-title>Development of hybrid viral vectors for gene therapy</article-title>. <source>Biotechnol Adv.</source> (<year>2013</year>) <volume>31</volume>:<fpage>208</fpage>&#x2013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.biotechadv.2012.10.001</pub-id><pub-id pub-id-type="pmid">23070017</pub-id></mixed-citation>
      </ref>
      <ref id="B197">
        <label>197.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larocca</surname><given-names>RA</given-names></name><name><surname>Abbink</surname><given-names>P</given-names></name><name><surname>Peron</surname><given-names>JP</given-names></name><name><surname>Zanotto</surname><given-names>PM</given-names></name><name><surname>Iampietro</surname><given-names>MJ</given-names></name><name><surname>Badamchi-Zadeh</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Vaccine protection against zika virus from Brazil</article-title>. <source>Nature.</source> (<year>2016</year>) <volume>536</volume>:<fpage>474</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/nature18952</pub-id><pub-id pub-id-type="pmid">27355570</pub-id></mixed-citation>
      </ref>
      <ref id="B198">
        <label>198.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>MW</given-names></name><name><surname>Cheng</surname><given-names>TJ</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Jan</surname><given-names>JT</given-names></name><name><surname>Ma</surname><given-names>SH</given-names></name><name><surname>Yu</surname><given-names>AL</given-names></name><etal/></person-group>. <article-title>A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses</article-title>. <source>Proc Natl Acad Sci U S A.</source> (<year>2008</year>) <volume>105</volume>:<fpage>13538</fpage>&#x2013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0806901105</pub-id><pub-id pub-id-type="pmid">18765801</pub-id></mixed-citation>
      </ref>
      <ref id="B199">
        <label>199.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escolano</surname><given-names>A</given-names></name><name><surname>Steichen</surname><given-names>JM</given-names></name><name><surname>Dosenovic</surname><given-names>P</given-names></name><name><surname>Kulp</surname><given-names>DW</given-names></name><name><surname>Golijanin</surname><given-names>J</given-names></name><name><surname>Sok</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice</article-title>. <source>Cell.</source> (<year>2016</year>) <volume>166</volume>:<fpage>1445</fpage>&#x2013;<lpage>58.e12</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.07.030</pub-id><pub-id pub-id-type="pmid">27610569</pub-id></mixed-citation>
      </ref>
      <ref id="B200">
        <label>200.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>rd Annual meeting &amp; pre-conference programs of the society for immunotherapy of cancer (SITC 2018): Washington DC USA</collab></person-group>
<article-title>7-11 November 2018</article-title>. <source>J Immunother Cancer.</source> (<year>2018</year>) <volume>6</volume>:<fpage>114</fpage>
<pub-id pub-id-type="doi">10.1186/s40425-018-0423-x</pub-id><pub-id pub-id-type="pmid">30400835</pub-id></mixed-citation>
      </ref>
      <ref id="B201">
        <label>201.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>RB</given-names></name><name><surname>Morrow</surname><given-names>MP</given-names></name><name><surname>Kraynyak</surname><given-names>KA</given-names></name><name><surname>Sylvester</surname><given-names>AJ</given-names></name><name><surname>Cheung</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Immune therapy targeting E6/E7 oncogenes of human paillomavirus type 6 (HPV-6) reduces or eliminates the need for surgical intervention in the treatment of HPV-6 associated recurrent respiratory papillomatosis</article-title>. <source>Vaccines.</source> (<year>2020</year>) <volume>8</volume>:<fpage>56</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines8010056</pub-id><pub-id pub-id-type="pmid">32013270</pub-id></mixed-citation>
      </ref>
      <ref id="B202">
        <label>202.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diehl</surname><given-names>MC</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Daniels</surname><given-names>SE</given-names></name><name><surname>Tebas</surname><given-names>P</given-names></name><name><surname>Khan</surname><given-names>AS</given-names></name><name><surname>Giffear</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Tolerability of intramuscular and intradermal delivery by CELLECTRA((R)) adaptive constant current electroporation device in healthy volunteers</article-title>. <source>Hum Vaccin Immunother.</source> (<year>2013</year>) <volume>9</volume>:<fpage>2246</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.4161/hv.24702</pub-id><pub-id pub-id-type="pmid">24051434</pub-id></mixed-citation>
      </ref>
      <ref id="B203">
        <label>203.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>Y</given-names></name><name><surname>Furtado</surname><given-names>L</given-names></name><name><surname>Tergas</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Brooks</surname><given-names>R</given-names></name><name><surname>McCall</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A Phase I trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer</article-title>. <source>Int J Radiat Oncol Biol Phys.</source> (<year>2020</year>) <volume>107</volume>:<fpage>487</fpage>&#x2013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijrobp.2020.02.031</pub-id><pub-id pub-id-type="pmid">32151670</pub-id></mixed-citation>
      </ref>
      <ref id="B204">
        <label>204.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richner</surname><given-names>JM</given-names></name><name><surname>Himansu</surname><given-names>S</given-names></name><name><surname>Dowd</surname><given-names>KA</given-names></name><name><surname>Butler</surname><given-names>SL</given-names></name><name><surname>Salazar</surname><given-names>V</given-names></name><name><surname>Fox</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Modified mRNA vaccines protect against zika virus infection</article-title>. <source>Cell.</source> (<year>2017</year>) <volume>168</volume>:<fpage>1114</fpage>&#x2013;<lpage>25.e10</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.02.017</pub-id><pub-id pub-id-type="pmid">28222903</pub-id></mixed-citation>
      </ref>
      <ref id="B205">
        <label>205.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Espeseth</surname><given-names>AS</given-names></name><name><surname>Cejas</surname><given-names>PJ</given-names></name><name><surname>Citron</surname><given-names>MP</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>DiStefano</surname><given-names>DJ</given-names></name><name><surname>Callahan</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection</article-title>. <source>NPJ Vaccines.</source> (<year>2020</year>) <volume>5</volume>:<fpage>16</fpage>. <pub-id pub-id-type="doi">10.1038/s41541-020-0163-z</pub-id><pub-id pub-id-type="pmid">32128257</pub-id></mixed-citation>
      </ref>
      <ref id="B206">
        <label>206.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>D</given-names></name><name><surname>Gonzalez-Duarte</surname><given-names>A</given-names></name><name><surname>O\'Riordan</surname><given-names>WD</given-names></name><name><surname>Yang</surname><given-names>CC</given-names></name><name><surname>Ueda</surname><given-names>M</given-names></name><name><surname>Kristen</surname><given-names>AV</given-names></name><etal/></person-group>. <article-title>Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis</article-title>. <source>N Engl J Med.</source> (<year>2018</year>) <volume>379</volume>:<fpage>11</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1716153</pub-id><pub-id pub-id-type="pmid">29972753</pub-id></mixed-citation>
      </ref>
      <ref id="B207">
        <label>207.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadler</surname><given-names>CR</given-names></name><name><surname>Bahr-Mahmud</surname><given-names>H</given-names></name><name><surname>Celik</surname><given-names>L</given-names></name><name><surname>Hebich</surname><given-names>B</given-names></name><name><surname>Roth</surname><given-names>AS</given-names></name><name><surname>Roth</surname><given-names>RP</given-names></name><etal/></person-group>
<article-title>Elimination of large tumors in mice by mRNA-encoded bispecific antibodies</article-title>. <source>Nat Med.</source> (<year>2017</year>) <volume>23</volume>:<fpage>815</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4356</pub-id><pub-id pub-id-type="pmid">28604701</pub-id></mixed-citation>
      </ref>
      <ref id="B208">
        <label>208.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beissert</surname><given-names>T</given-names></name><name><surname>Perkovic</surname><given-names>M</given-names></name><name><surname>Vogel</surname><given-names>A</given-names></name><name><surname>Erbar</surname><given-names>S</given-names></name><name><surname>Walzer</surname><given-names>KC</given-names></name><name><surname>Hempel</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A Trans-amplifying RNA vaccine strategy for induction of potent protective immunity</article-title>. <source>Mol Ther.</source> (<year>2020</year>) <volume>28</volume>:<fpage>119</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2019.09.009</pub-id><pub-id pub-id-type="pmid">31624015</pub-id></mixed-citation>
      </ref>
      <ref id="B209">
        <label>209.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahin</surname><given-names>U</given-names></name><name><surname>Kariko</surname><given-names>K</given-names></name><name><surname>Tureci</surname><given-names>O</given-names></name></person-group>. <article-title>mRNA-based therapeutics&#x2013;developing a new class of drugs</article-title>. <source>Nat Rev Drug Discov.</source> (<year>2014</year>) <volume>13</volume>:<fpage>759</fpage>&#x2013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1038/nrd4278</pub-id><pub-id pub-id-type="pmid">25233993</pub-id></mixed-citation>
      </ref>
      <ref id="B210">
        <label>210.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stensballe</surname><given-names>LG</given-names></name><name><surname>Nante</surname><given-names>E</given-names></name><name><surname>Jensen</surname><given-names>IP</given-names></name><name><surname>Kofoed</surname><given-names>PE</given-names></name><name><surname>Poulsen</surname><given-names>A</given-names></name><name><surname>Jensen</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study</article-title>. <source>Vaccine.</source> (<year>2005</year>) <volume>23</volume>:<fpage>1251</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2004.09.006</pub-id><pub-id pub-id-type="pmid">15652667</pub-id></mixed-citation>
      </ref>
      <ref id="B211">
        <label>211.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moorlag</surname><given-names>S</given-names></name><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group>. <article-title>Non-specific effects of BCG vaccine on viral infections</article-title>. <source>Clin Microbiol Infect.</source> (<year>2019</year>) <volume>25</volume>:<fpage>1473</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2019.04.020</pub-id><pub-id pub-id-type="pmid">31055165</pub-id></mixed-citation>
      </ref>
      <ref id="B212">
        <label>212.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>E</given-names></name><name><surname>Sanz</surname><given-names>J</given-names></name><name><surname>Dunn</surname><given-names>JL</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Mendonca</surname><given-names>LE</given-names></name><name><surname>Pacis</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis</article-title>. <source>Cell.</source> (<year>2018</year>) <volume>172</volume>:<fpage>176</fpage>&#x2013;<lpage>90.e19</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.12.031</pub-id><pub-id pub-id-type="pmid">29328912</pub-id></mixed-citation>
      </ref>
      <ref id="B213">
        <label>213.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>S</given-names></name><name><surname>Jasny</surname><given-names>E</given-names></name><name><surname>Schmidt</surname><given-names>KE</given-names></name><name><surname>Petsch</surname><given-names>B</given-names></name></person-group>. <article-title>New vaccine technologies to combat outbreak situations</article-title>. <source>Front Immunol.</source> (<year>2018</year>) <volume>9</volume>:<fpage>1963</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.01963</pub-id><pub-id pub-id-type="pmid">30283434</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>